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The fungal pathogen Zymoseptoria tritici (formerly Septoria tritici) causes Septoria tritici 
blotch (STB), one of the most yield reducing diseases of wheat worldwide. In addition to 
cultural control measures and the cultivation of wheat varieties with a level of disease 
resistance, STB control relies heavily on the application of foliar fungicides with different 
modes of action. The demethylation inhibitors (DMIs) have been one of the most widely 
applied fungicides for many decades and belong to one of the most important fungicide 
modes of action in STB management. DMIs inhibit the sterol 14α-demethylase, an essential 
enzyme in the ergosterol biosynthesis pathway, encoded by the CYP51 gene of fungi. 
Widespread and intensive use of the DMIs over time has led to a continuous negative shift 
in the sensitivity of Z. tritici towards DMIs that have been used for a long time. This shift in 
sensitivity is mainly driven by the accumulation of mutations in the CYP51 gene resulting in 
the selection of various CYP51 haplotypes. More recently, CYP51 overexpression and an 
increased efflux activity, based on the overexpression of the MFS1 transporter, have been 
shown to be additional mechanisms affecting DMI sensitivity of Z. tritici. Inserts in the 
CYP51 promotor (CYP51p) and MFS1 promotor (MFS1p) were observed to be responsible 
for CYP51 and MFS1 overexpression. The prevalence and contribution of different DMI 
resistance mechanisms to a reduced DMI sensitivity of Z. tritici were investigated in isolates 
from across Europe in 2016 and 2017. The CYP51 gene of all isolates was sequenced and 
the CYP51p and MFS1p was investigated for inserts in order to determine the character of 
the CYP51 haplotypes as well as to identify CYP51 overexpression or if an increased efflux 
activity was occurring in these isolates.   
Detection of new mutations in CYP51, although not necessarily correlated with distinct 
changes in DMI sensitivity of Z. tritici, demonstrated that evolution of CYP51 is still ongoing. 
Additionally, new combinations of existing alterations resulted in the emergence and 
identification of new CYP51 haplotypes not previously described in the literature. As a result 
of the identification of numerous new haplotypes, it was decided to establish a new 
nomenclature in order to describe all 57 CYP51 haplotypes found in Z. tritici across 2016 
and 2017 as well as to facilitate the future designation of newly emerging haplotypes. 
Thirteen of the 57 CYP51 haplotypes were observed to represent around 89% of all isolates 
and were designated as ‘frequently found CYP51 haplotypes’. Among these thirteen most 
frequent CYP51 haplotypes, isolates carrying haplotypes C8, G1, and F3 showed highest 
sensitivity to epoxiconazole, followed by haplotypes E4 and F2 with moderate adaptation 
and haplotypes F4, E3, D13, E5, F8, H4, and H6, all carrying the alteration S524T, 
conferring the highest level of adaptation. In vitro sensitivity data for these haplotypes and 
different DMIs indicated limited cross-resistance between epoxiconazole as well as 
prothioconazole compared to mefentrifluconazole. These results were supported by in vivo 
Abstract XV 
 
selection studies that indicated overall a different trend in the selection pattern for CYP51 
haplotypes by the two DMI fungicides prothioconazole and mefentrifluconazole.  
A heterogenous distribution of ‘frequently found CYP51 haplotypes’ was observed across 
Europe demonstrating an east-west gradient in DMI adaptation of Z. tritici. In the Western 
European countries Ireland, UK, and the Netherlands, the majority of the Z. tritici 
populations were composed of haplotypes expressing a moderate or high adaptation to 
epoxiconazole. In Central Europe, for example in Germany and Poland, the majority of the 
populations were composed of haplotypes conferring highest sensitivity or moderate 
adaptation among all ‘frequently found CYP51 haplotypes’. In Eastern Europe, a high 
frequency of haplotypes with the highest sensitivity among all ‘frequently found CYP51 
haplotypes’ was observed. Nevertheless, compared to past studies, an ongoing shift 
towards a reduced DMI sensitivity was observed across Europe, especially in intensive 
wheat growing areas.  
Further investigation of the isolates in this study found 121, 863, 868, and 300 bp inserts in 
CYP51p. The 121, 863, and 868 bp inserts were assumed to be equivalent to the already 
published 120, 862, and 866 bp inserts. Therefore, the 121 bp insert was named as 120 bp, 
the 863 bp as 862 bp, and the 868 bp as 866 bp insert in the course of this work. Previously, 
the 120 bp insert in CYP51p was shown to be associated with CYP51 overexpression, 
unlike the 862 and 866 bp inserts which are probably not. On average, a 5- to 8-fold 
reduction in epoxiconazole sensitivity was correlated to the 120 bp insert in this work, 
whereas the 300, 862, and 866 bp inserts were only associated with a small impact on 
sensitivity, if at all. In 2016, CYP51 overexpression based on the 120 bp insert was 
detected, with the exception of Denmark, in isolates from every investigated country in a 
low to moderate frequency. However, an increase in the frequency was observed for some 
countries in 2017. The 120 bp insert was mainly detected in isolates with the F2 haplotype, 
however, for the first time, this insert was also detected in conjunction with other CYP51 
haplotypes further demonstrating an ongoing evolution of CYP51 overexpression and 
CYP51p.  
Across all isolates, seven different inserts with a length of 150, 267, 308, 338, 369, 377, or 
519 bp were detected in MFS1p. The 150, 338, 369, and 519 bp inserts have been 
published before and are associated with MFS1 overexpression. Among those, the 519 bp 
insert is correlated with highest MFS1 expression in literature. In this work, in vitro sensitivity 
data for epoxiconazole revealed that the 519 bp insert in MFS1p was correlated with up to 
an 8-fold reduction in sensitivity, whereas the remaining inserts only conferred a minor 
impact on sensitivity to epoxiconazole. In the 2016 isolates, the 519 bp insert was only 
detected at a low frequency in Germany, Poland, and in countries of Western Europe. 
Shorter MFS1p inserts were mainly detected in Ireland and UK. In contrast, the prevalence 
of smaller MFS1p inserts increased in the 2017 isolates although their frequency was 
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generally still at a low level (with the exception of Ireland and the Netherlands). The 
frequency of the 519 bp insert was relatively stable in isolates from both years.  
Overall, it was shown that the occurrence of CYP51 haplotypes was still the most frequent 
and important mechanism conferring a reduction in sensitivity to DMIs by Z. tritici in Europe. 
Nevertheless, an increase in the frequency of isolates exerting CYP51 overexpression and 
those exhibiting increased efflux activity was observed compared to earlier studies. 
Glasshouse data demonstrated that DMIs can still contribute to disease control, and in 
some cases give full control, of STB even if isolates expressed CYP51 overexpression 
and/or an increased efflux in addition to also carrying moderately or highly adapted CYP51 
haplotypes. However, in order to prevent the further increase and spread of further adapted 
CYP51 haplotypes plus additional resistance mechanisms in the Z. tritici population across 
Europe, anti-resistance-management strategies should be a high priority in the use of DMIs. 
In addition, especially integrated disease management strategies, such as the appropriate 
choice of cultivars, should be applied in order to keep STB disease pressure low and 
consequently reduce the number of fungicide applications. Moreover, resistance-
management strategies may exploit the limited cross-resistance between different DMIs, 
for example, by the use of mixtures or alternation of different DMI fungicides. However, 
control strategies should also incorporate the use of fungicides with different MOAs. The 
aim of all these strategies is to reduce selection of adapted Z. tritici isolates and 
consequently to prolong the efficacy of DMIs in STB management.  
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1 Introduction  
1.1 Wheat cultivation  
Domestication of wheat is thought to have started 10.000 years ago in the Fertile Crescent 
(Lev-Yadun et al., 2000; Peng et al., 2011). Today, wheat is the most widely grown crop in 
the world and the most important cereal cultivated in the EU (Fones and Gurr, 2015). Wheat 
is grown from the far North from 67°N in Norway, Finland, and Russia to 45°S in Argentina 
and Chile (Gustafson et al., 2009). Modern wheat varieties belong to two species. Around 
95% of the world wheat production is derived from hexaploid bread wheat (Triticum 
aestivum) and the remaining 5% from tetraploid hard or durum wheat (T. durum) (Peng et 
al., 2011). Wheat is mainly produced for human consumption and animal feed, however, it 
is also used as a raw material for biofuels and for alcoholic distillation. Additionally, wheat 
straw serves for livestock bedding, roof thatching and basket-making (Gustafson et al., 
2009; Fones and Gurr, 2015).  
In 2017, wheat was grown on around 220 million hectares worldwide and a global harvest 
of 771 million metric tons was achieved (FAO, 2019). The largest quantities of wheat were 
produced in Asia followed by Europe and America. The top 5 countries with the highest 
wheat production within Europe were Russia, France, Ukraine, Germany and UK (FAO, 
2019). Since the green revolution, a significant increase in grain production was achieved 
based on the development of high yielding wheat- and rice varieties (Khush, 1999). Due to 
a steadily increasing global population and changing diets, the demand for food is predicted 
to increase by 70% by 2050 (FAO, 2009; Beddington et al., 2011; O’Driscoll et al., 2014). 
At the same time agricultural production is challenged by adverse effects through climatic 
change and is facing the need for climate-resilient production systems that are sustainable 
(Beddington et al., 2011). Additionally, abiotic environmental factors such as salinity, water- 
and nutrient supply as well as biotic factors such as animal pests, plant pathogens, and 
weeds threaten agricultural production (Oerke, 2006; Haggag et al., 2015). At a worldwide 
scale, potential losses of wheat yields due to pests have been estimated to be close to 50% 
(Oerke, 2006). Oerke (2006) described that highest potential yield losses are due to 
competition with weeds, that can be managed mechanically or chemically, followed by plant 
pathogens and animal pests that are mainly managed based on synthetic chemicals. The 
importance of plant pathogens increases with increasing crop productivity. Therefore, in 
Western Europe, under conditions of intensive agricultural production, the potential losses 
due to plant pathogens were as high as that of weeds (Oerke, 2006).  
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Rust diseases (Puccinia striiformis, Puccinia triticina) and powdery mildew (Blumeria 
graminis) are known as serious diseases of wheat (Jørgensen et al., 2014). Due to 
mycotoxin production also Fusarium head blight (Fusarium spp.) is considered as an 
increasing problem in wheat production (Bottalico and Perrone, 2002; Jørgensen et al., 
2014). Nevertheless, in Europe, the most prevalent and yield reducing fungal disease of 
wheat remains Septoria tritici blotch (STB) caused by the fungal pathogen 
Zymoseptoria tritici (Jørgensen et al., 2014; Fones and Gurr, 2015).  
1.2 Septoria tritici blotch and its causal agent 
Zymoseptoria tritici  
1.2.1 Relevance  
The ascomycetous fungal pathogen Zymoseptoria tritici (Desm.) Quaedvlieg and Crous is 
the causal agent of Septoria tritici blotch (STB), an important disease of wheat grown in 
temperate climates worldwide (Orton et al., 2011; Fones and Gurr, 2015; Torriani et al., 
2015). In fields cultivated with STB susceptible wheat varieties, severe epidemics of STB 
can cause yield losses of up to 50% (Eyal et al., 1987). Within the European Union (EU), 
STB is the most prevalent and devastating foliar disease of wheat (Jørgensen et al., 2014; 
Fones and Gurr, 2015; Torriani et al., 2015). In the EU, approximately 70% of fungicides 
applied annually in cereal production target the control of Z. tritici in wheat demonstrating 
its high economic relevance (Ponomarenko et al., 2011; Torriani et al., 2015). Annual losses 
in Europe caused by STB are estimated to be $400 million (Ponomarenko et al., 2011).  
1.2.2 Taxonomy  
Z. tritici was named Septoria tritici Roberge in Desmaz. until 2011 and is the anamorph of 
the fungus (Desmazières, 1842; Quaedvlieg et al., 2011; Eyal et al., 1987). The teleomorph 
of Z. tritici is Mycosphaerella graminicola (Fuckel) J Schroeter in Cohn (Sanderson, 1976). 
In 2011, a new genus named Zymoseptoria was founded to accommodate Septoria-like 
species found on graminicolous hosts (Quaedvlieg et al., 2011). In their work, Quaedvlieg 
et al. (2011) identified that species in the Zymoseptoria genus can be separated from the 
Septoria genus based on molecular phylogeny studies. Additionally, species of the 
Zymoseptoria genus are characterised morphologically by their yeast-like growth in culture 
and the formation of up to three different conidial types, namely pycnidial conidia, 
phragmospores on aerial hyphae, and yeast-like growth proliferation via microcyclic 
conidiation (Quaedvlieg et al., 2011). Z. tritici belongs to the class of the Dothideomycetes, 
the order Capnodiales and the family Mycosphaerellaceae (EPPO, 2019). 
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1.2.3 Disease cycle, infection process and epidemiology 
Z. tritici has developed various opportunities to survive the intercrop period in winter wheat 
cultivation and thus to provide primary inoculum at wheat seedling emergence. Ascospores, 
pycnidiospores as well as mycelium can all overwinter on plant material such as wheat 
seeds, stubble, debris, wheat volunteers and grass species (Suffert et al., 2011). Under 
field conditions seed transmission of Z. tritici is believed to be unlikely (Jones and Cooke, 
1969; Suffert et al., 2011). Z. tritici is able to infect a few grass species as alternative hosts 
which may play a role in long-term conservation of inoculum. However, so far, the precise 
role of alternative hosts in epidemiology of STB is not fully clear (Brokenshire, 1975; Ao and 
Griffiths, 1976; Suffert et al., 2011). Wind-dispersed ascospores are thought to be the main 
source for primary infection of wheat seedlings in autumn (Shaw and Royle, 1989a; Eriksen 
and Munk, 2003). Ascospores of Z. tritici are produced in fruiting bodies of the sexual stage, 
named pseudothecia, ascocarps or perithecia (Eyal et al., 1987; Suffert et al., 2011). A 
bipolar and heterothallic mating system with two opposite mating types (MAT1-1 and MAT1-
2), that are needed for sexual reproduction and generation of ascospores, was identified for 
Z. tritici (Kema et al., 1996a). A positive correlation between the frequency of pseudothecia 
and the infection density is assumed due to a higher chance of opposite mating types to 
encounter under high infection densities compared to lower densities (Cowger et al., 2002). 
Pseudothecia were found regularly during the growing season but appear around 30 to 55 
days later than pycnidia. Pseudothecia remain active on senescent leaves as well as on 
plant debris and act as ascospore source for later infections (Hunter et al., 1999; Eriksen 
and Munk, 2003; Suffert et al., 2011). In the Northern Hemisphere, release of ascospores 
follows a seasonal pattern with a first peak in late autumn and a second peak at the end of 
the growing season in summer (Hunter et al., 1999; Eriksen and Munk, 2003; Suffert et al., 
2011). Although ascospores are thought to be the main source for primary infection of wheat 
seedlings in autumn, also rain-splash dispersed pycnidiospores from wheat debris could 
act as primary inoculum when wheat is stubble sown or later sown than the main period of 
ascospore release (Shaw and Royle, 1989a; Holmes and Colhoun, 1975; Brown et al., 
1978; Shaw, 1987; Eriksen and Munk, 2003). 
The disease cycle of STB caused by Z. tritici is shown in Figure 1 (extracted from 




Figure 1: Disease cycle of Septoria tritici blotch caused by Zymoseptoria tritici on wheat. 
(Figure was extracted from Ponomarenko et al., 2011). 
Primary infection starts with germination of asco- or pycnidiospores at the leaf surface and 
penetration of the host via stomata (Kema et al., 1996b). A latent phase of 10-14 days 
without visible symptoms follows in which the fungus grows slowly in the apoplast in close 
contact to wheat mesophyll cells (Kema et al., 1996b; Keon et al., 2007). Based on this 
latent phase Z. tritici has often been referred to as a hemibiotrophic pathogen (Keon et al., 
2007; Brunner et al., 2013). However, proof of the acquisition of nutrients by Z. tritici during 
the asymptomatic growth phase remains unclear, as it does not develop haustoria or other 
intracellular feeding structures (Kema et al., 1996b; Rudd et al., 2008). Compared to 
biotrophic fungal pathogens growth of Z. tritici appears more similar to endophytes (Joosten 
et al., 1990; Solomon and Oliver, 2001; Thomma et al., 2005; Keon et al., 2007; Rudd et 
al., 2015; Sánchez-Vallet et al., 2015). Sánchez-Vallet et al. (2015) suggested that nutrients 
stored in the spore may serve as a food source during the asymptomatic phase. 
Additionally, some cell wall degrading enzymes are specifically expressed possibly 
indicating that host cell wall components may be degraded and serve as nutrition for the 
fungus without causing major damage to the plant (Sánchez-Vallet et al., 2015). The 
expression profile of plant cell wall degrading enzymes indicates an important role of these 
enzymes in plant colonization, although the number of cell wall degrading enzymes is 
smaller in Z. tritici compared to other fungal pathogens (Goodwin et al., 2011; Brunner et 
al., 2013). Uptake of released nutrients is believed to be mediated by sugar and amino acid 
transporters expressed during the asymptomatic phase (Keon et al., 2007; Yang et al., 
2013; Brunner et al., 2013; Kellner et al., 2014). In Z. tritici only two effectors Mg1LysM and 
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Mg3LysM have been observed to be essential for the successful infection process. Both 
effectors prevent activation of chitin-triggered-immunity and consequently, prevent growth 
inhibition of Z. tritici during the asymptomatic phase (de Jonge et al., 2010; Marshall et al., 
2011; Sánchez-Vallet et al., 2013, 2015). After the latent phase, Z. tritici switches to a 
necrotrophic lifestyle and disease symptoms appear as irregular chlorotic lesions that 
develop later into necrotic lesions carrying brown pycnidia (Eyal et al., 1987; O’Driscoll et 
al., 2014; Keon et al., 2007). Typical symptoms of Z. tritici in a wheat field are shown in 
Figure 2. 
 
Figure 2: Disease symptoms of Z. tritici. A: Symptoms of Z. tritici on a wheat leaf showing black 
conidia within necrotic lesions. This picture was kindly provided by Bill Clark, Technical Director, 
NIAB. B: Top view of Z. tritici infection on wheat. C: Front view of Z. tritici infection on wheat. Pictures 
B and C were kindly provided by Dieter Strobel, technical manager, BASF SE.  
The factors that trigger the switch from asymptomatic to necrotrophic growth are still 
unknown (Sánchez-Vallet et al., 2015). Environmental factors as well as several pathogen 
related mechanisms, including the production of protein effectors are supposed to play a 
role in the induction of necrosis (Keon et al., 2007; Rudd et al., 2008; Brunner et al., 2013; 
Mirzadi Gohari et al., 2015; Rudd et al., 2015; Sánchez-Vallet et al., 2015). During the 
necrotrophic phase the growth of the fungus becomes more rapid and asexual sporulation 
structures, the pycnidia that form pycnidiospores are produced (Keon et al., 2007; O’Driscoll 
et al., 2014). Pycnidiospores are dispersed by rain-splash and are considered to be the 
main source of inoculum for secondary infections throughout the growing season (Holmes 
and Colhoun, 1975; Shaw, 1987; Suffert et al., 2011). Pycnidiospores lead to local 
secondary infections on uninfected leaves of the same plant and spread the disease 
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upwards through the canopy as well as to plants nearby. Therefore, several cycles of 
multiplication, even within one leaf layer, can occur during the growing season leading to 
rapid development of epidemics under favourable conditions (Shaw and Royle, 1993; 
Ponomarenko et al., 2011). Pycnidiospores in pycnidia were found to stay viable for several 
month on infected wheat debris, thus also serving as an additional source for inoculum 
overwinter (Hilu and Bever, 1957; Suffert et al., 2011).  
Temperature and humidity are important factors influencing STB infection of wheat (Holmes 
and Colhoun, 1974). Wet weather and temperatures between 17 to 25°C are favourable for 
Z. tritici infections (Holmes and Colhoun, 1974; Eyal et al., 1987). Under artificial conditions 
7°C and a period of only 24 h in a moisture chamber with high humidity were not sufficient 
to produce infections (Holmes and Colhoun, 1974; Eyal et al., 1987). It was observed that 
temperatures below -2°C in the early stages of growth reduce the risk of a STB infection on 
winter wheat (Fones and Gurr, 2015). As secondary infections are driven by pycnidiospores 
dispersed by rain splash, the occurrence of rain events (5-10 mm rainfall at one day or 10 
mm rain in total over two or three consecutive days with at least 1 mm rain) is a crucial 
factor influencing the speed of STP epidemics (Holmes and Colhoun, 1975; Shaw, 1987; 
Thomas et al., 1989; Suffert et al., 2011). Consequently, Z. tritici is favoured by cool, humid 
climates often found in EPPO´s “Maritime Zone” including Northern France, Germany, and 
UK (Holmes and Colhoun, 1974; Bouma, 2005; Fones and Gurr, 2015; Goodwin, 2019).  
1.2.4 Genetics 
The genome of Z. tritici was the first and most complete sequence of a filamentous fungus 
to be studied in 2011 (Goodwin et al., 2011). The complete genome of Z. tritici (isolate 
IPO323) has a total size of 39.7 Mb and consists of 21 chromosomes that carry 10,933 
predicted genes (Goodwin et al., 2011). The genome was shown to consist of 13 core 
chromosomes and eight dispensable chromosomes that can be lost without visible effects 
on the fitness of the fungus (Wittenberg et al., 2009; Goodwin et al., 2011). On the core 
chromosomes, which contain 88% of the genome, close to 59% of the genes could be 
annotated, whereas only 10% of the genes could be annotated on the dispensable 
chromosomes, which contain 12% of the genome (Goodwin et al., 2011; Dhillon et al., 
2014). The dispensable chromosomes contain redundant genes that represent copies of 
genes present on core chromosomes and the majority of the annotated genes are coding 
for putative transcriptome factors or otherwise function in gene regulation or signal 
transduction (Goodwin et al., 2011). Variation in the chromosome number of the Z. tritici 
genome is meiotically generated during the sexual cycle of the fungus (Wittenberg et al., 
2009; Goodwin et al., 2011). It was believed that Z. tritici shows a high level of sexual 
reproduction leading to a high degree of genetic variation (Chen and McDonald, 1996; 
Schnieder et al., 2001). Indeed, a high genetic variability within Z. tritici populations, even 
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within a single wheat field, resulting in many different molecular phenotypes was observed 
(McDonald and Martinez, 1990; Schnieder et al., 2001; reviewed in Simón et al., 2012). 
Dhillon et al. (2014) described in their studies that at least 17% of the Z. tritici genome was 
estimated to be repetitive. These repeated elements did not contain tandem repeats and 
low-copy repetitive families with fewer than ten repeats per family. Additionally, 5.7% of the 
genome was shown to consist of these low-copy repetitive families. In their studies, Dhillon 
et al. (2014) also identified that the largest fraction of all repetitive elements was built by 
class I transposable elements (transposable elements that amplify via an RNA 
intermediate). Dispensable chromosomes showed a significantly higher frequency of 
transposable- and repetitive elements compared to the core chromosomes (Dhillon et al., 
2014). Translocations in the genome due to transposable elements provide a broad range 
in genetic variation and may lead to chromosome length polymorphisms often found in the 
Z. tritici genome (McDonald and Martinez, 1991; Goodwin et al., 2001; Daboussi and Capy, 
2003; Wittenberg et al., 2009). A high plasticity of the Z. tritici genome based on 
polymorphisms in length and number of chromosomes is supposed to play an important 
role in strategies of Z. tritici populations to adapt to adverse biotic and abiotic conditions in 
wheat fields (Wittenberg et al., 2009; Orton et al., 2011).  
1.3 Disease management of Septoria tritici blotch in 
wheat  
In wheat, control of STB is achieved by an integrated disease management approach 
including cultural practices, breeding of resistant wheat varieties and the application of 
chemical fungicides (Orton et al., 2011; Jørgensen et al., 2014). As yield losses are mainly 
driven by STB infections on the flag, second and third leaf of wheat plants, it is of major 
relevance in STB control to prevent infections on these top three leaves (Shaw and Royle, 
1989b; Thomas et al., 1989).  
1.3.1 Cultural methods 
Cultural control measures comprising the adjustment of the sowing date, the crop density, 
the input of fertilizer, the crop rotation and tillage can affect severity of fungal diseases in 
wheat (Jørgensen et al., 2014). Compared to other fungal pathogens disease severity of 
STB is less affected or unaffected by crop rotation or tillage systems (Schuh, 1990; 
Gladders et al., 2001; Brown and Hovmøller, 2002). However, widening the crop rotation to 
2-5 years between wheat crops or implementing a crop rotation with non-cereal crops were 
demonstrated to reduce STB severity compared to fields of consecutive wheat cultivation 
(Pedersen and Hughes, 1992; Bailey et al., 2001). This observation may be explained by a 
reduced availability of inoculum in the early growing stages (Suffert et al., 2011). 
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Nevertheless, in areas with a high intensity of wheat production such as Northern Europe, 
wind-dispersed ascospores are estimated to be available in all growing regions serving as 
the main source of primary inoculum in the early season (Eriksen and Munk, 2003). Another 
factor influencing STB severity is the sowing date. Early sowing of wheat increases the risk 
for severe STB epidemics due to a longer development of early-sown crops. This longer 
development favours initial infections and multiplication resulting in a higher amount of 
inoculum at the end of winter compared to late-sown crops (Shaw and Royle, 1993; 
Jørgensen et al., 1997). Consequently, later drilling can reduce disease incidence of STB, 
however, very late sowing can also reduce yields (Gladders et al., 2001; Jørgensen et al., 
1997). Additionally, STB severity may be affected by crop density. Low seed rates result in 
a more open crop canopy that favours secondary infections of STB by splash-born 
pycnidiospores (Bjerre et al., 2006; Jørgensen et al., 1997). On the other hand, high seed 
rates may increase the risk of lodging associated with reduced yields (Fischer and Stapper, 
1987; Berry et al., 2000). Under favourable weather conditions development of Z. tritici was 
also demonstrated to be promoted by high nitrogen fertilization (Simón et al., 2003). All in 
all, the application of cultural control measures alone in STB management is challenging 
because a method reducing the risk of one disease may enhance the risk of another 
(Jørgensen et al., 2014). Additionally, some of the described measures may have a 
negative impact on yield resulting in reluctance of the farmers to adopt cultural control 
measures in their cropping systems (Jørgensen et al., 2014; O’Driscoll et al., 2014). 
1.3.2 Variety resistance and mixtures  
Cultivation of resistant wheat varieties is a relevant approach in STB management (Orton 
et al., 2011; Jørgensen et al., 2014). Breeding for Z. tritici resistance has become a major 
focus of wheat breeding programmes and considerable progress has been achieved in 
understanding the genetics of STB resistance during the last 20 years (Arraiano and Brown, 
2006; Brown et al., 2015). Two types of STB resistance are known in wheat. The first type 
is specific (qualitative) resistance that is near-complete and oligogenically controlled by 
major genes with large effects. This resistance type is isolate dependent and follows a gene-
for-gene relationship (Brading et al., 2002; Arraiano and Brown, 2006; Brown et al., 2015). 
In contrast, the second type, quantitative/partial resistance, is incomplete and polygenically 
controlled by several to many genes with small to moderate effects (Jlibene et al., 1994; 
Zhang et al., 2001; Brown et al., 2015). This type of resistance is isolate independent 
(Chartrain et al., 2004). So far, 21 resistance genes conferring qualitative STB resistance 
were identified and mapped in wheat (Brown et al., 2015). Growing of resistant varieties 
with qualitative resistance, however, led to selection of adapted Z. tritici isolates that were 
able to overcome the resistance (Cowger et al., 2000; reviewed in Brown et al., 2015). 
Consequently, breeding for qualitative resistance traits alone probably does not represent 
an approach for durable STB resistance (Brown et al., 2015). In contrast to this, 
Introduction 9 
 
quantitative/partial resistance is more durable but less studied and harder to breed for 
(Orton et al., 2011). Moreover, breeding for STB resistance was observed to be associated 
with a reduced yield potential of wheat varieties. Therefore, modern breeding strategies aim 
to identify quantitative trait loci for STB resistance that are not associated with yield losses 
(Torriani et al., 2015). Breeding strategies that include numerous partial resistance genes, 
pyramiding of several R genes, mutating susceptibility genes, or combination of all three 
components may represent a more durable approach in STB control (Orton et al., 2011; 
O’Driscoll et al., 2014; Brown et al., 2015). Only a handful of wheat varieties moderately 
resistant to STB are cultivated across the majority of wheat fields in Europe (Fones and 
Gurr, 2015). As STB resistance usually appears as a quantitative trait (reviewed in Brown 
et al., 2015) cultivar resistance alone is often not sufficient to keep disease levels low 
enough at a level that does not impair yield and fungicides also have to be applied 
(Jørgensen et al., 2014; Heick et al., 2017a). It was observed that fungicide applications 
had a positive effect on yield even in cultivars ranked as the most STB resistant (Jørgensen 
et al., 2014). This finding may also be attributed to the fact that disease resistance seldomly 
covers all relevant fungal diseases of wheat and fungicide treatments may have additional 
positive physiological effects on the crop (Bartlett et al., 2002). Nevertheless, it was 
demonstrated that growing resistant cultivars reduced potential yield losses and the 
expected fungicide costs in field trials in Denmark, France, Sweden and UK (Jørgensen et 
al., 2008). Therefore, in order to provide an integrated approach in STB management, 
further breeding and cultivation of disease-resistant and high-yielding cultivars is 
recommended for the future (Jørgensen et al., 2014).   
Another approach in integrated STB management was proposed to be cultivation of cultivar 
mixtures that consist of susceptible and resistant wheat varieties. The utility of cultivar 
mixtures in STB control, however, is discussed controversially. On the one side it was 
shown that compared to their pure stand the severity of STB was reduced in cultivar 
mixtures (Mille et al., 2006; Gigot et al., 2013; Vidal et al., 2017). On the other side, it was 
demonstrated that the ability of cultivar mixtures to reduce disease severity was variable 
between years and influenced by environmental conditions (Cowger and Mundt, 2002). 
Moreover, efficiency in disease control and overall performance of a cultivar mixture cannot 
be predicted based solely on the performance of the single cultivars and little information is 
available how to select cultivars to mix (Finckh and Mundt, 1992; Mille et al., 2006).  
1.3.3 Chemical control of Z. tritici and introduction to fungicides 
Today, as cultural control measures can have negative impact on wheat yields (Jørgensen 
et al., 2014; O’Driscoll et al., 2014) and growing of resistant cultivars does often lead to 
insufficient suppression of the disease, management of Z. tritici still relies to a major extent 
on the application of chemical fungicides (Cools et al., 2013; Heick et al., 2017a; Omrane 
et al., 2017; Kildea et al., 2019). Since more than 200 years fungicides have been applied 
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to plants in order to protect them against- and/or eradicate established fungal infections 
(Brent and Hollomon, 2007a; Oliver and Hewitt, 2014). Due to the application of fungicides, 
diseases can be controlled and the productivity of crop production is increased (Oerke, 
2006).  
Over one century ago, chemical disease control started with the application of basic agents 
such as copper, sulphur and organic mercury. Today, fungicides are a major element in 
crop cultivation and help to protect crop yields and quality (Oerke, 2006; Oliver and Hewitt, 
2014; Lucas et al., 2015). In 2019, around 235 molecules, that belong to several chemical 
classes, exist for fungal disease control (FRAC, 2019). Modern fungicides are characterised 
according to their chemical structure, their mode of action (MOA) and their properties for 
crop protection (Oliver and Hewitt, 2014). Differentiation is made between single-site 
fungicides (single-site MOA) that target a single cellular process and multi-site inhibitors 
(multi-site MOA) that attack a range of cellular processes (Lucas et al., 2015). Moreover, 
fungicides are differentiated between systemic and not systemic fungicides, as well as 
between fungicides with protectant, curative or eradicative activity (Oliver and Hewitt, 2014).  
Non-systemic fungicides are surface-acting molecules with protectant activity, as they are 
not taken up by the plant (Oliver and Hewitt, 2014). A protectant fungicide is applied before 
fungal infections occur and inhibits early stages in the infection process. Multi-site inhibitors 
are often non-systemic fungicides with protectant activity (Oliver and Hewitt, 2014). A 
disadvantage of these fungicides is that their action is limited to treated foliage and they 
need to be used in a preventative approach. Therefore, repeated applications are required 
for complete spray coverage of the target crop during the growing season (Oliver and 
Hewitt, 2014; Hollomon, 2015). In contrast to this, systemic fungicides penetrate the plant 
tissue and are distributed within the entire plant. This feature enables not only protection of 
plant parts that were directly sprayed with fungicides, but additionally other plant parts as 
newly formed tissues are protected (Oerke, 2006). Systemic fungicides often show 
protectant and curative (after infection) activity and act as single-site inhibitors (Brent and 
Hollomon, 2007a, 2007b; Oliver and Hewitt, 2014). Compared to non-systemic fungicides, 
systemic fungicides often provide a longer period of disease control (Oliver and Hewitt, 
2014). Their introduction has enabled a greater flexibility in fungicide application timing and 
displayed the prerequisite for application of disease thresholds and forecast systems 
(Oerke, 2006; Brent and Hollomon, 2007a; Oliver and Hewitt, 2014). Different approaches 
have been developed in STB management based on combinations of variable parameters 
such as the estimate of current disease severity, key weather variables, and crop 
development in order to optimize fungicide usage and to support treatment decisions 
(Hansen et al., 1994; Verreet et al., 2000; Moreau and Maraite, 2000; Milne et al., 2003; 
Newe et al., 2003; Jørgensen et al., 2014, 2017a).  
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Across different European countries, the number of fungicide applications in STB control 
and in winter wheat in general, varies between one to four applications per season with an 
average of two treatments (Jørgensen et al., 2014; Lucas et al., 2015; Heick et al., 2017a; 
Kildea et al., 2019). Thereby, the intensity of fungicide usage does not only differ between 
countries but also within countries (Jørgensen et al., 2014). In their work, Jørgensen et al. 
(2014) compared the pesticide use in winter wheat between Germany, France, the United 
Kingdom and Denmark based on sold amounts of pesticides and national surveys from 
2006 and 2007. Their results revealed that usage of fungicides in Denmark is much lower 
compared to the other countries. A marked difference in the fungicide usage between 
Northern France and Southern France was observed with a lower treatment frequency in 
the South. Compared to France, fungicide usage in Germany was higher, but overall, the 
highest fungicide usage was observed in UK. These differences may be explained due to 
different disease severities, diverse climatic conditions, differences in the attitude for 
economic optimization, different operating policy plans that aim to reduce pesticide use, 
diverse organisation of advice to farmers, and variable pesticide prices (Jørgensen et al., 
2014). 
Currently, four classes of fungicides are mainly used in management of STB. These consist 
of multi-site fungicides such as chlorothalonil and the single-site classes of the C-14 
demethylation inhibitors (DMIs), the quinone outside inhibitors (QoIs) and the succinate 
dehydrogenase inhibitors (SDHIs) (Jørgensen et al., 2018; Heick et al., 2017a; Kildea et al., 
2019).  
The multi-site inhibitor chlorothalonil forms chlorothalonil-reduced glutathione derivates in 
cells. As enzyme activity and cell viability is supposed to be controlled by the glutathione 
concentration in cells, the loss of glutathione by derivate formation with chlorothalonil and 
the lack of regeneration of the reduced thiol could explain its fungicidal activity (Tillman et 
al., 1973). Chlorothalonil was introduced in the mid-1960s, mainly for the control of Septoria 
spp. in cereals, Phytophthora infestans in potatoes and Botrytis spp. in vegetables as well 
as ornamentals. Chlorothalonil is an important and widely used mixing partner for QoI, DMI, 
and SDHI fungicides. Mixtures of chlorothalonil with single-site fungicides should protect 
the latter ones against fungicide resistance (Oliver and Hewitt, 2014). Nevertheless, due to 
revocation of its registration (European Commission, 2019), chlorothalonil will be removed 
for the European market by the season 2021. 
The QoIs, commonly named strobilurins, inhibit the electron transport chain in complex III 
(bc1 complex) of mitochondrial respiration (Becker et al., 1981) and first launches were in 
1996 for control of cereal diseases (Ypema and Gold, 1999; Bartlett et al., 2002). QoIs show 
a broad spectrum of activity against several fungal pathogens from the ascomycetes, 
basidiomycetes and oomycetes. On the other side, they have no or low effects on non-
target organisms, low acute toxicity to animals and are rapidly degraded in soil resulting in 
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a beneficial environmental profile (Oliver and Hewitt, 2014; Lucas et al., 2015). The two first 
synthetic QoIs were kresoxim-methyl and azoxystrobin (Ammermann et al., 1992; Godwin 
et al., 1992; Sauter et al., 1999) which were followed by several other QoIs, for example, 
pyraclostrobin, trifloxystrobin, and picoxystrobin (Bartlett et al., 2002).  
SDHIs inhibit the succinate dehydrogenase (SDH, also known as complex II), a relevant 
enzyme of the citric acid cycle and the mitochondrial respiratory chain (Hägerhäll, 1997). 
Inhibition of SDH results in energy deficiency and in release of active oxygen that explain 
the fungicidal activity of SDHIs (Oliver and Hewitt, 2014). In 1966, the first SDHIs, 
oxycarboxin and carboxin were released (von Schmeling and Kulka, 1966; Oliver and 
Hewitt, 2014). Several SDHIs followed between the 1970s and the end of the 1990s, but 
their activity was limited to basidiomycetes (Glättli et al., 2011). In 2002, due to further 
structural changes, boscalid, the first SDHI with a broad range of activity against fungal 
pathogens of the basidiomycota and ascomycota, was released (Stammler et al., 2007, 
2008a; Glättli et al., 2011). The launch of boscalid initiated the release of a series of new 
SDHI compounds by several agrochemical companies including for example the 
compounds bixafen, fluopyram, fluxapyroxad, isopyrazam, benzovindiflupyr and 
penthiopyrad (Glättli et al., 2011; Stammler et al., 2015). The relevance of SDHIs in crop 
protection increased quickly making them rank with QoIs and DMIs in importance and 
market share (Oliver and Hewitt, 2014; Torriani et al., 2015).  
DMIs belong to the fungicide class of the sterol biosynthesis inhibitors (SBIs). The SBI 
fungicide class consists of four sub-groups that all inhibit different target enzymes in the 
sterol biosynthesis pathway. These sub-groups are represented by the DMIs, the amines, 
the keto-reductase inhibitors, and the squalene-epoxidase inhibitors of which the latter ones 
are not used commercially in agriculture. The DMI group shows the largest number of 
fungicidal compounds and the broadest spectrum of activity across all SBI groups (FRAC, 
2019). DMIs have been the most widely used fungicides in the management of STB in the 
last decades (Parker et al., 2011; Cools and Fraaije, 2013). As DMIs are the investigated 
fungicide class in the present work, their mode of action and other properties are introduced 
in more detail in the following chapter.  
1.3.4 Demethylation inhibitors (DMIs) 
The first DMIs were introduced around the 1970s and 40 DMI compounds followed until 
2015 (Ziogas and Malandrakis, 2015). DMIs show a broad spectrum of activity against a 
range of economically important plant pathogenic ascomycetes and basidiomycetes on 
arable crops, viticulture, and plantation crops. An exception is represented by oomycetes 
pathogens because they do not have an ergosterol biosynthesis pathway (Oliver and 
Hewitt, 2014; FRAC, 2019). DMIs belong to several chemical groups, consisting of 
piperazines, pyridines, pyrimidines, imidazoles, triazoles, and triazolinthiones. A few 
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pyrimidines (e.g. fenarimol) and imidazoles (e.g. prochloraz) have gained market relevance 
in agriculture. The triazole group, however, is commercially the most important and consists 
of the highest number of compounds across all DMIs (Oliver and Hewitt, 2014; FRAC, 
2019). The present work focuses on compounds of the triazole group.  
Within the triazole group, marked relevant fungicides are represented by epoxiconazole 
(BASF SE), cyproconazole (formerly Sandoz, today Syngenta), triadimenol (Bayer), 
tebuconazole (Bayer), propiconazole (Janssen Pharmaceutica), and the triazolinthione 
prothioconazole (Bayer) (Oliver and Hewitt, 2014). In 2019, a new DMI, mefentrifluconazole 
(BASF SE), was registered and became available on the European market in 2020. As 
shown in Figure 3, the molecular structure of the triazoles is characterised by a nitrogen 
containing heterocycle with a lipophilic moiety (Mercer, 1993; Lamb et al., 1999). The 
structure of the azole theme of the triazolinthione, prothioconazole is different compared to 
the triazoles and shows a thio-group in the nitrogen-heterocycle. This thio-group, however, 
is lost during the activation process of the compound after exposure to plants (Oliver and 
Hewitt, 2014).  
 
Figure 3: Chemical structure of important triazoles and prothioconazole, a triazolinthione. 
Figure was extracted and modified from Oliver and Hewitt, 2014. 
The target of DMI fungicides is the sterol 14α-demethylase (CYP51 enzyme), a cytochrome 
P450 monooxygenase catalysing the removal of the C14-methyl group from 24-
methylendihydrolanosterol (eburicol) in ergosterol biosynthesis pathway (Figure 4) 
(Yoshida and Aoyama, 1984, 1987; Gadher et al., 1983; Bossche et al., 1984; Oliver and 
Hewitt, 2014). The CYP51 enzyme is suggested to be a membrane bound protein localised 
in the endoplasmatic reticulum in close association with a flavoprotein (NADPH) that is 
necessary for the electron transfer in sterol 14-demethylation (Mercer, 1993; Parker et al., 
2011; Kelly and Kelly, 2013). Inhibition of sterol 14-demethylation results in the 
accumulation of precursor sterols and in reduced ergosterol synthesis (Yoshida and 
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Aoyama, 1984, 1987; Baldwin, 1983, 1990; Gadher et al., 1983; Baloch et al., 1984; Kelly 
et al., 1995; Lamb et al., 1996). Ergosterol is the major sterol in fungi and serves as an 
important structural component in the architecture of cell membranes (Siegel, 1981; Mercer, 
1993). Therefore, reduced ergosterol availability and the accumulation of precursor sterols 
lead to membrane disfunction (Siegel, 1981; Lamb et al., 1999; Becher and Wirsel, 2012; 
Oliver and Hewitt, 2014). Incorporation of precursor sterols was shown to result in 
decreased rigidity and increased fluidity of the plasma membrane (Abe et al., 2009). 
Furthermore, it is proposed that 14-methylated intermediates are toxic, and accumulation 
may also be responsible for growth inhibition (Kelly et al., 1995; Akins, 2005).  
The number of CYP51 genes within different fungal species was observed to vary between 
one, two or even three genes that encode CYP51 proteins falling into three different clades 
named CYP51A, CYP51B and CYP51C (Becher et al., 2011; Becher and Wirsel, 2012). 
CYP51A and CYP51B were identified, for example, in species of Magnaporthe, 
Pyrenophora, Penicillium, and Fusarium. Some species show only one CYP51A and one 
CYP51B protein, however, also others exist that show an additional duplication of CYP51A 
or CYP51B (Becher et al., 2011; Becher and Wirsel, 2012; Fan et al., 2013). The CYP51C 
clade was only detected in species of Fusarium that show three CYP51 genes falling into 
all three clades (Becher et al., 2011). Z. tritici carries a single MgCYP51 gene (hereafter 
referred to as CYP51) falling into clade CYP51B (Becher and Wirsel, 2012; Lucas et al., 
2015).  
 
Figure 4: Part of the ergosterol biosynthesis pathway in fungi. Picture was extracted from Kuck 
et al., 2012 (modified). The first five reactions of ergosterol biosynthesis pathway and enzymes 
involved in these reactions are shown.  
DMIs show protective as well as curative activity in control of Z. tritici (Jørgensen et al., 
2018). As MgCYP51 from Z. tritici (hereafter referred to as CYP51) has not been crystallised 
so far, homology models based on the crystal structure of other organisms are used to 
Introduction 15 
 
investigate the CYP51 protein structure and binding of triazoles in Z. tritici. It is expected 
that CYP51 of Z. tritici forms a typical P450 fold with a usually conserved structural core 
around the prosthetic haem group in the active site of the protein (Mullins et al., 2011). DMIs 
bind to CYP51 through direct interaction with the prosthetic haem group. Within this 
interaction the nitrogen atom (N-4) of the triazole ring forms a sixth ligand with the haem 
and the lipophilic moiety of N-1 binds to the amino acid tertiary structure of the active site 
and substrate channel (Jefcoate, 1978; Bossche et al., 1984; Lamb et al., 2003). The latter 
interaction probably explains differences in inhibition of CYP51 by different DMIs and their 
selectivity for different organisms (Mercer, 1993). The triazolinthione, prothioconazole, is 
suggested to bind not through direct coordination to the haem (Parker et al., 2011). 
However, the observed effectiveness of prothioconazole in vivo cannot be explained by 
inhibition that is expected from binding characteristics. Therefore, it is suggested that 
metabolization of prothioconazole to the desthio metabolite, a triazole, in planta and/or in 
vivo in the fungus may be necessary for the antifungal activity (Parker et al., 2011; Fraaije 
et al., 2012; Parker et al., 2013). Further studies, however, are needed to explore these 
hypotheses (Parker et al., 2011, 2013).  
1.4 Fungicide resistance  
Evolution is an ongoing process in all organisms comprising the ability of all species to 
evolve continuously in order to adapt to changes in their environment (Seidl and Thomma, 
2014). In crop cultivation fungicides are part of this environment and exert selection 
pressure on fungal populations, hence forcing them to evolve mechanisms to overcome the 
lethal effects of a fungicide treatment (Hollomon, 2015; Lucas et al., 2015). An acquired, 
stable and heritable genetic alteration that enables a fungus to overcome harmful effects of 
a fungicide is defined as fungicide resistance (Delp and Dekker, 1985).  
In fungal pathogens, four mechanisms have been documented that may confer fungicide 
resistance. These mechanisms include the alteration of the target site of the fungicide, the 
overexpression of the target site, the exclusion of the fungicide from the cell and, in rare 
cases, detoxification of the fungicide (Oliver and Hewitt, 2014; Lucas et al., 2015; reviewed 
FRAC, 2019).  
In phytopathogenic fungi the most common resistance mechanism is the alteration of the 
target site due to mutations in the encoding genes (Ma and Michailides, 2005; Brent and 
Hollomon, 2007a; Jørgensen et al., 2019). Random mutations in the genome occur in all 
living organisms in a low natural rate (Ma and Michailides, 2005; Brent and Hollomon, 
2007a). These mutations can result in changes of the amino acid sequence and 
consequently in an altered shape of the target protein that reduces the binding affinity of a 
fungicide (Brent and Hollomon, 2007a; FRAC, 2019). Alteration of the target site often 
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results in cross-resistance between fungicides of the same MOA group but not exclusively 
(Oliver and Hewitt, 2014). Compared to the sensitive population a resistant individual has a 
competitive advantage under fungicide application (van den Bosch et al., 2014; Oliver and 
Hewitt, 2014). Whereas application of the fungicide removes the majority of the sensitive 
population, the resistant mutant is selected and may become dominant under continued 
selection pressure of the fungicide (Ma and Michailides, 2005; Brent and Hollomon, 2007a; 
Oliver and Hewitt, 2014; Lucas et al., 2015). In the absence of fungicide application, the 
fitness of resistant individuals determines their persistence in a fungal population. Target 
site alterations are often associated with a reduced fitness in resistant individuals compared 
to the sensitive population. If a so-called fitness penalty/fitness cost exists, the frequency of 
resistant individuals may decrease in the absence of fungicide selection pressure (Ma and 
Michailides, 2005; Oliver and Hewitt, 2014; Ishii, 2015).  
The second known resistance mechanism is the overexpression of the target enzyme based 
on the upregulation of the encoding gene (Lucas et al., 2015; FRAC, 2019). A higher 
number of target enzymes may increase the likelihood of an interaction with the natural 
substrates. Consequently, cellular processes can occur to some degree despite the 
presence of a fungicide (FRAC, 2019). In phytopathogenic fungi, overexpression of the 
target enzyme is not a widespread mechanism. Nevertheless, it was reported in some cases 
(Lucas et al., 2015). CYP51 overexpression was detected for example in Penicillium 
digitatum, Venturia inaequalis and in Z. tritici (Hamamoto et al., 2000; Schnabel and Jones, 
2001; Cools et al., 2012).  
Increased active efflux by membrane bound transporters, in literature commonly referred to 
as multidrug resistance (MDR), was shown to be the third mechanism contributing to 
fungicide resistance (de Waard et al., 2006; Coleman and Mylonakis, 2009; Hahn and 
Leroch, 2015). Thereby, overexpression of ABC- or MFS-type multidrug transporters confer 
an increased efflux activity that prevents the accumulation of toxic fungicide concentrations 
at the target site inside fungal cells (de Waard et al., 2006; Hahn and Leroch, 2015). MDR 
is well known from bacteria as well as from human cancer cells and was described for 
human fungal pathogens such as Candida albicans and C. glabrata (Grkovic et al., 2002; 
Morschhäuser, 2010; Wu et al., 2014). So far, the importance of increased efflux activity in 
plant pathogenic fungi is still under evaluation (Omrane et al., 2015; Jørgensen et al., 2019) 
and differently discussed. 
The fourth known resistance mechanism is the detoxification of fungicides based on 
metabolic enzymes as glutathione transferases, esterases or cytochrome P450s (Jabs et 
al., 2001; Leroux et al., 2002; Lucas et al., 2015; Sevastos et al., 2017). Enhanced 
metabolism conferring detoxification of pesticides is a widespread mechanism in herbicide 
resistance of weeds (Yu and Powles, 2014) and in insecticide resistance of insects (Li et 
al., 2007). In contrast to this, metabolization of fungicides is rare in fungi (Oliver and Hewitt, 
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2014; Lucas et al., 2015) and was only reported in a few species for example in 
V. inaequalis (Jabs et al., 2001), Botrytis cinerea (Leroux et al., 2002), and 
Fusarium graminearum (Sevastos et al., 2017). 
In literature, two patterns of fungicide resistance emergence are described, ‘qualitative’ 
(also named ‘single-step’ or ‘disruptive’) resistance and ‘quantitative’ (also named ‘multi-
step’ or ‘continuous’) resistance (Brent and Hollomon, 2007a). ‘Qualitative’ resistance is 
often accompanied by a sudden, considerable loss of fungicide efficacy and the emergence 
of a clearly distinguishable sensitive and resistant population. This resistance pattern is 
mainly caused by single mutations in major genes and therefore controlled monogenically 
(Brent and Hollomon, 2007a; de Miccolis Angelini et al., 2015). Development of QoI 
resistance in several pathogens based on the single amino acid alteration G143A in CYTB 
is an example of ‘qualitative’ resistance emergence (Gisi et al., 2002; Fraaije et al., 2002, 
2005; Lesniak et al., 2011). ‘Quantitative’ resistance is characterised through a slow, 
gradual and continuous shift of a sensitive fungal population towards increased resistance 
levels. Usually, this resistance pattern relies on mutations in several genes (polygenic) with 
a low individual effect on the phenotype (minor genes). Additionally, accumulation of several 
mutations within a single target-site encoding gene was reported (polyallelic). Additive 
effects of multiple mutated minor genes or mutations within a single gene can result in an 
increased and varying level of resistance and consequently in a gradual emergence of 
resistance. As a result, a continuous range of sensitivity across adapted sub-populations is 
observed (Sanglard et al., 1998; Brent and Hollomon, 2007a; Cools and Fraaije, 2008; de 
Miccolis Angelini et al., 2015). Quantitative resistance emergence was described for 
example for ethirimol resistance in B. graminis (Hollomon, 1981) and for DMI resistance in 
Z. tritici (Stergiopoulos et al., 2003; Cools et al., 2005; Cools and Fraaije, 2008).  
The risk of fungicide resistance development is influenced by the biology of the pathogen, 
the chemical factors of the fungicide and the agricultural measures (treatment measures) 
(Brent and Hollomon, 2007a; Hollomon, 2015). For example, pathogens with a short life 
cycle, high spore production, a sexual stage and rapid, long-distance dispersal of spores 
are more prone to emergence of fungicide resistance than pathogens without these 
properties (Brent and Hollomon, 2007a, 2007b). The fungicide associated risk is affected 
by the chemical class of the fungicide, the mode of action, and properties of action. Systemic 
fungicides with a single target site show a higher risk for resistance development compared 
to non-systemic fungicides and fungicides with multi-site action (Brent and Hollomon, 
2007b; Oliver and Hewitt, 2014; Hollomon, 2015). Single-site fungicides have one 
biochemical target. Hence, a single gene mutation can rapidly lead to resistance. In 
contrast, multi-site inhibitors target multiple biochemical processes and a combination of 
several mutations would be required for resistance. Therefore, resistance emergence for 
multi-sites is generally much slower and less likely (Hollomon, 2015). The pathogen and 
fungicide associated risk are inherent and mostly out of the growers control, however, the 
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treatment measures can vary and can be adjusted to reduce the risk of resistance 
development (Brent and Hollomon, 2007a, 2007b; Hollomon, 2015). In general, the risk can 
be reduced by reducing the fungicides use and by employing cultural measures or 
appropriate choice of cultivars that do not favour disease development. Additionally, 
frequency and dose of a fungicide application as well as the agricultural system (protected 
or arable cropping) can affect development of fungicide resistance (Brent and Hollomon, 
2007a, 2007b; Grimmer et al., 2015).  
Since the 1970s, occurrence of fungicide resistance has increased and has become an 
important issue in a broad range of phytopathogenic fungi associated with the introduction 
and widespread use of fungicides with specific MOAs (Brent, 2012; Lucas et al., 2015). As 
a result, in 1981 the Fungicide Resistance Action Committee (FRAC), an industry run group 
of specialists from agrochemical manufacturers, was founded. In this organisation 
resistance issues are discussed, and fungicide resistance management guidelines are 
published annually. These guidelines provide information for various crops and pathogens 
about how to apply fungicides and at the same time maintain a good anti-resistance 
management (FRAC, 2019). Strategies of anti-resistance management will be discussed at 
a later point in the present work.  
1.4.1 Resistance to demethylation inhibitors in phytopathogenic 
fungi  
In many fungal plant pathogens, resistance to DMIs evolved gradually and slowly over the 
last 20 years (Oliver and Hewitt, 2014) based on emergence of different resistance 
mechanisms. In several pathogens single target-site alterations within CYP51 and/or the 
accumulation of different alterations was shown to be responsible for DMI adaptation (Délye 
et al., 1997; Wyand and Brown, 2005; Cools and Fraaije, 2008; Stammler et al., 2008b; 
Rehfus et al., 2019). Interestingly, some alterations could be detected at homologous 
positions across different plant pathogenic fungi and human pathogens, for example, Y137F 
in Z. tritici that was also identified at homologous positions in Erysiphe necator; Phakopsora 
pachyrhizi, B. graminis and C. albicans. Instead, others occurred solely in one species or 
genus (Becher and Wirsel, 2012; Schmitz et al., 2014; Mair et al., 2016). In contrast to most 
target site alterations that confer resistance against single-site fungicides of other MOAs, 
mutations in CYP51 often affect only sensitivity to a specific or a limited group of DMIs. 
Therefore, they confer only incomplete cross-resistance across all DMI fungicides 
(Stammler et al., 2008b; Cools et al., 2013; Ziogas and Malandrakis, 2015).  
The second mechanism contributing to DMI resistance is the overexpression of CYP51. 
This phenomenon was detected in different plant pathogens for example V. inaequalis 
(Schnabel and Jones, 2001), Cercospora beticola (Bolton et al., 2012), P. triticina 
(Stammler et al., 2009), P. pachyrhizi (Schmitz et al., 2014) and Z. tritici (Cools et al., 2012). 
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CYP51 overexpression is often based on alterations (e.g. insertions) in the predicted 
regulatory region of the CYP51 gene (Schnabel and Jones, 2001; Cools et al., 2012; 
reviewed in Cools et al., 2013). This mechanism was shown to confer lower resistance 
levels than CYP51 target site alterations in many pathogens, however, affects sensitivity to 
all DMIs (reviewed in Cools et al., 2013).  
The third mechanism affecting DMI resistance is an enhanced efflux activity. Whereas this 
mechanism is well established in human pathogens, its importance remains less clear in 
plant pathogens (Morschhäuser, 2010; Cools et al., 2013). So far, in plant pathogens it has 
only been described for example in B. cinerea (Kretschmer et al., 2009), 
Oculimacula yallundae (Leroux et al., 2013) and Z. tritici (Stammler and Semar, 2011; 
Leroux and Walker, 2011; Omrane et al., 2015). Overexpression of ABC- or MFS-type 
multidrug transporters conferring an increased efflux activity (de Waard et al., 2006; Hahn 
and Leroch, 2015) was shown to rely on mutations in transcription factors or on insertions 
in the promotor region regulating the expression of transporter genes (Coste et al., 2006; 
Kretschmer et al., 2009; Omrane et al., 2015, 2017). Compared to the relatively high 
fungicide resistance levels conferred by target site mutations, MDR confers low to medium 
resistance levels (Hahn and Leroch, 2015).  
The presence of several CYP51 paralogues may be advantageous under DMI selection 
pressure as costs of changes in the enzyme structure or an increased gene expression may 
be compensated by the presence of an unchanged CYP51 paralogue (Cools et al., 2013). 
Nevertheless, solely a few studies exist about the function of multiple CYP51 paralogues 
and further research is necessary to elucidate this topic (Ziogas and Malandrakis, 2015).  
Despite a long-term and widespread use of DMIs, control failures of these fungicides are 
rare in the field (Cools et al., 2013). The time period until fungicide resistance was detected 
after the market launch of DMI fungicides varied for several pathogens. For example, 
compared to other pathogens, emergence of DMI resistance was relatively fast in 
B. graminis f. sp. graminis and O. yallundae where the first detection of resistance was only 
3 to 5 years after introduction. In many other pathogens, for example, in B. graminis f. 
sp. tritici, Z. tritici, V. inaequalis, and P. triticina, the first detection of resistance took a lot 
longer, with up to 10 years or more after introduction (Stanis and Jones, 1985; reviewed in 
Jørgensen et al., 2019). The occurrence of resistant strains does not necessarily result in 
field failure of fungicides as the resistance levels are often low and incomplete cross-
resistance across DMIs can exist (Stammler et al., 2008b; Cools et al., 2013). Nevertheless, 
the continued intensive use of DMIs has led to the development of resistance levels that 
can now reach more critical levels in some regions accompanied with marked reduction in 




1.4.2 Fungicide resistance in Z. tritici  
The pathogen associated risk for the development of fungicide resistance in Z. tritici is 
classified as being medium (Brent and Hollomon, 2007b). For all three single-site fungicide 
classes mainly used in the control of STB (QoIs, SDHIs, DMIs) resistant isolates can be 
detected in the field, however their frequencies and distribution vary across Europe (Fraaije 
et al., 2005; Lucas and Fraaije, 2008; Cools and Fraaije, 2013; Rehfus, 2018; FRAC, 2019).  
Resistance of Z. tritici to QoI fungicides occurred soon after their introduction and was 
shown to rely on the alteration G143A in CYTB leading to high resistance levels against 
QoIs (Gisi et al., 2002; Fraaije et al., 2005). A rapid increase in the frequency of isolates 
carrying the G143A was observed even two seasons after its initial retrospective detection 
in 2001 in UK (Fraaije et al., 2005). Already in 2006, more than 90% of STB isolates in 
Northwest Europe carried alteration G143A (Jørgensen et al., 2019) making QoIs inefficient 
in the control of Z. tritici in these regions (Lucas and Fraaije, 2008).  
The first SDHI resistant Z. tritici isolates were detected in 2012 (FRAC, 2019). SDHI 
resistance is based on different SDH alterations, for example, B-N225I, B-T268I/A, C-T79N, 
C-N86S, C-W80S, and C-H152R. It was observed that some alterations confer high 
resistance levels, whereas others only lead to a lower resistance level in vitro and in planta 
(Rehfus, 2018; FRAC, 2019). In 2018, frequency of isolates with low resistance levels 
increased in Northern Germany, Ireland, the Netherlands, and the United Kingdom (UK) 
with alterations C-T79N and C-N86S being the most frequent ones. A low frequency of 
isolates with low resistance factors were found in other countries. The overall frequency of 
isolates showing moderate resistance factors (C-H152R) was low. So far, no reduced field 
performance of SDHIs is reported (FRAC, 2019).  
The first isolates with a reduced DMI sensitivity were identified in a time period from 1993 
to 2002 by Mavroeidi and Shaw (2005). Since then a gradual shift in the sensitivity of Z. tritici 
populations towards a reduced DMI sensitivity was observed for DMIs currently on the 
European market (Fraaije et al., 2007; Cools et al., 2011; Lucas et al., 2015). Until 2008, no 
reduced field performance of DMIs in control of Z. tritici was reported, although different 
CYP51 haplotypes were detected in field populations and a shift towards a reduced DMI 
sensitivity was measured in vitro. Nevertheless, a decline in the field efficacy of DMIs was 
observed in recent years, however, with varying levels of DMI efficacy across different DMIs 
and countries of Europe (Clark, 2006; Heick et al., 2017a; Jørgensen et al., 2017b; Strobel 
et al., 2017; Blake et al., 2018; Jørgensen et al., 2018). The underlying resistance 
mechanisms were observed to be complex and diverse (Cools and Fraaije, 2013; Leroux 
and Walker, 2011) and will be deciphered in the next chapter.  
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1.4.3 DMI resistance mechanisms in Z. tritici  
All three resistance mechanisms known to confer reduced DMI sensitivity in several plant 
pathogens (described in chapter 1.4.1) were identified in Z. tritici. The most common 
mechanism is the alteration of CYP51 (Cools and Fraaije, 2013; Cools et al., 2013). 
Additionally, CYP51 overexpression and an increased efflux through overexpression of 
membrane bound transporters was shown to reduce DMI sensitivity of Z. tritici (Leroux and 
Walker, 2011; Cools et al., 2012; Omrane et al., 2015).  
So far, more than 30 alterations in CYP51 based on mutations and deletions in the CYP51 
gene have been described (Cools and Fraaije, 2013). These alterations were observed to 
accumulate and to occur in several combinations resulting in distinct CYP51 haplotypes 
(Brunner et al., 2008; Cools and Fraaije, 2013). A heterogenous frequency of CYP51 
alterations was observed over time and across Europe (Leroux et al., 2007; Brunner et al., 
2008; Stammler et al., 2008b; Stammler and Semar, 2011). Brunner et al. (2008) suggested 
that new CYP51 mutations and new combinations of mutations conferring increasing DMI 
adaptation arose locally in North-West Europe either through de novo mutations or through 
intragenic recombination. Subsequently, they were spread eastwards through wind-
dispersed ascospores (Brunner et al., 2008). Alterations L50S, D134G, V136A/C, S188N, 
A379G, I381V, Y459D, Y461N, N513K, and S524T as well as deletion of Y459 and G460 
were most commonly found in modern European Z. tritici populations (Stammler et al., 
2008b; Cools and Fraaije, 2013). As most of these alterations occur in combination, it is 
difficult to assess their individual effect on triazole sensitivity and CYP51 enzyme activity 
(Lucas et al., 2015). Nevertheless, heterologous expression of ScCYP51 mutations in a 
Saccharomyces cerevisiae mutant and comparison of the sensitivity of resistant phenotypes 
only differing in specific CYP51 alterations allowed the characterisation of individual 
mutations (Fraaije et al., 2007; Leroux et al., 2007; Cools et al., 2010, 2011; Leroux and 
Walker, 2011). It was observed that some alterations such as L50S, S188N, and N513K 
confer no effect on DMI sensitivity (Leroux et al., 2007; Cools and Fraaije, 2013), whereas 
alterations V136A, I381V, S524T and alterations or deletions at positions 459-461 result in 
a decreased sensitivity to DMIs (Fraaije et al., 2007; Leroux et al., 2007; Cools et al., 2010, 
2011; Leroux and Walker, 2011; Cools and Fraaije, 2013). Some of the CYP51 alterations 
have contrasting effects on sensitivity to different DMIs and lead to CYP51 haplotypes 
showing incomplete cross-resistance between different DMIs (Leroux et al., 2007; Fraaije 
et al., 2007; Cools et al., 2011). Alteration V136A, for example, causes a reduced sensitivity 
to epoxiconazole, prothioconazole, prochloraz, and propiconazole, whereas sensitivity to 
tebuconazole, triadimenol, and difenoconazole remains high (Cools et al., 2011; Leroux and 
Walker, 2011; Lucas et al., 2015). In contrast to this, alteration I381V affects sensitivity to 
most triazoles, especially tebuconazole, whereas sensitivity to prochloraz is increased 
(Fraaije et al., 2007; Leroux et al., 2007). It is suggested that the Z. tritici population is able 
to continuously adapt to changing patterns of fungicide use based on the fact that resistance 
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first evolved for older DMIs as triadimenol and tebuconazole and afterwards for each newly 
introduced DMI. This circumstance has led to the emergence of increasingly complex 
CYP51 haplotypes based on the accumulation of additional alterations in CYP51 (Cools 
and Fraaije, 2013; Lucas et al., 2015; Jørgensen et al., 2019). Emergence of alteration 
S524T (Stammler et al., 2008b) is the latest confirmation of this assumption as this alteration 
is now often found in CYP51 haplotypes that show increased adaptation to the two currently 
most effective and widely used triazoles epoxiconazole and prothioconazole (Cools et al., 
2011; Lucas et al., 2015).  
Different approaches were used to classify CYP51 haplotypes, among them the most 
commonly used R-type system that categorises different CYP51 haplotypes into triazole 
resistant types (‘tri R-types’) and additionally follows the putative evolution of CYP51 
(Leroux et al., 2007; Leroux and Walker, 2011). This R-type system has been a valid tool in 
the past, however, has not been updated recently, whereas increasingly complex CYP51 
haplotypes continued to occur (Stammler and Semar, 2011; Cools and Fraaije, 2013; 
Buitrago et al., 2014). To date, many CYP51 haplotypes without a R-type description exist. 
Due to the accumulation of several alterations in CYP51, it is no longer a convenient 
approach to describe resistant isolates simply by listing of all alterations as it has been done 
for other pathogens. Therefore, a new approach to describe CYP51 haplotypes was 
developed in the course of the present work.  
The second mechanism contributing to DMI resistance in Z. tritici is the overexpression of 
CYP51 (Stergiopoulos et al., 2003; Cools et al., 2012). A constitutive 10- to 40- fold CYP51 
overexpression was observed in isolates which showed a 7- to 16-fold reduction in DMI 
sensitivity in vitro (Cools et al., 2012). As CYP51 overexpression is known to rely in many 
cases on alterations (e.g. insertions) in the predicted regulatory region (Schnabel and 
Jones, 2001; Cools et al., 2012, 2013), the MgCYP51 promotor region (hereafter referred 
to as CYP51p) was investigated for Z. tritici (Chassot et al., 2008; Cools et al., 2012; 
Omrane et al., 2015). A high polymorphism in CYP51p and prevalence of small inserts (8 
to 30 bp) were identified across field isolates of Z. tritici (Omrane et al., 2015). Nevertheless, 
overexpression of CYP51 could only be correlated to a 120 bp insert in CYP51p of Z. tritici 
(Cools et al., 2012). Another CYP51p insert of around 1000 bp was identified in isolates 
showing a reduced DMI sensitivity compared to isolates with the same CYP51 haplotype 
without a CYP51p insert (Chassot et al., 2008). However, more recent studies revealed that 
the precise size of this insert is either 862 bp or 866 bp and that these two inserts have no, 
or at least not a standalone, distinct impact on CYP51 expression (Omrane et al., 2015; 
Kildea et al., 2019). In contrast to CYP51 alterations that can affect several DMIs differently, 
CYP51 overexpression affects sensitivity to all DMIs (complete cross-resistance) (Cools et 
al., 2012; Cools and Fraaije, 2013).  
Introduction 23 
 
The third mechanism contributing to DMI resistance of Z. tritici is an increased active efflux 
of membrane bound transporters. This assumption was made after the detection of Z. tritici 
isolates that showed a reduced sensitivity to triazoles (cross-resistance) and simultaneously 
to some unrelated compounds as tolnaftate and terbinafine as well as to some SDHIs 
(Leroux and Walker, 2011). Although several transporter genes were identified to be 
overexpressed in isolates which showed cross-resistance between unrelated compounds, 
the overexpression of the MgMFS1 transporter (hereafter referred to as MFS1 transporter) 
was strongest indicating that this transporter plays a major role in increased efflux activity 
of Z. tritici (Omrane et al., 2015, 2017). As observed for CYP51p, a high polymorphism in 
the MgMFS1 promotor region (hereafter referred to as MFS1p), including small insertions 
between 1 to 29 bp, was observed in isolates expected to exert increased efflux (Omrane 
et al., 2015). However, constitutive overexpression of the MgMFS1 gene (hereafter referred 
to as MFS1 gene) was shown to rely on different larger insertions in MFS1p, namely a 150, 
338, 369, and 519 bp insert (Omrane et al., 2015, 2017). Based on their results, Omrane et 
al. (2017) proposed a classification for different MFS1p inserts. The 519 bp insert was 
labelled as type I insert, the 338 and 369 bp inserts were labelled as type II, and the 150 bp 
insert was labelled as type III. The 519 bp insert is associated with the highest MFS1 
overexpression, whereas type II and type III inserts confer significantly lower MFS1 
overexpression compared to isolates with the 519 bp insert (Omrane et al., 2015, 2017). 
Research into the frequency and distribution of MFS1p inserts across European Z. tritici 
populations and knowledge about the effect of an increased efflux on DMI sensitivity is in 
its infancy.  
In this work, CYP51 genes and CYP51p or MFS1p regions of pathogens other than Z. tritici 




2 Objectives  
Fungicide resistance monitoring and characterisation of resistance mechanisms is essential 
for the establishment of anti-resistance management strategies, thereby ensuring the 
sustainable use of fungicides in the European market. A shift in DMI sensitivity of Z. tritici 
has been reported over many years associated with the emergence and combination of 
CYP51 alterations. Distinct CYP51 haplotypes developed and occurred over time and 
space in Europe. More recently, it has been shown that CYP51 overexpression and an 
increased efflux activity additionally affect DMI sensitivity in Z. tritici. In this study, isolates 
from the European DMI sensitivity monitoring of 2016 and 2017 were analysed. The aim 
was to identify the frequency of different DMI resistance mechanisms in Z. tritici across 
Europe and to characterise their effect on DMI adaptation. Therefore, the following topics 
were investigated and discussed in this work:  
• Detection of CYP51 haplotypes, CYP51 overexpression and an increased efflux 
activity in Z. tritici  
• Development of a new nomenclature for labelling CYP51 haplotypes 
• Determination of the effect on DMI sensitivity associated with new CYP51 alterations  
• In vitro sensitivity evaluation of isolates carrying different DMI resistance 
mechanisms  
• Detection of the frequency and distribution of different DMI resistance mechanisms 
across Europe  
• Analysis of cross-resistance between different DMIs 
• In vivo sensitivity evaluation of isolates carrying different DMI resistance 
mechanisms  
• Estimation about further evolution and spread of different DMI resistance 
mechanisms  
• Discussion of consequences for efficacy of DMIs in the field and implication for 
future DMI field performance  
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3 Material and Methods 
3.1 Technical equipment 
In Table 1, technical equipment used during the present study is listed. Devices such as 
centrifuges, incubators, thermomixer and pipettes, typically used in laboratories are not 
included.  
Table 1: Technical equipment used. 
Equipment Company 
Airbrush (nozzle size 0.8 mm), 
SATAminijet® 3000 B HVLP 
SATA GmbH & Co. KG, Kornwestheim, DE  
Analytical balance, MC 410S  Sartorius AG, Göttingen, DE 
Application chamber SPK08 (applying 
400 L/ha) 
BASF SE, Ludwigshafen, DE 
Blue light transillumination, UVT-28 BE Herolab GmbH Laborgeräte, Wiesloch, DE 
Gel documentation system, EasyDoc 
plus 
Herolab GmbH Laborgeräte, Wiesloch, DE 
Gel electrophoresis, Sub-Cell GT Basic 
System  
Bio-Rad Laboratories Inc., Hercules, US 
Inoculation station  BASF SE, Ludwigshafen, DE 
KNF Laboport® vacuum pump KNF Neuberger GmbH, Freiburg, DE 
Macherey-NagelTM NucleoVac 96 
Vacuum Manifold  
Macherey-Nagel GmbH & Co. KG, Düren, DE 
Macherey-NagelTM NucleoVac Vacuum 
Regulator 
Macherey-Nagel GmbH & Co. KG, Düren, DE 
Microscope, Leica DMLB Leica Mikrosysteme Vertrieb GmbH, Wetzlar, DE 
PowerPacTM Basic Power Supply Bio-Rad Laboratories Inc., Hercules, US  
Real-Time PCR Thermocycler, q-Tower3 Analytik Jena AG, Jena, DE 
Spectrophotometer, NanoDrop 2000 Thermo Fisher Scientific Inc., Waltham, US 
SunriseTM absorbance reader TECAN Group AG, Männerdorf, CH 
Thermal cycler, DNA Engine DYAD  Bio-Rad Laboratories Inc., Hercules, US 
Thermal cycler, Mastercycler gradient  Eppendorf AG, Hamburg, DE 
Thermal cycler, peqSTAR 96X Universal 
Gradient  
VWR International GmbH, Darmstadt, DE 
Thermal cycler, MJ Research PTC-200 
Gradient 
Bio-Rad Laboratories Inc., Hercules, US  
Tissue Lyser, Mixer Mill MM200 Retsch GmbH, Haan, DE 
UV light transillumination, UVT-28 ME-
HC 
Herolab GmbH Laborgeräte, Wiesloch, DE 
XC10 Color Camera Olympus Deutschland GmbH, Hamburg, DE 
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3.2 Chemicals and consumables 
Chemicals and consumables used in this study are shown in Table 2. 
Table 2: Chemicals and consumables used. 
Chemicals/Consumables Company  
0.2 mL Thermo Strips Thermo Fisher Scientific Inc., Waltham, US 
6x Orange DNA loading dye Fermentas GmbH, St. Leon-Rot, DE 
8 cm plant pots Pöppelmann GmbH und Co. KG, Lohe, DE 
96-well microtiter plates VWR International GmbH, Darmstadt, DE  
96-well PCR plates  4titude® Ltd., Wotton, UK 
ABgeneTM 48-deep well plates  Thermo Fisher Scientific Inc., Waltham, US 
Aceton Bernd Kraft GmbH, Duisburg, DE 
Adhesive PCR Seal 4titude® Ltd., Wotton, UK 
BactoTM Peptone Becton, Dickinson and Company, Franklin Lakes, US 
Biozym LE Agarose Biozym Biotech Trading GmbH, Wien, AT 
C-Chip disposable haemocytometer NanoEnTek Inc., Seoul, KR 
ClipTipTM pipette tips Thermo Fisher Scientific Inc., Waltham, US 
Combitips advanced Eppendorf AG, Hamburg, DE 
DEPC-water Ambion Inc., Austin, US 
Deltalab cotton swabs (sterile) Deltalab, Barcelona, ES 
DifcoTM Agar Becton, Dickinson and Company, Franklin Lakes, US 
DifcoTM ISP medium 2  Becton, Dickinson and Company, Franklin Lakes, US 
Dimethylsulfoxid (DMSO) AppliChem GmbH, Darmstadt, DE 
EDTA  Calbiochem, Merck KGaA, Darmstadt, DE 
Eppendorf Safe-Lock Tubes Eppendorf AG, Hamburg, DE 
Ethanol Sigma Aldrich, St. Louis, US 
Ethidium bromide (10 mg/mL)  Thermo Fisher Scientific Inc., Waltham, US 
Falcon tubes Sarstedt AG & Co. KG, Nümbrecht, DE 
Gauze Lohmann & Rauscher GmbH & Co. KG, Neuwied, DE 
GelGreen nucleic acid stain (10.000x) Biotium, Inc., Hayward, US 
Glacial acetic acid Honeywell Specialty Chemicals Seelze GmbH, 
Seelze, DE 
Glycerol VWR International GmbH, Darmstadt, DE 
Meliseptol® Foam pure B. Braun Melsungen AG, Melsungen, DE 
O´GeneRuler, 1 kb DNA Ladder Fermentas GmbH, St. Leon-Rot, DE 
Petri dish (Ø 92 mm) Greiner Bio-One International GmbH, Frickenhausen, 
DE 
InvitrogenTM UltraPureTM DNA Typing 
GradeTM 50x TAE Buffer 
Thermo Fisher Scientific Inc., Waltham, US 
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Chemicals/Consumables Company  
TipOne® RPT filter tips Starlab GmbH, Ahrensburg, DE 
RNase Away Molecular Bio-Products Inc., San Diego, US 
Streptomycin sulphate  Sigma Aldrich, St. Louis, US  
Tris Base, Molecular biology grade Merck KGaA, Darmstadt, DE 
Tween® 80 Merck KGaA, Darmstadt, DE 
Ultra Clear Cap Strips  Thermo Fisher Scientific Inc., Waltham, US  
Yeast Extract Merck KGaA, Darmstadt, DE 
3.3 Enzymes and kits 
Enzymes and kits used in the present study can be seen in Table 3.  
Table 3: Enzymes and kits used. 
Name  Company 
DreamTaqTM Hot Start 2x PCR Master 
Mix  
Thermo Fisher Scientific Inc., Waltham, US 
MaximaTM Hot Start 2x PCR Master Mix Thermo Fisher Scientific Inc., Waltham, US 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel GmbH & Co. KG, Düren, DE 
NucleoSpin® 96 PCR Clean-up Macherey-Nagel GmbH & Co. KG, Düren, DE 
NucleoSpin® Plant II  Macherey-Nagel GmbH & Co. KG, Düren, DE 
NucleoSpin® 8 Plant II  Macherey-Nagel GmbH & Co. KG, Düren, DE 
NucleoSpin® 96 Plant II  Macherey-Nagel GmbH & Co. KG, Düren, DE 
PhusionTM Hot Start, High-Fidelity DNA 
Polymerase Master Mix 
Thermo Fisher Scientific Inc., Waltham, US 
TakyonTM No ROX Probe 2x MasterMix 
dTTP 
Eurogentec, Seraing, BE 
3.4 Buffers and solutions 
In Table 4, buffers and solutions used during this work are listed.  
Table 4: Buffers and solutions used. 
Name Composition Notes 
10% aceton 10% (v/v) acetone   
TAE buffer (50x) 2 M Tris Base 
1 M acetic acid 
5 mM EDTA  
dilution of stock solution to 1x working 
solution with deionized water 
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Name Composition Notes 
TAE buffer (1x) TAE buffer (50x) 
InvitrogenTM UltraPureTM 
DNA Typing GradeTM 
dilution of stock solution to 1x working 
solution with deionized water 
Tris-HCl buffer (10x) 0.5 M Tris base  pH 8 (with HCl), autoclaved, dilution of 
stock solution to 1x working solution with 
sterile water  
3.5 Growth media 
Growth media used for cultivation of Z. tritici are shown in Table 5. 
Table 5: Growth media used. 
Name Composition Notes 
Inoculation medium  0.02% Tween 80 (v/v)  
ISP2-agar with 
streptomycin  
3.8% (w/v) ISP medium 2  
(0.003% (w/v) 
streptomycin sulphate) 
autoclaved, pH 7.2, cooled to 60°C before 
addition of streptomycin (100 mg/mL 
stock solution, sterile filtered, to  
100 mg/L)  
Malt medium with 
glycerol 
2% (w/v) malt extract 
15% (v/v) glycerol 
autoclaved 
YBG medium d.c.  2% (w/v) BactoTM Peptone 
2% (w/v) yeast extract  
4% (v/v) glycerol 
autoclaved, pH 6.8 
3.6 Oligonucleotides 
Table 6 lists oligonucleotides used as primers for PCR reactions and for Sanger sequencing 
in the present work. In addition, the used polymerase, annealing temperature, and 
target/purpose are shown. Oligonucleotides were synthesized internally at BASF SE with 
exception of probe St-Cyp51-524 that was purchased from Eurogentec. 
Table 6: Oligonucleotides used. The sequence in 5’→ 3’ orientation, annealing temperature (Tm), 
and target/purpose are shown. 
Name Sequence (5‘->3‘) Tm (°C) Target/purpose 
KES 540 (fw) ATGGGTCTCCTCCAGGAAGTC 
69 
amplification and 
sequencing CYP51 KES 541 (rv) TCAGTTCTTCTCCTCCTTCTCCTC 
KES 2192 (fw) CCTCGACAACATCCTCTG 
63.5 
amplification and 
sequencing CYP51 KES 2193 (rv) GCATAAGATCCACCTATGG 
KES 2223 (rv) TGAGCTCCTTGATACTGCCGTCG 50 sequencing CYP51  
KES 2283 (fw) ATCCTCTGTGCCAATTTCTC 50 sequencing CYP51 
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Name Sequence (5‘->3‘) Tm (°C) Target/purpose 
KES 2136 (fw)1 GTGGCGAGGGCTTGACTAC 
64 amplification CYP51p 
KES 2188 (rv)  GTCTGGCCGAATTGCGCGTC 
KES 2143 (fw)2 ACATGATCCCTGATCCGTTC 
58 amplification MFS1p 
KES 2144 (rv)2 CGGCGACTTCTTGCTGAA 
KES 2334 (fw)3 GCAAGGATTCGGACTTGACG 
63 amplification MFS1p 
KES 2335 (rv)3 CTGCCGGTATCGTCGATGAC 
KES 1139 (fw) GTACGGATTACAGCAGTTTGTTCGG 
60 
MAMA primer S524 in 
CYP51 
KES 1144 (rv) CCAAGTCTTCCACTTCAGTTCTTCT qPCR for S524 or 
T524 in CYP51  
KES 1138 (fw) GTACGGATTACAGCAGTTTGTTCTC MAMA primer T524 in 
CYP51 
St-Cyp51-524 TAAAGZGGGEGAGPAGGPA probe (6´FAM) for 
detection S524T in 
CYP51 
1 sequence is extracted from Cools et al., 2012, KES 2136 = Mg51-proF 
2 sequence is extracted from Omrane et al., 2015, KES 2143 = Z4_110044_FW, KES 2144 = 
Z4_110044_RV 
3 sequence is extracted from Omrane et al., 2017, KES 2334 = MFS1_2F, KES 2335 = MFS1_4R 
3.7 Fungicides 
The sensitivity of Z. tritici isolates was tested with different DMIs that are available on the 
European market with the exception of tolnaftate that is not registered in agriculture (Table 
7). Microtiter tests were performed by EpiLogic (Freising, Germany) with the commercially 
available formulation of epoxiconazole and mefentrifluconazole. Instead of prothioconazole, 
the metabolite prothioconazole-desthio (technical active ingredient (a.i.) purchased from 
Sigma Aldrich) was used as it is suggested that this metabolite confers antifungal activity of 
prothioconazole (Parker et al., 2011; Fraaije et al., 2012; Parker et al., 2013). In glasshouse 
studies performed in this work only commercially available formulations of epoxiconazole, 
mefentrifluconazole and prothioconazole were used. The technical active ingredient 
tolnaftate was purchased from Sigma Aldrich. 
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1Structural formulas extracted from PubChem, 2019 
3.8 Software 
Software used during the present work is listed in Table 8. 
Table 8: Software used. 
Name  Company  
BLAST BASF SE, Ludwigshafen, DE  
Geneious R11 Biomatters, Auckland, NZ  
EditSeq DNASTAR Inc., Madison, US 
E-workbook suite/Labbook IDBS, Guildford, UK 
MagellanTM  TECAN Group AG, Männerdorf, CH 
MegAlignTM Pro  DNASTAR Inc., Madison, US 
Molecular Operating Environment 
(MOA) 
Chemical Computing Group Inc., Montreal, CA 
Primer3Plus BASF SE, Ludwigshafen, DE 
qPCRsoft® 3.4 Analytik Jena AG, Jena, DE 
RESLAB BASF SE, Ludwigshafen, DE 
RStudio 3.6.1 RStudio Inc., Boston, US 
SeqManTM Pro DNASTAR Inc., Madison, US 
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3.9 Fungal isolates 
Fungal isolates used in this study were obtained from BASF European internal routine 
sensitivity monitoring or from a monitoring programme on trial sites.  
3.9.1 European routine sensitivity monitoring 
STB-infected leaves were collected during European internal routine sensitivity monitoring 
of BASF SE at commercially treated fields across different countries in Europe in 2016 and 
2017, in order to receive an overview about the DMI sensitivity of regional Z. tritici 
populations. Sampling was planned and conducted by BASF SE and subsequently samples 
were shipped to the company EpiLogic (Freising, Germany). Afterwards, EpiLogic 
generated single pycnidia isolates and tested their sensitivity to different DMIs in microtiter 
tests. All microtiter tests described in this chapter for isolates from routine sensitivity 
monitoring were performed from EpiLogic. The routine sensitivity monitoring in 2016 and 
2017 was performed with epoxiconazole. In 2016, a representative collection of 331 isolates 
was selected out of all isolates of the routine monitoring and additionally tested for their 
sensitivity to mefentrifluconazole and prothioconazole-desthio in microtiter tests. These 
isolates were transferred to BASF SE and further analysed in this work. In 2016, isolates 
from the Western European countries Ireland, UK, France, and the Netherlands were 
analysed as well as from the Central European countries Germany, Poland and Czech 
Republic. Additionally, isolates from the North European countries Denmark and Sweden 
were tested. In 2017, 512 isolates were tested for their sensitivity towards epoxiconazole. 
A subset of 90 isolates of these 512 isolates was additionally tested for their sensitivity to 
mefentrifluconazole and prothioconazole-desthio. All isolates from routine sensitivity 
monitoring in 2017 were transferred to BASF SE and further analysed in this work. In 2017, 
isolates from the Western European countries Ireland, UK, France and the Netherlands 
were tested as well as from the Central European countries Germany, Poland, Czech-
Republic and Slovakia. Moreover, isolates were analysed from the Eastern European 
countries Russia and Ukraine, the South-East European country Bulgaria as well as from 
the Southern European countries Italy and Spain. Isolate details are given in supplementary 
Table 22. 
3.9.2 Trial site monitoring 
Infected Z. tritici leaf samples were collected in 2016 from a field trial in Ireland, Germany, 
France, and Denmark, respectively, in order to analyse changes in the occurrence and 
frequency of CYP51 haplotypes after solo-treatment of DMIs. Samples were taken in 
untreated, prothioconazole (Proline®) and mefentrifluconazole (Revysol®) treated plots, 
respectively, resulting in 3 samples per field trial. These samples were sent to the company 
EpiLogic and they generated 10 isolates per sample resulting in a total number of 120 
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isolates. These isolates were analysed for their CYP51 haplotypes in the current work. 
Isolate details are shown in supplementary Table 23.  
3.9.3 Cultivation of Z. tritici isolates 
Isolates of Z. tritici were cultivated at ISP2 streptomycin agar plates at 18°C with a 12 h dark 
and 12 h light cycle and were transferred to fresh plates every 7-14 days with a sterile cotton 
swab. Isolates were cultivated for 7 days before they were used in microtiter or glasshouse 
tests. Long-term storage was performed in 2% (w/v) malt medium with 15% (v/v) glycerol 
at -80°C. 
3.10 Cultivation of wheat plants for glasshouse tests 
Fungicide sensitivity studies with Z. tritici in the glasshouse were performed with the wheat 
cultivar ‘Riband’. Inoculation with fungal spores was performed on wheat plants at growth 
stage BBCH 11. For this reason, around 10 wheat seedlings per pot were cultivated in 
Universal perlite soil (BASF SE) at 20°C with 16 h light in the glasshouse until BBCH 11. 
3.11 Molecular biological methods 
3.11.1 Isolation of genomic DNA 
Genomic DNA was extracted from fungal material (conidia, mycelia) of Z. tritici that was 
transferred from ISP2 streptomycin agar plates to a 2 mL Eppendorf tube. After addition of 
a metal bead, the fungal material was frozen for 20-30 min on dry ice and subsequently 
homogenized in an oscillating mill for 1 min at 20 Hz. DNA was extracted using NucleoSpin® 
Plant II (single column extraction) or NucleoSpin® 8/96 Plant II Kits (48-/96-well vacuum 
processing) according to the manufacturers’ protocol for the extraction from plant material 
utilizing lysis buffer PL1. If necessary, purity and concentration of DNA was determined at 
a Nanodrop2000 photometrically. DNA was stored for short-time at 4°C and for long time 
storage at -20°C. 
3.11.2 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was performed to amplify target DNA sequences. In 
Table 6 (chapter 3.6), the pathogen specific oligonucleotides that were used are listed. PCR 
reactions, as shown in Table 9, were prepared in a clean bench to avoid contaminations 
and a sample with DEPC-water instead of target DNA served as a negative control (NTC). 
Volumes given in Table 9 were doubled for a PCR reaction with a final volume of 50 µl. 
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Table 9: Components of PCR reactions. 
Component Volume (µl) in a final volume of 25 µl 
2x Master Mix (Maxima/DreamTag/Phusion 
Flash) 
12.50 
DEPC-H2O  7.50 
Primer forward (10 pmol/µl) 1.25 
Primer reverse (10 pmol/µl) 1.25 
Template DNA 2.5 
 
Depending on the purpose of the experiment, different DNA polymerases were used. 
MaximaTM Hot Start and DreamTaqTM Hot Start Taq polymerases were used for 
identification and sequencing of inserts in CYP51p and MFS1p, whereas PhusionTM High-
Fidelity polymerase, that shows a proofreading activity, was used for sequencing of CYP51. 
A schematic procedure of a PCR reaction is provided in Table 10. Annealing temperatures 
and elongation time were adjusted in each PCR reaction according to Table 6 in chapter 
3.6.  
Table 10: Schematic procedure of a PCR reaction programme. MaximaTM Hot Start, DreamTaqTM 
Hot Start Taq polymerases or PhusionTM High-Fidelity polymerase were used. Annealing 
temperature and elongation time were adjusted depending on the pair of oligonucleotides and DNA 
polymerase used. 
Function Temperature (°C) 
Maxima or  
DreamTaq/Phusion 
Time (min) 
Maxima or  
DreamTaq/Phusion 
Cycles 
Initial denaturation 95/98 4:00/0:30 1 
Denaturation 95/98 0:15/0:10  
Annealing 50-72 0:30/0:05 35-39 
Elongation 72 1:00 per kb/0:15 per kb  
Final elongation 72 5:00 1 
Cooling 4 ∞  
 
Amplified DNA fragments were subsequently used for PCR clean-up, sequencing, SNP 
detection by qPCR or for identification of insertions in CYP51p or MFS1p.  
3.11.3 Gel electrophoresis  
Agarose gel electrophoresis was used to separate amplified DNA fragments in order to 
visualise the exact size or for subsequent clean-up. If the exact size of the DNA fragments 
needed to be identified, for example, in promotor insertion studies, ethidium bromide was 
added to 1% TAE agarose gels and the DNA fragments were visualised under UV-light. 1% 
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TAE agarose gels without ethidium bromide but GelGreen in samples and loading dye were 
used if DNA fragments needed to be excised from the gel for subsequent PCR clean-up. 
DNA fragments on these gels were visualised with blue light (430-490 nm). Gels were run 
at 80 V for 60-120 min and the results were analysed with the EasyDoc plus gel 
documentation system. Amplified DNA fragments with correct size were excised from the 
gels and transferred to a 2 mL Eppendorf tube for subsequent clean-up and Sanger 
sequencing. 
3.11.4 PCR clean-up 
For subsequent sequencing, amplified DNA fragments were cleaned-up from excised 
agarose gel slices using the NucleoSpin® Gel and PCR Clean-up kit according to the 
manufacturers’ protocol. In contrast to the protocol, DNA fragments were solved using 
400 µl NTI buffer under shaking at 800 rpm at a ThermoMixer. NucleoSpin® 96 PCR Clean-
up kit was used for large scale clean-up of 96-well PCR plates directly after PCR (without 
previous separation of DNA fragments on an agarose gel). PCR products were eluted in 
90 µl elution buffer NE after following the manufacturers’ protocol for manual vacuum 
processing.  
3.11.5 Sequencing 
Sequencing of purified PCR products was performed via Sanger sequencing internally in 
BASF SE or by the external companies SeqLab (Göttingen, Germany) and Eurofins MWG 
Operon (Ebersberg, Germany). CYP51p and MFS1p were sequenced with oligonucleotides 
used for the respective PCR reaction. Details for sequencing of the CYP51 gene are 
described in chapter 3.13. Sequence analysis was conducted with the programmes 
DNASTAR Lasergene (DNASTAR, Madison, US) and Geneious (version R11) from 
Biomatters (Auckland, New Zealand). Contigs of two or three sequence reads were 
generated with SeqMan Pro. MegAlign or Geneious were used to compare nucleotide and 
protein sequences among themselves. Internal BLAST search of BASF SE or BLAST 
search of NCBI was applied for verification of the sequence origin and for research 
purposes.  
3.11.6 SNP detection via quantitative real-time PCR (qPCR) 
Quantitative real-time PCR was used to detect the presence of alteration S524T in CYP51 
of single isolates for which sequencing of CYP51 stopped before this position. The qPCR 
assay was already established internally in BASF SE before this work and is based on 
TaqMAMA genotyping. The TaqMAMA assay combines a 5’ nuclease polymerase chain 
reaction utilizing a fluorogenic DNA probe (TaqMan®) with a mismatch amplification 
mutation assay (MAMA). The TaqMan probe is an oligonucleotide labelled with a reporter 
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dye (5’ end) and a quencher dye (3’ end). During elongation DNA polymerase degrades the 
probe and the reporter dye is liberated from the quencher dye resulting in measurable 
fluorescence (Glaab and Skopek, 1999). The increase of fluorescence is proportional to the 
amplified PCR product in each cycle. The MAMA assay enables quantitative discrimination 
of SNPs between alleles by exploiting MAMA primers that are either specific for the wild 
type or for the mutated sequence. Specificity and discrimination between alleles are 
increased by an additional mismatch in both sequences besides the nucleotide exchange 
of the investigated SNP (Cha et al., 1992; Glaab and Skopek, 1999).  
QPCR reactions were prepared in a clean bench as described in Table 11 to avoid 
contamination and a sample with DEPC water instead of target DNA served as a negative 
control (NTC). Light conditions were reduced as much as possible during preparation of 
qPCR reactions, as TaqMan probes are sensitive to light.  
Table 11: Components of a qPCR reaction with MAMA primers and TaqMan probe. 
Component Volume (µl) in a final volume of 25 µl 
Takyon NoROX Probe MasterMix dTTP (2x)  12.50 
DEPC-H2O  7.25 
KES 1138 or 1139 forward (10 pmol/µl) 1.25 
KES 1144 reverse (10 pmol/µl) 1.25 
St-Cyp51-524 TaqMan probe (10 pmol/µl) 0.25 
Template DNA 2.50 
 
Oligonucleotides KES 1139 and KES 1144 were used for detection of the wild type allele 
and oligonucleotides KES 1138 and KES 1144 were used for detection of the mutated allele 
(oligonucleotides shown in Table 6). QPCR reactions were run on the qTower3 from Qiagen 
with the programme shown in Table 12.  
Table 12: Programme used for qPCR reactions. 
Function Temperature (°C) Time (min) Cycles 
Initial denaturation 95 5:00 1 
Denaturation 95 0:10 
40 
Annealing & Elongation 60 0:45 
 
Fluorescence was measured at the end of elongation after each cycle and the Ct values 
were determined with the software qPCRsoft 3.4 from Analytik Jena (Jena, Germany). The 
number of qPCR cycles that are required until a predefined threshold is exceeded is 
described by the Ct value. Allele frequencies of sensitive and resistant alleles were 
calculated according to the formula of Germer et al. (2000): 
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Frequency of allele1 = 1/(2ΔCt + 1), 
where ΔCt = (Ct of allele1-specific PCR) – (Ct of allele2-specific PCR).  
A DNA sample with 100% sensitive allele and a DNA sample with 100% mutated allele 
served as verification of each run. 
3.12 Fungicide sensitivity tests  
Microtiter tests were performed in the laboratory in order to test the in vitro sensitivity of 
Z. tritici isolates towards different compounds. Sensitivity studies in the glasshouse were 
performed with Z. tritici isolates in order to test efficacy of DMIs in vivo, under conditions 
that are more realistic to field conditions compared to in vitro studies.  
3.12.1 Microtiter tests  
Microtiter tests were performed by EpiLogic (for DMI sensitivity) and during this work (for 
tolnaftate sensitivity) to calculate the EC50 of Z. tritici isolates for different compounds. The 
EC50 value describes the effective concentration that leads to 50% inhibition of fungal growth 
compared to growth in the untreated control. Fungicides used are shown in Table 7. 
Sensitivities of Z. tritici isolates towards DMIs were tested in vitro with the commercial 
formulations of epoxiconazole and mefentrifluconazole and the technical grade of 
prothioconazole-desthio. These microtiter tests were performed by EpiLogic. Microtiter tests 
with technical grade of tolnaftate were performed for identification of an increased efflux 
activity in Z. tritici isolates. These microtiter tests with tolnaftate were part of this work. 
Fungicides were tested in 7 concentrations which were selected based on intrinsic activity 
of the fungicides and are given in Table 13. Technical grades were dissolved in DMSO, 
whereas formulations were dissolved in sterile deionized water. 
Table 13: Tested fungicide concentrations in microtiter tests. 
Fungicide  Tested concentrations (mg/L) 
Epoxiconazole  0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3 
Mefentrifluconazole 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1 
Prothioconazole-desthio 0, 0.00064, 0.0032, 0.016, 0.08, 0.4, 2, 10 
Tolnaftate 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 
 
Microtiter tests were performed in 96-well microtiter plates as described in the “SEPTTR 
microtiter monitoring method BASF 2009 V1” on the website of FRAC (FRAC, 2019) with 
slight modifications. The procedure is explained in the following by means of tolnaftate as 
these microtiter tests were performed during this work. The microtiter method of EpiLogic 
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is also based on this procedure. A 10,000 mg/L stock solution was prepared with technical 
grade of tolnaftate in DMSO. This stock solution was used to prepare a double concentrated 
dilution series in sterile deionized water. At first, intermediate dilutions of 200 mg/L and 60 
mg/L were prepared in 25 mL Falcon tubes. Afterwards, these dilutions were used to 
prepare a fungicide dilution series in a 48-deep-well plate as shown in Figure 5. Fifty µl of 
double concentrated fungicide dilution was mixed with 50 µl of spore suspension in the 96-
well microtiter plates resulting in the final test concentration. 
 
Figure 5: Preparation of fungicide dilution series of tolnaftate for microtiter tests. Dilution 
series was prepared double concentrated and afterwards mixed with spore suspension in a ratio of 
1:1.  
Spore suspensions were prepared with Z. tritici isolates that have been cultivated for 7 days 
on ISP2 streptomycin agar plates. Spores of Z. tritici were transferred to 4 mL of YBG d.c. 
medium with a sterile cotton swab. Spore density was determined by counting the spores 
in a haemocytometer (C-Chip) under the light microscope. Spore density was adjusted to a 
final concentration of 1.6 x 104 spores/mL in YBG d.c. medium and stored at 4°C until they 
were added to the fungicide dilution series in the microtiter plates. Each isolate was tested 
in 4 replicates. Additionally, a blank containing media and fungicide solution without spores 
was also tested in 4 replicates at each microtiter plate. Consequently, 2 isolates could be 
tested at one 96-well microtiter plate. The schematic set-up of a microtiter plate is shown in 
Figure 6.  
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Figure 6: Schematic set-up of a 96-well microtiter plate in microtiter test. Row A serves as water 
control and no fungicide is added. Over rows B-H fungicide concentration is increasing. Columns 1-
4 are composed of fungicide and media without fungal spores and serve as blank. Columns 5-8 
contain spores in four replicates of isolate A and columns 9-12 contain spores in four replicates of 
isolate B. The picture was taken from picture pool of BASF SE.  
After addition of the fungal spores, microtiter plates were put into plastic bags and incubated 
at 18°C in darkness for 7 days. Afterwards, fungal growth was measured in a photometer 
at 405 nm and optical density (OD) values were transferred into an excel spreadsheet using 
the software MagellanTM (version 7.2). EC50 values were calculated with E-WorkBook 
Suite/Labbook (IDBS, Germany) based on the following formula:  
f(x) = 100% * (1-1/(1 + exp(b(log(x) – log(e))))) 
100% = maximum, b = slope, e = EC50 
3.12.2 Fungicide sensitivity tests in the glasshouse  
Fungicide sensitivity tests in the glasshouse were performed to test the efficacy of different 
DMIs for Z. tritici isolates that show a DMI adaptation in microtiter tests under conditions 
that are more realistic to field conditions compared to in vitro studies.  
3.12.2.1 Fungicide application  
Fungicides were applied as a one-day preventative treatment in a spray chamber (SPK08) 
of BASF SE with flat fan nozzles and a water volume which corresponds to 400 L/ha. Wheat 
seedlings cultivated according to chapter 3.10 were sprayed with the full registered field 
dose rate of commercially available formulations of epoxiconazole (Opus®), prothioconazole 
(Proline®) and mefentrifluconazole (Revysol®). Full registered field dose rates are 
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125 g a.i./ha epoxiconazole, 200 g a.i./ha prothioconazole and 150 g a.i./ha 
mefentrifluconazole. In total, 100 mL of fungicide solution was applied to a maximum of 16 
plant pots simultaneously. Per treatment and isolate 3 replicates were conducted. The test 
was performed in a fully randomised experimental design.  
3.12.2.2 Inoculation 
One day after fungicide application the treated wheat seedlings were inoculated with spore 
suspensions of different Z. tritici isolates. Four replicates of fungicide untreated wheat 
seedlings were used to determine growth of fungal isolates under untreated conditions. 
Z. tritici isolates were cultivated for 7 days on ISP2 streptomycin agar plates before 
inoculation. Spores were transferred with a sterile cotton swab into 20 mL of 0.02% 
Tween80-water. The spore suspension was filtered through two layers of gauze. 
Subsequently, a 1:10 dilution was prepared and spore density was determined by counting 
spores in a haemocytometer under the light microscope. The spore concentration was 
adjusted to a final density of 2.5x106 spores/mL in a final volume of 100 mL of 0.02% 
Tween80-water. Inoculation of wheat plants was performed with an airbrush (0.8 mm nozzle 
size). The plants were inoculated until a homogenous coverage of spore suspension 
droplets was visible without a run-off. The bottom of the glasshouse trolleys was covered 
with wet fleece and with a semipermeable foil above. Each isolate was placed on its own 
glasshouse trolley to avoid cross contamination. Inoculated plants were covered with a light 
permeable plastic box at the glasshouse trolley to allow Z. tritici penetration and were 
cultivated for 20-21 days in a glasshouse chamber with 80% humidity, 20°C and a light 
period of 15 h. Four days after inoculation the plastic surroundings were removed.  
3.12.2.3 Evaluation 
Diseased leaf area (%) was assessed visually 20-21 days post inoculation (dpi). All wheat 
leaves that were available at the time of fungicide application and Z. tritici inoculation were 
evaluated, but no leaves that occurred afterwards. Finally, the data of diseased leaf area 
were used to calculate the fungicide efficacy according to Abbott (1925) with the software 
RESLAB or E-WorkBook Suite:  
% efficacy = (% disease untreated - % disease treated) x 100% (% disease untreated)-1 
3.13 Determination of CYP51 haplotypes 
In this work, the CYP51 haplotypes of all isolates were determined. For this purpose, the 
CYP51 was amplified in a PCR and subsequently sequenced. Isolates from the routine 
sensitivity monitoring of 2016 and the isolates from the trial site monitoring of 2016 were 
used in a PCR (described in 3.11.2) with oligonucleotides KES 2192 and KES 2193 (shown 
in Table 6). The amplified PCR fragments were separated on an agarose gel, excised from 
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the gel (described in 3.11.3) and PCR clean-up from the agarose gel was performed 
(described in 3.11.4). Sanger sequencing was performed with oligonucleotides KES 2192, 
KES 2193 and an additional sequencing primer, KES 2223 (shown in Table 6). As this 
procedure was very labour-intensive, it was slightly changed for isolates from the routine 
monitoring of 2017. These isolates were used in a PCR with oligonucleotides KES 2192 
and KES 2193. The PCR products were directly cleaned-up after PCR without previous 
separation on an agarose gel. Sequencing was subsequently performed with 
oligonucleotides KES 2283 (shown in Table 6), KES 2193 and KES 2223. Oligonucleotide 
KES 2283 was used instead of KES 2192 to obtain specific sequencing results. Sequences 
were analysed as described in chapter 3.11.5 and SNPs in CYP51, corresponding amino 
acid exchanges, and consequently CYP51 haplotypes were identified. In a few cases the 
sequencing reaction stopped before the position of the known amino acid exchange S524T. 
The presence of this alteration was tested via qPCR in these cases as described in chapter 
3.11.6. 
3.14 Detection of CYP51 overexpression of Z. tritici 
An insert in CYP51p of Z. tritici was correlated to CYP51 overexpression (Cools et al., 
2012). All isolates from routine sensitivity monitoring of 2016 and 2017 were investigated 
for CYP51p inserts, to identify CYP51 overexpression in these isolates. A slightly modified 
version of a PCR method described by Cools et al. (2012) was used. Sequence of 
oligonucleotide KES 2136 was extracted from Cools et al. (2012), whereas KES 2188 was 
designed during this work and PCR conditions were adjusted (shown in Table 6). In this 
PCR, the regulatory region of CYP51 was amplified and the size of the PCR products was 
subsequently determined on agarose gels with ethidium bromide (shown in 3.11.3). To 
check, whether the inserts found during this work showed the same sequence as inserts 
already published from Cools et al. (2012), Omrane et al. (2015, 2017) and Kildea et al. 
(2019), a selection of amplified fragments of each size was sequenced. PCR products were 
excised from agarose gels, cleaned-up and sequencing was performed with 
oligonucleotides KES 2136 and KES 2188.  
3.15 Detection of increased efflux activity of Z. tritici  
In Z. tritici, it was shown that constitutive overexpression of the MFS1 gene coding for an 
MFS1 transporter confers increased efflux activity. Inserts in MFS1p were identified to be 
responsible for this overexpression (Omrane et al., 2015, 2017). All isolates from routine 
sensitivity monitoring of 2016 and 2017 were investigated for inserts in MFS1p with a PCR 
method extracted from Omrane et al. (2015) in order to identify an increased efflux activity. 
MFS1p was amplified with oligonucleotides KES 2143 and KES 2144 and the size of PCR 
Material and Methods 42 
 
products was subsequently determined on agarose gels with ethidium bromide. Isolates 
that did not show a PCR product were used in a second PCR extracted from Omrane et al. 
(2017) with oligonucleotides KES 2334 and KES 2335. Subsequently, the size of amplified 
PCR products was analysed again. Sequences of used oligonucleotides are shown in Table 
6. 
The size of some amplified fragments differed only slightly and could not be exactly 
determined with agarose gel electrophoresis. Therefore, these fragments were excised from 
agarose gels, cleaned-up and sequenced with oligonucleotides of the respective PCR 
method. Moreover, a selection of amplified DNA fragments of each size was additionally 
sequenced to check whether inserts found in this work show the same sequence as inserts 
already published from Omrane et al. (2015, 2017).  
The phenotypical effect of different MFS1p inserts on an increased efflux activity of Z. tritici 
isolates was determined by microtiter tests with tolnaftate. Tolnaftate sensitivity was tested 
for a selection of isolates (when available) for each identified MFS1p insert. Tolnaftate is a 
thiocarbamate that inhibits squalene epoxidase and is used against human fungal infections 
(Barrett-Bee et al., 1986), but not in agriculture. It was shown that an adaptation of Z. tritici 
isolates towards tolnaftate can indicate an increased efflux activity (Leroux and Walker, 
2011; Omrane et al., 2015). Microtiter tests with tolnaftate were performed as described in 
chapter 3.12.1.  
3.16 Homology modelling 
Homology modelling of the CYP51 protein of Z. tritici was performed by Dr. Ian Craig of 
BASF SE. The software Molecular Operating Environment (MOE) with standard setting for 
homology modelling was used. As no crystal structure of the CYP51 of Z. tritici is available 
so far, the ScCYP51 of Saccharomyces cerevisiae bound to R-desthioprothioconazole 
(PBD 5EAE) with a resolution of 2.1 Å was deployed as a structural template. The sequence 
identity of the template compared to CYP51 of Z. tritici amounts to 49%. Positions of amino 
acids at which alterations occur were manually highlighted in the wild type model.  
3.17 Bioinformatic analysis  
The programme Primer3Plus at an internal bioinformatics site from BASF SE 
(Bioinformatics@BASF) was used to design oligonucleotides for standard PCR and Sanger 
sequencing. The software EditSeq and SeqManTM Pro were used for editing of DNA 
sequences. The software MegAlignTM Pro and Geneious R11 were used to generate 
alignments of DNA and amino acid sequences. BLAST search was performed at the internal 
bioinformatics site of BASF SE or with BLAST search of NCBI. The qPCR was evaluated 
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using the software qPCR Soft® 3.4. The software used in this work and corresponding 
manufacturers are shown in Table 8. 
EC50 values in microtiter tests were calculated using the software MagellanTm and E-
WorkBook Suite/Labbook. Fungicide efficacy in sensitivity tests in the glasshouse were 
calculated using the software RESLAB or E-WorkBook Suite.  
The software RStudio (version 3.6.1) was used for statistical analysis. Significant 
differences between tolnaftate sensitivity obtained from microtiter tests were calculated with 
Kruskal-Wallis-Test (p = 0.05) followed by the post-hoc Nemenyi Test (p = 0.05) for data 
that are not normally distributed. Significant differences between fungicide efficacy in 
glasshouse tests were calculated between the grouped efficacies for adapted isolates and 
the efficacy for the reference isolate using Kruskall-Wallis-Test (p = 0.05) for data that are 




In this thesis, isolates derived from across Europe in annual routine sensitivity monitoring 
of 2016 (chosen sub-sample) and 2017 were investigated for different DMI resistance 
mechanisms. The CYP51 gene of all isolates was sequenced in order to identify CYP51 
haplotypes and, if present, new mutations in CYP51. New CYP51 mutations were tested 
for their effect on DMI sensitivity based on sensitivity comparisons between isolates differing 
in the presence or absence of a new CYP51 mutation. Additionally, protein homology 
modelling was used to assess the effect of CYP51 mutations that lead to amino acid 
alterations in the CYP51 enzyme in order to predict their effect on DMI binding. The 
sensitivities of all Z. tritici isolates were correlated to their respective CYP51 haplotypes to 
evaluate the impact on DMI sensitivity. Additionally, the frequency as well as distribution of 
CYP51 haplotypes across Europe was analysed. Isolates were investigated for CYP51 
overexpression and an increased efflux activity via promotor insertion studies and the 
effects on DMI adaptation were evaluated. Frequency and distribution of CYP51 
overexpression and increased efflux across Europe were analysed. CYP51 haplotypes 
were investigated for cross-resistance between different DMIs based on in vitro sensitivity 
studies and on the composition of CYP51 haplotypes after DMI treatment in field trials. The 
impact of different CYP51 haplotypes, CYP51 overexpression and increased efflux on DMI 
efficacy in vivo was tested in glasshouse studies in order to predict their impact on the field 
efficacy of DMIs.  
4.1 Identification of CYP51 haplotypes in Z. tritici 
During routine sensitivity monitoring of BASF, Z. tritici isolates were collected across 
different countries in Europe and tested for their sensitivity towards epoxiconazole in 2016 
and 2017. The sensitivity of isolates was tested in microtiter tests by EpiLogic. Afterwards, 
a collection of isolates (n=331) from sensitivity monitoring of 2016 and the complete set of 
isolates (n=512) from 2017 were analysed for mutations in CYP51 and the resulting CYP51 
haplotypes were determined in this work. The CYP51 gene was PCR-amplified and 
subsequently sequenced. Splicing of DNA sequences was virtually performed based on 
alignments with the cDNA sequence from the genome database. CYP51 haplotypes were 
determined based on mutations in the CYP51 gene that lead to amino acid alterations in 
the CYP51 enzyme. Therefore, CYP51 haplotypes will be described hereafter based on 
amino acid alterations in CYP51 (CYP51 alterations). Amino acid alterations found in 




Table 14: CYP51 alterations found in Z. tritici isolates investigated from routine sensitivity 
monitoring of 2016 and 2017. Wild type (WT) codon and codon of CYP51 mutations are shown. A 
deletion of an amino acid is described as ‘Del’. Amino acid alterations that have been already 
described for Z. tritici are categorised as ‘existing’. Amino acid alterations identified for the first time 
during this work are categorised as ‘new’. 
CYP51 alteration Codon WT → codon CYP51 mutant Occurrence (existing or new) 
L50S TTG → TCG existing 
K95M AAG → ATG new 
D134G GAT → GGT existing 
V136A GTT → GCT existing 
V136C GTT → TGT existing 
V136G GTT → GGT existing 
Y137F TAT → TTT existing 
S188N AGC → AAC existing 
L197V CTC → GTC new 
N284H AAC → CAC existing 
A318G GCG → GGG new 
I377V ATT → GTT new 
A379G GCT → GGT existing 
I381V ATC → GTC existing 
A410T GCT → ACT existing 
I452V ATC → GTC new 
Del K456 AAA → --- new 
Del E457 GAA → --- new 
Del D458 GAC → --- new 
Del Y459 TAT → --- existing 
Del G460 GGC → --- existing 
Del Y461 TAC → --- existing 
Del G462 GGC → --- existing 
Del L463 CTG → --- new 
Y459D TAT → GAT existing 
Y459P TAT → CCT existing 
Y459S TAT → TCT existing 
G460D GGC → GAC existing 
Y461S TAC → TCC existing 
Y461H TAC → CAC existing 
Y461N TAC → AAC new 
N507S AAT → AGT new 
N513K AAC → AAG existing 
S524T AGC → ACC existing 
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In total, 34 CYP51 alterations were identified across all investigated isolates. Twenty-three 
of those alterations have been already described for Z. tritici in literature. In contrast, 11 
new CYP51 alterations were detected that have not been described for Z. tritici so far. 
A single amino acid alteration was found in CYP51 of a few isolates, but in most cases 
combinations of more than one CYP51 alteration were identified. A new nomenclature was 
established during this work to enable description of all CYP51 haplotypes identified across 
all isolates. This nomenclature is composed of a combined letter and number code. The 
letter describes the total number of amino acid alterations in CYP51, whereas the number 
describes the specific combination of a defined number of amino acid alterations. For 
example, CYP51 haplotype C7 contains three specific amino acid alterations in CYP51 
(L50S, V136A, Y461H; shown in Table 15), whereas haplotype C8 contains another 
combination of three specific amino acid alterations in CYP51 (L50S, I381V, Y461H; shown 
in Table 15). The wild type CYP51 is described as WT. A list with CYP51 haplotypes 
detected in the past and assignment of the new nomenclature was published in the course 
of this work in Huf et al. (2018). 
All CYP51 haplotypes identified in isolates from routine sensitivity monitoring of 2016 and 
2017 are shown in Table 15 and the number of isolates that carried a respective haplotype 
is given.  
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Table 15: All CYP51 haplotypes identified in Z. tritici isolates investigated from routine 
sensitivity monitoring of 2016 and 2017. CYP51 haplotypes are shown in the caption and the table 
is consecutive over several pages. CYP51 haplotypes marked with an asterisk ‘*’ are described for 
the first time for Z. tritici. The wild type amino acid and the position is given in the first column of the 
table. The sign ‘-‘ indicates no change of the wild type amino acid. The abbreviation ‘del’ indicates a 
deletion of the respective amino acid. The year of detection and total number of isolates (No. of 
isolates) identified across both years is shown. These results have been previously published 







WT A2 A3 A14* A15* B8 B15* C2 C4 C6 C7 C8 
L50 - S - - - S - S S S S S 
K95 - - - - - - - - - - - - 
D134 - - - - - - - - - - - - 
V136 - - - - - - - - - A A - 
Y137 - - F - - - - - - - - - 
S188 - - - N - - - - - - - - 
L197 - - - - - - - - - - - - 
N284 - - - - - - - - - - - - 
A318 - - - - - - - - - - - - 
I377 - - - - - - - - - - - - 
A379 - - - - - - - - - - - - 
I381 - - - - - - V V V - - V 
A410 - - - - - - - - - - - - 
I452 - - - - V - - - - - - - 
K456 - - - - - - - - - - - - 
E457 - - - - - - - - - - - - 
D458 - - - - - - - - - - - - 
Y459 - - - - - - P S D - - - 
G460 - - - - - - - - - - - - 
Y461 - - - - - S - - - S H H 
G462 - - - - - - - - - - - - 
L463 - - - - - - - - - - - - 
N507 - - - - - - - - - - - - 
N513 - - - - - - - - - - - - 







































C9* C18 D2 D7 D9 D10 D13 D26* D27* E3 E4 E5 
L50 S S S S S S - S S S S S 
K95 - - - - - - - - - - - - 
D134 - - - - G - - - - - G - 
V136 A - - A A A C - - A A A 
Y137 - - - - - - - - - - - - 
S188 - N N - - - - - - - - - 
L197 - - - - - - - - - - - - 
N284 - - - - - - - - - - - - 
A318 - - - - - - - G - - - - 
I377 - - - - - - - - V - - - 
A379 - - - - - - - - - - - - 
I381 - - - - - V V V V V V V 
A410 - - - - - - - - - - - - 
I452 - - - - - - - - - - - - 
K456 - - - - - - - - - - - - 
E457 - - - - - - - - - - - - 
D458 - - - - - - - - - - - - 
Y459 - - - - - - - - - - - - 
G460 - - D - - - - - - - - - 
Y461 N - - S H H H H H S H H 
G462 - - - - - - - - - - - - 
L463 - - - - - - - - - - - - 
N507 - - - - - - - - - - - - 
N513 - K K - - - - - - - - - 







































E7* E8 E9* E21 E25* E26* E27* E28* E29* F1 F2 F3 
L50 S S S - - S S S S S S S 
K95 - - - - - - - M - - - - 
D134 - - G G - G - G - - - - 
V136 C C A A A A - G C - - C 
Y137 - - - - - - - - - - - - 
S188 - N - N - - N - - N N N 
L197 - - - - - - - - - - - - 
N284 - - - - - - - - - - - - 
A318 - - - - - - - - - - - - 
I377 - - - - - - - - - - - - 
A379 - - - - G - - - - G - - 
I381 V V V - V V V - V V V - 
A410 - - - - - - - - - - - - 
I452 - - - - - - - - - - - - 
K456 - - - - - - - - - - - - 
E457 - - - - - - - - - - - - 
D458 - - - - - - - - - - - - 
Y459 - - S - - Del Del - - D Del Del 
G460 - - - Del - - Del - - - Del Del 
Y461 H H - Del S - - S S - - - 
G462 - - - (Del)1 - - - - - - - - 
L463 - - - - - - - - - - - - 
N507 - - - - - - - - - - - - 
N513 - - - - - - - - - - K K 
S524 T - - - T - - - T T - - 
Year of 
detection 


















2 1 1 1 1 1 1 1 1 1 100 11 
1This deletion occurs either at position G460 or G462. The position could not be clarified with 












F4 F5 F6 F7 F8 F9* F10* F19* F20* G1 G2 G6* 
L50 S S S S S - S S S S S S 
K95 - - - - - - - - - - - - 
D134 - - - - G - G - G - - G 
V136 C A A A A C A A A - - A 
Y137 - - - - - - - - - - - - 
S188 N N N - - - - - - N N - 
L197 - - - - - - - - - - - - 
N284 - - - - - - - - - - - - 
A318 - - - - - - - - - - - - 
I377 - - - - - - - - - - - - 
A379 - - - G - G - - - G G - 
I381 V - - V V V V - V V V V 
A410 - - - - - - - - - - - - 
I452 - - - - - - - - - - - - 
K456 - - - - - - - - - - - - 
E457 - - - - - - - - - - - - 
D458 - - - - - - - - - - - - 
Y459 - Del Del - - Del - Del - Del Del Del 
G460 - Del Del - - Del - Del - Del Del Del 
Y461 H - - S H - S - H - - - 
G462 - - - - - - - - - - - - 
L463 - - - - - - - - - - - - 
N507 - - - - - - - - S - - - 
N513 - K - - - - - K - K - K 








































G7 H3 H4 H5 H6 H9 I1 I2* I4* 
L50 S S S S S S S S - 
K95 - - - - - - - - - 
D134 - - - - - - - G - 
V136 A - A - C - A A - 
Y137 - - - - - - - - - 
S188 N N N N N N N - - 
L197 - - - - - - - - V 
N284 - H - - - - - - - 
A318 - - - - - - - - - 
I377 - - - - - - - - - 
A379 G G G G G G G G - 
I381 V V V V V V V V - 
A410 - - - T - - - - - 
I452 - - - - - - - - - 
K456 - - - - - - - - Del 
E457 - - - - - - - - Del 
D458 - - - - - - - - Del 
Y459 - Del Del Del Del Del Del Del Del 
G460 - Del Del Del Del Del Del Del Del 
Y461 S - - - - - - - Del 
G462 - - - - - - - - Del 
L463 - - - - - - - - Del 
N507 - - - - - - - - - 
N513 - K - K - K K K - 
S524 T - T - T T T T - 










‘16 ‘16  
‘17 
No. of isolates 3 2 22 3 27 1 5 2 5 
 
Across all isolates, 57 CYP51 haplotypes, including the CYP51 wild type (WT), were 
identified. Twenty of those haplotypes (marked with an asterisk) were described for the first 
time for Z. tritici, whereas remaining CYP51 haplotypes have been already described in 
literature. The alignment of the amino acid sequence of each CYP51 haplotype (including 
haplotypes with new CYP51 alterations) is given in the supplements in Figure 36. Among 
all isolates, it was observed that the majority of the Z. tritici population was composed of 
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only a few CYP51 haplotypes. Most CYP51 haplotypes were identified in a low frequency 
or even in a single isolate. Across both years, 13 CYP51 haplotypes were identified in more 
than 10 isolates, respectively. Haplotype E4 was identified most frequently (n=231 isolates), 
followed by haplotypes C8 (n=140 isolates), G1 (n=101 isolates) and F2 (n=100 isolates). 
The remaining haplotypes identified in more than 10 isolates have been F8 (n=38 isolates), 
H6 (n=27 isolates), E5 (n=24 isolates), H4 (n=22 isolates), E3 (n=15 isolates), WT (n=14 
isolates), F4 (n=13 isolates), D13 (n=12 isolates) and F3 (n=11 isolates). These 13 CYP51 
haplotypes were found in a total of 748 isolates resulting in 88.7% of all investigated 
isolates. Consequently, the remaining 44 CYP51 haplotypes accounted for 11.3% of all 
isolates. Therefore, results in the current thesis focus in most cases on the 13 most frequent 
found CYP51 haplotypes hereafter described as ‘frequently found CYP51 haplotypes’. The 
remaining haplotypes will be described as ‘rarely found CYP51 haplotypes’ hereafter. In the 
following chapter, the impact of new CYP51 alterations on DMI sensitivity was evaluated, 
followed by the evaluation of DMI sensitivity of all CYP51 haplotypes.  
4.2 Impact of new amino acid alterations in CYP51 of 
Z. tritici  
To analyse if new CYP51 alterations show an impact on sensitivity of Z. tritici towards DMIs, 
the position of new amino acid alterations in the CYP51 enzyme was determined and 
epoxiconazole sensitivity was evaluated for isolates that only differ in the presence or 
absence of a new CYP51 alteration.  
4.2.1 Molecular characterisation of amino acid alterations in the 
CYP51 enzyme 
The location of new amino acid alterations within the CYP51 protein structure of Z. tritici 
was examined in order to predict a possible effect of these alterations on triazole binding. 
For this purpose, a homology model was used. Enzyme modelling was performed by Dr. 
Ian Craig (BASF SE). As no crystal structure of the CYP51 of Z. tritici is available so far, 
protein modelling was based on the X-ray from S. cerevisiae (PDB 5EAE). The CYP51 wild 
type enzyme was modelled and wild type amino acids identified as positions of new 





Figure 7: Homology model of the sterol 14-α demethylase enzyme (CYP51) of Z. tritici 
depicting the location of wild type amino acids identified as positions of new alterations. The 
homology model is based on the X-ray from S. cerevisiae (PDB 5EAE). The structure of the enzyme 
is shown in cartoon style (grey). The haem group (yellow, stick model) indicates the DMI binding site. 
Wild type amino acids observed to be subject of new alterations K95M, L197V, A318G, I377V, I452V, 
Del K456, Del E457, Del D458, Y461N, Del L463, N507S were highlighted in pink (stick model). A: 
Overview about all positions at which new amino acid alterations were identified. B: Closer view on 
the surrounding of the haem group. 
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Locations of amino acids identified as subject of new alterations were observed at different 
positions in the CYP51 enzyme. The prosthetic haem group (yellow) indicates the binding 
site of triazoles. Positions of amino acids N507 (30.1 Å), K95 (25.4 Å), and I452 (20.1 Å) 
are located far away from the haem group. Positions of amino acids L197 (17.6 Å), A318 
(12.9 Å), I377 (16.7 Å), K456 (18.5 Å), E457 (19.5 Å), D458 (17.2 Å), and L463 (16.2 Å) are 
localised in closer proximity to the haem. All distances between amino acid residues that 
were observed as positions of new or existing CYP51 alterations and the haem are listed in 
Table 24 in the supplements. Alteration Y461N emerged at position Y461 at which already 
existing alterations were identified. Residue Y461 is located 13.6 Å away from the haem 
group. Based on results of the enzyme modelling, a direct impact of new alterations at 
positions N507, K95, and I452 on triazole binding seems less likely compared with 
remaining new alterations due to the larger distances of N507, K95, and I452 to the haem 
group. Epoxiconazole sensitivity was evaluated in correlation to new CYP51 alterations in 
the following chapter to analyse if DMI sensitivity is affected by one of the new CYP51 
alterations.  
4.2.2 Impact of new CYP51 alterations on DMI sensitivity of 
Z. tritici 
The EC50 values of Z. tritici isolates carrying a new CYP51 alteration for epoxiconazole 
(determined in microtiter tests by EpiLogic) were plotted compared to EC50 values of wild 
type isolates in order to analyse the phenotypical impact of new CYP51 alteration on DMI 
sensitivity. As most of the new alterations only occurred in combination with other CYP51 
alterations, the sensitivity of isolates with new CYP51 alterations was compared to the 
sensitivity of isolates carrying CYP51 haplotypes that show the same combination of CYP51 
alterations and only differ in the presence of a new alteration. If an isolate with such a 
CYP51 haplotype was not available, the sensitivity of isolates with the new alterations was 
compared to isolates with a relatively similar CYP51 alteration background. An overview 
about CYP51 haplotypes that were compared in order to analyse the impact of respective 







Table 16: Overview about comparisons of CYP51 haplotypes to analyse the impact of new 
CYP51 alterations on DMI sensitivity.  CYP51 haplotypes marked with an asterisk ‘*’ are described 
for the first time for Z. tritici. 




L197V, Del K456, Del E457,  
Del D458, Del L463 
WT 
I4*: L197V, Del456-Del463 
A318G 
C8: L50S, I381V, Y461H 
D26*: L50S, A318G, I381V, Y461H 
I377V 
C8: L50S, I381V, Y461H 
D27*: L50S, I377V, I381V, Y461H 
Y461N 
C7: L50S, V136A, Y461H 
C9*: L50S, V136A, Y461N 
K95M 
D6: L50S, D134G, V136G, Y461S 
E28*: L50S, K95M, D134G, V136G, Y461S 
N507S 
E4: L50S, D134G, V136A, I381V, Y461H 
F20*: L50S, D134G, V136A, I381V, Y461H, N507S 
 
Comparison of EC50 values of epoxiconazole for all isolates carrying a CYP51 haplotype 
with a new alteration are shown in Figure 8. CYP51 haplotypes with a new alteration are 
marked in black and with an asterisk as they also represent new CYP51 haplotypes.  
Compared to the sensitivity of the wild type or already existing CYP51 haplotypes, isolates 
with alterations I377V (haplotype D27*), I452V (haplotype A15*), Y461N (haplotype C9*), 
or N507S (haplotype F20*) showed comparable sensitivities. These results indicate that 
alterations I377V, I452V, Y461N and N507S do not exert an additive effect on 
epoxiconazole adaptation. Moreover, only a small impact on epoxiconazole sensitivity (1.4-
fold higher adaptation) was correlated to alteration K95M (haplotype E28*) compared to 
isolates carrying haplotype D6.  
A 2.4-fold higher adaptation was observed in the isolate carrying alteration A318G 
(haplotype D26*) compared to the mean EC50 of haplotype C8. At this point, however, it 
should be noted that the isolate carrying alteration A318G additionally carry an insert in the 
MFS1p region that may confer a slight increased efflux activity (150 bp insert, shown in 
chapter 4.6.2 and 4.6.3). Therefore, it cannot be clarified at this point, if slightly higher 






Figure 8: DMI sensitivity of Z. tritici isolates carrying new CYP51 alterations. Sensitivity of 
CYP51 haplotypes carrying a new CYP51 alteration (marked in black and with an asterisk) were 
compared to the sensitivity of the CYP51 wild type or existing CYP51 haplotypes (marked in grey). 
EC50 values were determined in microtiter tests by the company EpiLogic and are shown for each 
tested isolate. The number of tested isolates per haplotype is shown in the diagram. Mean EC50 
values were calculated across all isolates carrying the same CYP51 haplotype if more than one 
isolate was identified.  
Isolates carrying alteration L197V combined with Del K456, Del E457, Del D458, and Del 
L463 (haplotype I4*) showed around a 3-fold higher adaptation to epoxiconazole compared 
to the wild type. Consequently, among all new CYP51 alterations identified in this work, 
L197V combined to these deletions showed the highest impact on epoxiconazole sensitivity. 
Nevertheless, the resistance level of isolates carrying alteration L197V, and Del 456-463 
was low compared to more adapted CYP51 haplotypes, for example, haplotype E4. 
Moreover, as alteration L197V and deletion of amino acid positions 456, 457, 458, and 463 
(haplotype I4*) occur in combination with deletion of positions 459, 460, 461, and 462, their 
individual effect cannot be assessed. Consequently, it cannot be clarified if adaptation of 
haplotype I4* is driven by alteration L197V, Del K456, Del E457, Del D458, or Del L463 or 
by alteration of positions 459-462.  
All in all, results indicate that none of the new CYP51 alterations could be correlated to 
distinct effects on epoxiconazole sensitivity that result in high resistance levels or in a 
pronounced additive effect on epoxiconazole adaptation compared to already existing 
CYP51 haplotypes. Therefore, these new CYP51 alterations were not investigated further 
for their own. Nevertheless, in the following chapter, CYP51 haplotypes with a new CYP51 
alteration were also used for sensitivity evaluation of epoxiconazole for all CYP51 
haplotypes found in this work.  
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4.3 DMI sensitivity of Z. tritici isolates carrying different 
CYP51 haplotypes  
Sensitivity of epoxiconazole was determined for all isolates obtained from the routine 
sensitivity monitoring of 2016 and 2017. EC50 values were gained from microtiter tests that 
were performed by the company EpiLogic. EC50 values of microtiter tests were plotted 
against the respective CYP51 haplotypes determined in the current work in order to 
investigate their impact on DMI sensitivity. Results are shown for the 13 ‘frequently found 
CYP51 haplotypes’ in Figure 9 and for the ‘rarely found CYP51 haplotypes’ in Figure 10.  
 
Figure 9: Epoxiconazole sensitivity of Z. tritici isolates with ‘frequently found CYP51 
haplotypes’ across 2016 and 2017. Isolates were obtained from BASF routine sensitivity 
monitoring. EC50 values were determined in microtiter tests by the company EpiLogic. The CYP51 
haplotypes, number of tested isolates, mean EC50 values, and standard deviations are shown. Mean 
EC50 and standard deviations were calculated over all EC50 values of isolates with the same CYP51 
haplotype. CYP51 haplotypes were arranged according to increasing adaptation.  
EC50 values of all isolates (n=748) carrying ‘frequently found CYP51 haplotypes’, including 
the wild type, ranged from 0.004 to 4.630 mg epoxiconazole L-1. Wild type isolates showed 
EC50 values ranging from 0.004 to 0.010 mg epoxiconazole L-1, thus represented a 2.5-fold 
difference in sensitivity. All other isolates with ‘frequently found CYP51 haplotypes’ showed 
a reduced sensitivity compared to the wild type with EC50 values ranging from 0.024 to 
4.630 mg epoxiconazole L-1. Among these, isolates carrying a C8 haplotype showed highest 
sensitivity for epoxiconazole with a mean EC50 of 0.143 mg a.i. L-1, followed by haplotypes 
G1 and F3 with a mean EC50 of 0.157 and 0.217 mg a.i. L-1, respectively. Isolates with a E4 
or F2 haplotype showed moderate adaptation to epoxiconazole with a mean EC50 of 0.454 
and 0.542 mg a.i. L-1, respectively. Comparisons between the sensitivity of different 
haplotypes enable predictions about the effect of single alterations. For example, haplotype 
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C8 and E4 only differ in alteration D134G and V136A. Higher EC50 values of most of the 
isolates with a E4 haplotype compared to isolates with a C8 haplotype demonstrate that 
these two alterations (D134G, V136A) lead to a further reduction in epoxiconazole 
sensitivity of Z. tritici. Adaptation of haplotype E4 and F2 was followed by higher adaptation 
of haplotypes F4, E3, D13, and E5 that showed similar mean EC50 values of 1.041, 1.082, 
1.093 and 1.104 mg a.i. epoxiconazole L-1, respectively. Isolates with haplotype F8 showed 
the third highest adaptation for epoxiconazole with a mean EC50 of 1.350 mg a.i. L-1 and 
isolates with haplotype H4 showed the second highest adaptation with a mean EC50 of 
1.400 mg a.i. L-1. Isolates with haplotype H6 showed highest adaptation for epoxiconazole 
with a mean EC50 of 2.266 mg a.i. L-1. Haplotypes F4, E3, D13, E5, F8, H4, and H6 have in 
common that they carry alteration S524T. This indicates that further reduction in 
epoxiconazole sensitivity compared to moderately adapted haplotypes E4 and F2 is 
probably driven by alteration S524T combined with other alterations.  
EC50 values of isolates carrying the 44 ‘rarely found CYP51 haplotypes’ are shown in 
comparison to the CYP51 wild type as a reference (Figure 10). EC50 values of all isolates 
(n=95) with ‘rarely found CYP51 haplotypes’ ranged from 0.006 to 3.055 mg 
epoxiconazole L-1. Across these haplotypes, EC50 values of isolates with an A2, A3, and 
A15* haplotype were located in the range of the sensitivity of wild type isolates. Ten CYP51 
haplotypes exert a low adaptation to epoxiconazole with EC50 or mean EC50 values between 
0.01 and 0.1 mg a.i. L-1. These haplotypes were C18 < A14* < I4* < B8 < D2 < B15* < E21 
< E27* < D9 < C4 (ranked according to increased adaptation). Twenty-five CYP51 
haplotypes showed EC50 or mean EC50 values between 0.1 and 1 mg epoxiconazole L-1. 
These haplotypes were C7 < C6 < C9* < F5 < D27* < C2 < E9* < F20* < F19* < F6 < E26* 
< D26* < D7 < E25* < D10 < F9* < E29* < H5 < H3 < G7* < G2 < F1 < H9 < E28* < G6* 
(ranked according to increased adaptation). Among all ‘rarely found CYP51 haplotypes’, 6 
haplotypes showed highest adaptation with EC50 or mean EC50 values larger than 1 mg 
epoxiconazole L-1. These haplotypes were E7* < E8 < F7 < I1 < F10* < I2* (ranked according 
to increased adaptation). It was observed that new CYP51 haplotypes (marked with an 
asterisk) showed varying sensitivities to epoxiconazole across the whole range of 
sensitivities of all ‘rarely found CYP51 haplotypes’. For example, epoxiconazole sensitivity 
of isolates carrying haplotype A14* or B15* was only slightly reduced compared to the wild 
type, whereas haplotypes E7*, F10*, and I2* belonged to the six haplotypes leading to the 





Figure 10: Epoxiconazole sensitivity of Z. tritici isolates with ‘rarely found CYP51 haplotypes’ identified across 2016 and 2017. Isolates were 
obtained from BASF routine sensitivity monitoring. EC50 values of wild type isolates are shown as a reference. EC50 values were determined in microtiter 
tests by the company EpiLogic. The EC50 values of each tested isolate per CYP51 haplotype is shown and the number of tested isolates is given in the 
diagram. Haplotypes that were described for the first time are marked with an asterisk. Mean EC50 values are shown for CYP51 haplotypes that were found 
in more than one isolate and were calculated over all isolates with the same haplotype. 
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Despite the observed variation of epoxiconazole sensitivity between different CYP51 
haplotypes, that is suggested to rely on the accumulation of different CYP51 alterations, a 
relatively large variation in epoxiconazole sensitivity was also identified among isolates 
within a CYP51 haplotype group. This variation in sensitivity may be attributable to 
additional resistance mechanisms such as CYP51 overexpression or an increased efflux 
activity. These mechanisms will be investigated and reported further in the course of this 
work. Beforehand, DMI adaptation in regional Z. tritici populations was investigated based 
on occurrence of CYP51 haplotypes and the knowledge about their epoxiconazole 
sensitivity obtained in this chapter.  
4.4 Composition and evolution of CYP51 haplotypes in 
regional Z. tritici populations across Europe  
Frequency and distribution of CYP51 haplotypes was analysed in different European 
countries to get an overview about the DMI adaptation of regional Z. tritici populations in 
2016 and 2017. In this chapter, frequency of each ‘frequently found CYP51 haplotype’ from 
2016 and 2017 is shown. Frequencies of ‘rarely found CYP51 haplotypes’ were summed 
up and referred to as ‘others’. Changes in haplotype frequency and occurrence between 
2016 and 2017 was analysed for chosen countries which were tested in both years.  
4.4.1 Frequency and distribution of CYP51 haplotypes in 2016  
In 2016, Z. tritici isolates gained from BASF routine sensitivity monitoring from 9 different 
European countries were investigated for their CYP51 haplotypes. The resulting distribution 
and frequencies of ‘frequently found CYP51 haplotypes’ are shown in Figure 11. The order 
of ‘frequently found CYP51 haplotypes’ in the legend of the diagram is arranged according 
to their increasing epoxiconazole adaptation (from WT: no adaptation to H6: highest 
adaptation), as observed in the previous chapter 4.3.  
In 2016, a heterogenous distribution and frequency of ‘frequently found CYP51 haplotypes’ 
was observed across the investigated countries in Europe. In that year, no isolate carrying 
a wild type CYP51 (CYP51 WT) was identified. Frequencies of haplotype C8, that showed 
highest sensitivity to epoxiconazole among the ‘frequently found CYP51 haplotypes’, 
ranged from 12.3 to 50% across Czech Republic, Denmark, France, Germany, Poland, and 
Sweden. In UK, only a single isolate with a C8 haplotype was observed and no isolate with 
this type was detected in Ireland and the Netherlands. Haplotype G1 was detected in all 
countries, with exception of Czech Republic and the Netherlands, in frequencies ranging 
from 3.2% in UK to 42.9% in Denmark. Only single isolates with a F3 haplotype were 
detected in France but in no other country. The most frequent haplotype across all tested 
countries was haplotype E4, expressing moderate adaptation to epoxiconazole among all 
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‘frequently found CYP51 haplotypes’. This haplotype was found in frequencies ranging 
between 18.4 to 48% in all countries with exception of Denmark and the Czech Republic. 
Haplotype F2 was found in frequencies ranging between 11 to 50% in Czech Republic 
(50%), UK (19%), the Netherlands (18.2%), Poland (14.3%), Germany (13.6%), and 
Sweden (11.1%). This haplotype was found in lower frequencies in France (5.5%) and in 
Ireland (4.3%). It should be noted at this point that the number of tested isolates in Denmark, 
Czech Republic, the Netherlands and Sweden was overall lower and consequently single 
isolates can result in high percentages of haplotypes compared to the remaining countries. 
 
Figure 11: Frequency and distribution of CYP51 haplotypes of Z. tritici across different 
European countries in 2016. Z. tritici isolates were obtained from BASF routine sensitivity 
monitoring. Frequency and distribution of each ‘frequently found CYP51 haplotype’ is shown. 
Frequencies of all ‘rarely found CYP51 haplotypes’ are summarised as others. The order of the 
‘frequently found CYP51 haplotypes’ in the diagram is arranged according to their increasing mean 
EC50 values for epoxiconazole, from CYP51 wild type (CYP51 WT, no adaptation) to haplotype H6 
(highest adaptation). The colour code for CYP51 haplotypes is given in the legend in the figure. The 
number of tested isolates is given under the respective pie chart. The size of the pie chart is 
increasing with the number of tested isolates per country. These results have been previously 
published partially in an altered figure (Figure 2) in Huf et al., 2018.  
Across all ‘frequently found CYP51 haplotypes’, haplotypes F4, E3, D13, E5, F8, H4, and 
H6 carry alteration S524T and were associated with the highest adaptation to 
epoxiconazole (described in chapter 4.3). Haplotype F4 was only found in Poland (6.1%) 
and UK (3.2%) and in a single isolate in France. Haplotypes E3 and E5 were mainly 
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detected in Ireland (E3: 8.6%, E5: 11.8%), followed by UK (E3: 4.8%, E5: 4.8%) and in 
single isolates in Poland and France but in no other country. Haplotype D13 was identified 
in UK (3.1%) and Poland (4.1%). Frequencies of haplotype F8 ranged from 9.1 to 14.3% 
across the Netherlands, Poland, UK, and Denmark. Single isolates with a F8 haplotype 
were found in France and Ireland, but no isolate with this haplotype was detected in Czech 
Republic, Germany, and Sweden. Highest frequency of the H4 haplotype was identified in 
UK (9.5%), followed by the Netherlands (9.1%), Germany (4.5%), and Ireland (4.3%). A 
single isolate with this type was found in France and Poland. The H6 haplotype was 
observed in Germany (13.6%), the Netherlands (9.1%), Ireland (7.5%), UK (6.3%), and 
Poland (6.1%). Only a single isolate with a H6 type was detected in France. Both haplotypes 
H4 and H6 were not found in Czech Republic, Denmark, or Sweden.  
In summary, these results show that in 2016 the highest frequency of haplotypes with 
alteration S524T was found in UK, Ireland, and the Netherlands. In these countries around 
27 to 43% of all isolates were composed of a ‘frequently found CYP51 haplotype’ with 
alteration S524T. Moreover, in these countries also ‘rarely found CYP51 haplotypes’ with 
alteration S524T were detected. Therefore, 45 to 50% of the Z. tritici populations in these 
countries carried a haplotype with alteration S524T (data not shown). The remaining Z. tritici 
populations were mainly composed of haplotypes expressing moderate adaptation to 
epoxiconazole. Compared to this, frequencies of alteration S524T were lower in France, the 
Central European countries Germany, Poland, and Czech Republic as well as in the North 
European countries Denmark and Sweden. In these countries the majority of the Z. tritici 
populations were composed of haplotypes C8, G1, E4, and F2 expressing lower or 
moderate adaptation to epoxiconazole across all ‘frequently found CYP51 haplotypes’. In 
Ireland, UK, and the Netherlands, haplotype C8 was only detected at low frequencies or 
was not detected at all. These results indicate that in 2016 an east-west gradient in the 
adaptation of Z. tritici across Europe could be observed with higher epoxiconazole 
adaptation in regional Z. tritici populations from UK, Ireland and the Netherlands compared 
to the remaining countries.  
4.4.2 Frequency and distribution of CYP51 haplotypes in 2017  
In 2017, Z. tritici isolates from 13 European countries obtained from BASF routine sensitivity 
monitoring were analysed for their CYP51 haplotypes. In Figure 12, the frequencies and 
distribution of ‘frequently found CYP51 haplotypes’ in 2017 are shown. The order of the 
‘frequently found CYP51 haplotypes’ in the diagram is arranged according to their 
increasing epoxiconazole adaptation (from WT: no adaptation to H6: highest adaptation) 
observed in chapter 4.3.  
Similar to 2016, a heterogenous distribution and frequency of ‘frequently found CYP51 
haplotypes’ was observed across the investigated countries in Europe in 2017. In that year, 
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isolates carrying the CYP51 WT were detected, namely in Bulgaria, Russia, and Slovakia 
in frequencies ranging from 9.1 to 15.8%. Isolates with a CYP51 WT were absent in the 
remaining countries.  
 
Figure 12: Frequency and distribution of CYP51 haplotypes of Z. tritici across different 
European countries in 2017. Z. tritici isolates were obtained from BASF routine sensitivity 
monitoring. Frequency and distribution of each ‘frequently found CYP51 haplotype’ is shown. 
Frequencies of all ‘rarely found CYP51 haplotypes’ are summarised as others. The order of the 
‘frequently found CYP51 haplotypes’ in the diagram is arranged according to their increasing mean 
EC50 values for epoxiconazole, from CYP51 wild type (CYP51 WT, no adaptation) to haplotype H6 
(highest adaptation). The colour code for CYP51 haplotypes is given in the legend in the figure. The 
number of tested isolates is given under the respective pie chart. The size of the pie chart is 
increasing with the number of tested isolates per country. 
Haplotype C8 was found in each tested country with exception of Ireland, UK, and the 
Netherlands. A high frequency of the C8 haplotype was found in Spain (100%), Slovakia 
(76.2%), and Czech Republic (75%). Frequencies ranging from 10.7 to 33.3% were found 
in Germany, France, Italy, Poland, Russia and Ukraine. In Bulgaria, 5.9% of all isolates 
showed a C8 haplotype. Highest frequencies of haplotype G1 were identified in Bulgaria 
(70.6%), Russia (39.4%), Ukraine (31.6%), and Italy (40%). In Germany, France, Ireland, 
Poland, and Slovakia frequencies of haplotype G1 ranged between 3.5 and 9.5%. In UK, 
the Netherlands, Spain, and Czech Republic, the G1 haplotype was not observed. 
Haplotype F3 was detected in Czech Republic, France, Germany, the Netherlands, and 
Poland in frequencies ranging from 1.2 to 8.3%. In 2017, similar to 2016, the most frequent 
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haplotype across all countries was haplotype E4, however, it was mainly detected in UK, 
the Netherlands, France, Germany, and Poland. Frequencies of this haplotype ranged from 
25 to 33.3% across Germany, the Netherlands, Poland, and UK and was highest in France 
(48%). A single isolate with an E4 haplotype was found in Ireland and Ukraine, but no isolate 
with an E4 haplotype was found in Russia, Bulgaria, Slovakia, Italy, Czech Republic, and 
Spain. Haplotype F2 was detected in higher frequencies in UK (37.5%), Germany (27.1%), 
and Poland (25.6%) compared to lower frequencies between 4.8% and 9.4% in Bulgaria, 
France, the Netherlands, Russia, and Slovakia. A single isolate with a F2 haplotype was 
identified in Ukraine. Isolates with haplotypes carrying alteration S524T such as F4, E3, 
D13, E5, F8, H4, and H6 were mainly found in Ireland, UK, and the Netherlands and in 
lower frequencies in some of the remaining countries. Haplotype F4 was found in 12.5% of 
all isolates in UK and in single isolates in Germany, Poland, and Ukraine. Haplotypes E3 
and E5 were mainly detected in Ireland with frequencies of 9.4% and 18.8%, respectively. 
A single isolate with a E5 haplotype was identified in France, however, none of these two 
types were found in any other country. Haplotype D13 was detected most frequently in the 
Netherlands (16.7%), followed by Ireland (6.3%). Again, also in 2017, it has to be pointed 
out that the number of tested isolates is lower for some countries such as Spain, the 
Netherlands, Czech Republic as well as Italy and consequently single isolates can result in 
high percentages of CYP51 haplotypes in these countries. Single isolates with a D13 
haplotype were found in Germany, France, Poland, and Russia. Frequencies of haplotype 
F8 was highest in UK and the Netherlands, followed by Ireland, Poland, and France. A 
single isolate with this haplotype was found in Germany and Russia. Frequencies of the H4 
haplotype accounted to 4.3% in UK and 6.3% in Germany and Ireland, respectively. The 
H6 haplotype was most frequently found in UK (8.6%), followed by Ireland (6.3%). Single 
isolates with this haplotype were found in Germany. In France and Poland, single isolates 
with a H4 and H6 haplotype were found, whereas these haplotypes were absent in the 
remaining countries. In general, no isolate with a ‘frequently found CYP51 haplotype’ 
carrying alteration S524T was found in Spain, Italy, Czech Republic, Slovakia, and Bulgaria. 
Only single isolates with such a haplotype were found in Russia and Ukraine.  
In conclusion, these results show that the majority of the Z. tritici populations in Southern 
and Eastern European countries were composed of CYP51 haplotypes C8 and G1 (lowest 
epoxiconazole adaptation among ‘frequently found CYP51 haplotypes’). In 2017, for 
France, Germany, and Poland, results of 2016 were confirmed, and the majority of the 
population was composed of the C8 and G1 haplotype and the moderately adapted 
haplotypes E4 and F2. Again, in these countries, frequencies of haplotypes with alteration 
S524T expressing highest epoxiconazole adaptation across all ‘frequently found CYP51 
haplotypes’ were lower compared to the Netherlands, Ireland, and UK. In these 3 countries 
the highest frequency of haplotypes with alteration S524T were found. These results 
confirm the east-west gradient in the adaptation of regional Z. tritici populations to 
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epoxiconazole which was already observed in 2016. In 2017, highest sensitivity of Z. tritici 
was observed in Eastern as well as Southern European countries. Increasing adaptation 
was observed in Germany, Poland as well as France and highest adaptation was observed 
in the Western European countries Ireland and UK as well as the Netherlands.  
Comparison of CYP51 haplotype frequencies between 2016 and 2017 across all isolates 
and all countries is not reasonable as the scope of tested countries differed between these 
two years. Changes in CYP51 haplotype frequencies over this period will be examined in 
the next chapter for some chosen countries that were tested in both years with a 
representative number of isolates.  
4.4.3 Comparison of CYP51 haplotype occurrence and frequency 
between 2016 and 2017 
The frequency and occurrence of CYP51 haplotypes was compared in selected countries 
between 2016 and 2017 to analyse changes of Z. tritici populations in composition of 
CYP51 haplotypes over a short period of time. Occurrence and frequency of CYP51 
haplotypes in Ireland, UK, Germany, Poland, and France in 2016 and 2017 are shown in 
Figure 13.  
In Ireland, a strong decrease (about ~34%) in the frequency of haplotype E4 and increase 
(about ~17%) of isolates carrying ‘rarely found CYP51 haplotypes’ was observed. The 
majority of these isolates showed alteration S524T (data not shown). Additionally, the 
frequency of ‘frequently found CYP51 haplotypes’ carrying alteration S524T increased in 
2017 compared to 2016 indicating a further shift towards a reduced DMI sensitivity in 
Ireland. In contrast to this, a slight decrease (about ~5%) of ‘frequently found CYP51 
haplotypes’ with alteration S524T and mainly an increase (about ~19%) of moderately 
adapted haplotype F2 was observed in UK. However, it should be noted that the sampling 
in Ireland and UK was restricted in 2017. A lower number of isolates was tested compared 
to 2016 in both countries and especially in UK, samples derived from a lower number of 
locations. The limited sampling in 2017 may contribute to the overall composition of CYP51 
haplotypes in these two countries.  
In Germany, Poland, and France, the composition of CYP51 haplotypes of the Z. tritici 
populations stayed relatively stable between 2016 and 2017. In these countries Z. tritici 
populations were mainly composed of the ‘frequently found CYP51 haplotypes’ in both 
years. Nevertheless, especially in Germany and Poland, changes in the frequency of these 
haplotypes were observed. In Germany, mainly the frequency of haplotype F2 increased 
(about ~14%), whereas in Poland both haplotypes E4 and F2 increased (both about ~11%, 
respectively). Frequency of isolates carrying haplotypes C8 and G1 slightly decreased in 
Germany (C8 around ~6%, G1 around ~3%). In Poland, only frequency of haplotype G1 
slightly decreased (about ~3%), whereas frequency of haplotype C8 slightly increased 
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(about ~6%) in 2017. In France, a slight decrease in the frequency of haplotype G1 (about 
~5%) was observed and frequency of isolates with haplotype F2 slightly increased (about 
~4%) indicating a slight further shift towards a reduced sensitivity. However, changes were 
small across both years in France. The frequency of isolates carrying a haplotype with 
alteration S524T stayed relatively stable in Germany and France and even decreased in 
Poland (data not shown). Moreover, the frequency of other haplotypes (‘rarely found CYP51 
haplotypes’) decreased in Poland in 2017. A slight decrease in the frequency of other 
haplotypes was also detected in Germany, whereas their total frequency stayed stable in 
France. 
 
Figure 13: Comparison of the composition of CYP51 haplotypes of Z. tritici between 2016 and 
2017 in different European countries. Z. tritici isolates were obtained from BASF routine sensitivity 
monitoring. Frequency and distribution of each ‘frequently found CYP51 haplotype’ is shown. 
Frequencies of all ‘rarely found CYP51 haplotypes’ are summarised as others. The order of the 
‘frequently found CYP51 haplotypes’ in the diagram is arranged according to their increasing mean 
EC50 values for epoxiconazole, from CYP51 wild type (CYP51 WT, no adaptation) to haplotype H6 
(highest adaptation). The colour code for CYP51 haplotypes is given in the figure and the number of 
tested isolates is shown under the respective pie chart. Composition of CYP51 haplotypes from 2016 
and 2017 is shown for A: Ireland, B: United Kingdom (UK), C: Germany, D: Poland, and E: France. 
These results have been previously published in an altered figure (Figure 1) in Huf et al., 2020.  
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All in all, the results demonstrate that, over a short period of time, development of CYP51 
haplotype composition of Z. tritici populations between 2016 and 2017 was dependent on 
the country. In Ireland, a further shift towards a reduced epoxiconazole sensitivity is 
indicated, whereas no clear further shift was observed for UK. In Germany, a slight decrease 
of isolates with haplotypes conferring highest sensitivity to epoxiconazole across all 
‘frequently found CYP51 haplotypes’ and an increase of haplotypes expressing moderate 
adaptation indicate a gradual further shift towards a reduced sensitivity. Minor changes in 
the frequency of CYP51 haplotypes were observed in France which indicate a slight further 
shift towards a reduced sensitivity between 2016 and 2017. Changes in the frequency of 
CYP51 haplotypes in Poland indicate no further shift towards a reduced sensitivity between 




4.5 CYP51 overexpression in Z. tritici  
In addition to the accumulation of CYP51 alterations, CYP51 overexpression was shown to 
affect sensitivity of Z. tritici towards DMIs (Leroux and Walker, 2011; Cools et al., 2012). A 
10- to 40-fold CYP51 overexpression was associated with a 120 bp insert in CYP51p of 
Z. tritici (Cools et al., 2012). Additionally, an 862 bp and 866 bp CYP51p insert was 
identified. However, these inserts were assumed not to alter CYP51 expression (Chassot 
et al., 2008; Leroux and Walker, 2011; Omrane et al., 2015; Kildea et al., 2019). In the 
current work, all Z. tritici isolates from routine sensitivity monitoring were tested for inserts 
in CYP51p in order to identify an increased CYP51 expression. The effect of identified 
inserts on the sensitivity of Z. tritici to epoxiconazole was analysed and finally, occurrence 
and distribution of these inserts in Europe was evaluated.  
4.5.1 Identification of CYP51 overexpression in Z. tritici isolates 
All Z. tritici isolates obtained from the routine sensitivity monitoring of 2016 and 2017 were 
investigated for inserts in CYP51p, based on a PCR detection method, in order to identify 
CYP51 overexpression. Additionally, amplified CYP51p fragments were sequenced for a 
selection of isolates (CYP51p wild type and isolates with a CYP51p insert) to check whether 
inserts identified in the current work show similar sequences compared to inserts previously 
described in literature.  
Amplification of CYP51p resulted in four different sizes of DNA fragments across all 
investigated isolates. Isolates without an insert showed a CYP51p fragment of ~350 bp. 
Additionally, fragments of ~500, ~700, and ~1200 bp were detected indicating the presence 
of a CYP51p insert in these isolates.  
Sequencing of different wild type fragments (n=15) with ~350 bp revealed that all tested 
isolates showed small CYP51p inserts with a length varying from 8 to <30 bp compared to 
the reference strain IPO323 (alignment shown in Figure 37 in the supplements). As 
described in the introduction (chapter 1.4.3), a high polymorphism and occurrence of small 
inserts in CYP51p is known for Z. tritici, but only a 120 bp insert was associated with CYP51 
overexpression. Therefore, in this work, it was focused on detection of inserts >50 bp and 
remaining isolates were regarded to carry a CYP51 wild type promotor (WT CYP51p). 
Sequencing of CYP51p fragments with a length of ~500, ~700, or ~1200 bp revealed four 
different inserts with a length of 121, 300, 863, and 868 bp.  
The complete sequence of the 121 bp insert in CYP51p of Z. tritici is shown in the alignment 
in Figure 38 in the supplementary material. The insertion of this insert is located at position 





Figure 14: Insertion sites of the 121 bp insert in CYP51p of Z. tritici. Extract of the complete 
DNA sequence alignment of an isolate carrying the WT CYP51p (St IPO323) and isolates carrying 
the 121 bp insert is shown. Left and right insertion site of the insert is indicated by the arrows. 
Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are 
highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The 
insertion site of the 121 bp insert is located -83 bp upstream of the CYP51 start codon (numbering 
based on WT CYP51p of St IPO323). The alignment was performed with MUSCLE algorithm. 
The 863 and 868 bp inserts were observed to be almost identical to each other (sequence 
identity 97%). Complete sequences of the 863 and 868 bp inserts are depicted in Figure 40 
and Figure 41 in the supplements. As shown in Figure 15, the insertion site of the 863 bp 
insert is located -207 bp upstream of the CYP51 start codon, whereas the 868 bp insert was 
inserted at position -184 bp (numbering based on WT CYP51p of St IPO323). A sequence 
duplication of respectively 13 or 14 bp was observed at both insertion sites in isolates 
carrying the 863 or 868 bp insert. 
 
Figure 15: Insertion sites of the 863 and 868 bp inserts in CYP51p of Z. tritici. Extract of the 
complete DNA sequence alignment of isolates carrying a WT CYP51p (St IPO323, St 6631) and 
isolates carrying either the 863 or 868 bp insert. The second isolate with a WT CYP51p (St 6631) 
was aligned for correct alignment. Nucleobases of the reference sequence of St IPO323 and all 
disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine 
= green, cytosine = blue). Left and right insertion sites of the inserts are indicated by the arrows. 
Alignments were performed with MUSCLE algorithm. A: Extract of the DNA sequence alignment of 
the WT CYP51p and isolates carrying the 863 bp insert. The insertion site of the 863 bp insert is 
located -207 bp upstream of the CYP51 start codon (numbering based on WT CYP51p of St IPO323). 
A sequence duplication with a length of 14 bp (boxed) was observed in isolates carrying the 863 bp 
insert. B: Extract of the DNA sequence alignment of the WT CYP51p and isolates carrying the 868 bp 
insert. The insertion site of the 868 bp insert is located -184 bp upstream of the CYP51 start codon 
(numbering based on WT CYP51p of St IPO323). A sequence duplication with a length of 13 bp 
(boxed) was observed in isolates carrying the 868 bp insert. 
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Due to the high sequence similarity between the 863 and 868 bp inserts, no distinction was 
made between those two inserts in the current work. They were grouped together and will 
be described as inserts of around ~900 bp.  
In this work, a CYP51p insert with a length of 300 bp was detected for the first time. The 
complete sequence of this insert is shown in supplementary material (Figure 39). The 
insertion site of the 300 bp insert is located -107 bp upstream of the CYP51 start codon 
(numbering based on WT CYP51p of St IPO323, Figure 16). A sequence duplication of 
12 bp was observed located at both insertion sites in isolates carrying the 300 bp insert.  
 
Figure 16: Insertion sites of the 300 bp insert in CYP51p of Z. tritici. Extract of the complete 
DNA sequence alignment of an isolate carrying the WT CYP51p (St IPO323) and isolates carrying 
the 300 bp insert is shown. Left and right insertion site of the insert is indicated by the arrows. 
Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are 
highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The 
insertion site is located -118 bp upstream of the CYP51 start codon (numbering based on WT 
CYP51p of St IPO323). A sequence duplication with a length of 12 bp (boxed) was observed in 
isolates carrying the 300 bp insert. The alignment was performed with MUSCLE algorithm.  
In Table 17, the number of Z. tritici isolates with an insert in CYP51p is shown for all 
investigated isolates from routine sensitivity monitoring of 2016 and 2017 (n=843). 
Additionally, the number of Z. tritici isolates with an insert in CYP51p is shown separately 









Table 17: Number of Z. tritici isolates with a wild type CYP51p (WT CYP51p) or a CYP51p insert 
across all CYP51 haplotypes (All), summarised for ‘rarely found CYP51 haplotypes’ and 
separated for each ‘frequently found CYP51 haplotype’. Isolates that did not produce an 






Length of CYP51p insert 
(bp)  n.a. 
 121  300  ~900 
 















C8  9  -  -  130  1 
D13  1  -  -  11  - 
E3  -  -  -  15  - 
E4  1  -  -  229  1 
E5  1  -  -  22  1 
F2  6  92  -  2  - 
F3  11  -  -  -  - 
F4  -  -  -  13  - 
F8  -  -  -  38  - 
G1  78  1  2  20  - 
H4  -  -  -  22  - 
 H6  1  -  -  26  - 
 Rarely found   48  4  2  40  1 
 All  169  97  4  568  5 
 
CYP51p inserts were identified in different frequencies across all tested isolates. In total, 
169 isolates showed a WT CYP51p. Among all isolates with ‘frequently found CYP51 
haplotypes’, the highest frequency of the WT CYP51p (n=78) was found in isolates with 
CYP51 haplotype G1. All isolates with haplotype F3 and, with the exception of one isolate, 
all isolates with a WT CYP51 haplotype showed a WT CYP51p.  
The 121 bp insert in CYP51p was detected in 97 isolates. This insert was mainly identified 
in isolates with CYP51 haplotype F2 (n=92 isolates). From 100 isolates with a F2 haplotype, 
92 carried the 121 bp insert in CYP51p. In addition, this insert was found in a single isolate 
with haplotype F6, C2, D7, H3, and G1, respectively. The number of isolates with a CYP51p 
insert separated for each ‘rarely found CYP51 haplotype’ is shown in Table 25 in the 
supplementary material. The 300 bp insert was only detected in 4 isolates. Two of those 
isolates showed the ‘frequently found CYP51 haplotype’ G1. Additionally, it was found in 
one isolate with a H9 and a C9 haplotype, respectively. In total, 568 isolates showed an 
insert of ~900 bp. With the exception of the WT CYP51 haplotype and haplotype F3, a 
~900 bp insert was observed in combination with each ‘frequently found CYP51 haplotype’. 
Moreover, almost all isolates with a ‘frequently found CYP51 haplotype’ additionally showed 
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a ~900 bp insert in CYP51p, with the exception of the WT CYP51 haplotype and haplotypes 
F2, F3, and G1.  
In summary, across all investigated isolates, the ~900 bp insert in CYP51p was found most 
frequently, followed by the WT CYP51p, the 121 bp insert, and the 300 bp insert. The effect 
of these CYP51p inserts on epoxiconazole sensitivity of Z. tritici was evaluated in the 
following chapter.  
4.5.2 DMI sensitivity of Z. tritici isolates correlated to inserts in 
CYP51p 
The EC50 values of Z. tritici isolates carrying the same CYP51 haplotype but differing in the 
presence or absence of a CYP51p insert were compared to analyse the impact of different 
inserts on the sensitivity to epoxiconazole. Thereby, all CYP51 haplotypes for which EC50 
values of isolates with and without a CYP51p insert were available from routine sensitivity 
monitoring of 2016 and 2017 were used (Figure 17, Figure 18). Single EC50 values were 
used in cases when only one isolate was detected, and mean EC50 values were calculated 
when more than one isolate was identified with a similar CYP51 haplotype and with a WT 
CYP51p or a CYP51p insert. Only isolates without an additional increased efflux activity (no 
insert in MFS1p, further information is given in chapter 4.6) were included in sensitivity 
evaluation of this chapter in order not to bias a possible effect that may be associated with 
CYP51p inserts.  
In Figure 17, it is shown that Z. tritici isolates with a 121 or 300 bp insert in CYP51p showed 
higher adaptation towards epoxiconazole than isolates without an insert. Across all 
haplotypes (except the wild type), mean EC50 values of isolates without an insert ranged 
from 0.070 to 0.134 mg epoxiconazole L-1, whereas EC50 or mean EC50 values of isolates 
with the 121 bp insert ranged from 0.532 to 0.996 mg epoxiconazole L-1. Isolates with the 
121 bp insert showed on average a 5- to 8-fold higher adaptation compared to isolates with 
the same CYP51 haplotype but without this insert. Among all isolates with haplotype F2 and 
the 121 bp insert, EC50 values ranged from 0.166 to 1.199 mg epoxiconazole L-1. Isolates 
carrying a F2 haplotype but no CYP51p insert showed a mean EC50 for epoxiconazole of 
0.074 mg a.i. L-1. On average, isolates carrying haplotype F2 and the 121 bp insert showed 
a 7-fold higher epoxiconazole adaptation than isolates carrying haplotype F2 with the WT 
CYP51p. The most sensitive isolate with a F2 haplotype and the 121 bp insert showed 
around a 2-fold higher adaptation, whereas adaptation was 16-fold higher in the least 






Figure 17: Sensitivity of Z. tritici isolates carrying the 121 or 300 bp insert in CYP51p. EC50 
values were determined in microtiter tests by EpiLogic and are shown for isolates carrying the same 
CYP51 haplotype but differing in the presence of a wild type CYP51 promotor (WT CYP51p) or either 
the 121 or 300 bp inserts. Sensitivity of the CYP51 wild type (WT) is shown as a reference. Single 
EC50 values are shown when only one isolate was detected, and mean EC50 values and standard 
deviations were calculated when more than one isolate was identified per haplotype and with a WT 
CYP51p or a CYP51p insert. Mean EC50 and standard deviations were calculated over all isolates 
with the same CYP51 haplotype and a WT CYP51p or a CYP51p insert, respectively. Some standard 
deviations are smaller than the symbol itself. The number of tested isolates per haplotype with a WT 
CYP51p or a CYP51p insert is given in the diagram.  
Isolates with the 300 bp insert in CYP51p showed a mean EC50 of 0.301 mg 
epoxiconazole L-1, whereas isolates with the same CYP51 haplotype and a WT CYP51p 
showed a mean EC50 of 0.105 mg epoxiconazole L-1. Therefore, isolates carrying the 300 bp 
insert showed around a 3-fold higher adaptation to epoxiconazole compared to isolates with 
the same CYP51 haplotype and a WT CYP51p.  
The effect of the CYP51p inserts around ~900 bp on sensitivity to epoxiconazole is shown 
in Figure 18. The comparison of epoxiconazole sensitivity for isolates differing in the 
presence or absence of a ~900 bp insert in CYP51p could be done for 11 CYP51 
haplotypes. In five CYP51 haplotype groups (C7, C8, D13, E4, E5), no clear difference was 
observed between the EC50 or mean EC50 values of isolates with a ~900 bp insert compared 
to isolates with the same haplotype and a WT CYP51p. In the six remaining haplotype 
groups (D9, F2, F5, F7, G1, H6), isolates with a ~900 bp insert showed around a 1.5- to 
3.5-fold higher adaptation compared to isolates with the same haplotype and a WT CYP51p. 
Across these haplotypes, EC50 or mean EC50 values of isolates with a WT CYP51p ranged 
from 0.060 to 0.994 mg epoxiconazole L-1, whereas EC50 or mean EC50 of isolates with a 




Figure 18: Sensitivity of Z. tritici isolates carrying a ~900 bp insert in CYP51p. EC50 values for 
epoxiconazole were determined in microtiter tests by EpiLogic and are shown for isolates carrying 
the same CYP51 haplotype but differing in the presence of a wild type CYP51 promotor (WT 
CYP51p) or a ~900 bp insert. Sensitivity of the CYP51 wild type (WT) is shown as a reference. Single 
EC50 values are shown when only one isolate was detected, and mean EC50 values and standard 
deviations were calculated when more than one isolate was identified per haplotype and with a WT 
CYP51p or a ~900 bp insert. Mean EC50 and standard deviations were calculated over all isolates 
with the same haplotype and a WT CYP51p or a ~900 bp insert, respectively. Some standard 
deviations are smaller than the symbol itself. The number of tested isolates per haplotype with a WT 
CYP51p or a ~900 bp insert is given in the diagram.  
In Figure 17 and Figure 18, isolates with different CYP51 haplotypes and a WT CYP51p 
showed on average a 9- to 166-fold higher epoxiconazole adaptation compared to the 
sensitivity of wild type isolates (CYP51 wild type, WT CYP51p and WT MFS1p). As this 
higher adaptation is conferred by isolates with different CYP51 haplotypes but a WT 
CYP51p and WT MFS1p, it is probably based on the combination of CYP51 alterations 
alone. Additionally, CYP51 wild type isolates analysed in this work showed a 2.5-fold 
difference in epoxiconazole sensitivity (described in chapter 4.3). Compared to these 
values, results shown in this chapter indicate that the impact on epoxiconazole sensitivity 
associated with the ~900 and 300 bp inserts in CYP51p appears of minor relevance. An 
additive effect due to CYP51 overexpression, based on the 121 bp insert in CYP51p, on 
adaptation of Z. tritici towards epoxiconazole was observed. Therefore, prevalence of 
CYP51 overexpression was investigated in Z. tritici populations across Europe in the 
following chapter.  
4.5.3 Frequency and distribution of inserts in CYP51p of Z. tritici 
across Europe  
The occurrence and frequency of inserts in CYP51p of Z. tritici was analysed for all countries 
investigated in the routine sensitivity monitoring from 2016 and 2017 to identify the 
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frequency of CYP51 overexpression in regional Z. tritici populations across Europe. The 
resulting frequency and distribution of CYP51p inserts in Z. tritici is shown in Figure 19.  
 
Figure 19: Frequency and distribution of inserts in CYP51p of Z. tritici across different 
European countries. Isolates were obtained from BASF routine sensitivity monitoring of 2016 and 
2017. Frequency of isolates carrying the wild type CYP51p (WT CYP51p) and frequencies of isolates 
with a CYP51p insert of 121, 300 or ~900 bp are shown. For some isolates, no amplicon was 
observed after PCR (n.a.). The colour code for CYP51p inserts is given in the legend in the figure. 
The number of tested isolates is given under the respective pie chart and the size of the pie chart is 
increasing with the number of tested isolates per country. A: Distribution and frequency of inserts in 
CYP51p in 2016. B: Distribution and frequency of inserts in CYP51p in 2017. These results have 




In 2016, frequencies of isolates carrying a WT CYP51p ranged between 9.1 and 25% across 
all countries, with the exception of UK and the Netherlands. In these two countries no isolate 
with a WT CYP51p was detected. The majority of investigated isolates showed a ~900 bp 
insert in CYP51p. This insert was identified in each country in high frequencies ranging from 
50 to 86%. The 121 bp insert, associated with the highest impact on epoxiconazole 
sensitivity among all identified inserts (described in chapter 4.5.2), was detected in all 
investigated countries with the exception of Denmark. However, frequencies of the 121 bp 
insert were lower than frequencies of the ~900 bp insert. Frequencies of the 121 bp insert 
were lowest in Ireland (4.3%) and France (5.5%). In Germany, the Netherlands, Poland, 
and Sweden, the frequency of this insert ranged between 11.1 and 18.2%. The highest 
frequencies were observed in Czech Republic (25%) and UK (22.2%). High frequencies of 
the 121 bp insert in Czech Republic may be attributable to the lower sample size in this 
country because single isolates show a high impact on frequency distribution under these 
circumstances. The 300 bp insert was only found in 3 isolates. Two of these isolates were 
detected in UK and one was found in Denmark.  
In 2017, high frequencies of isolates carrying a WT CYP51p were detected in East and 
South-East European countries such as Bulgaria (94.1%), Russia (66.7%), and Ukraine 
(57.9%) as well as in Italy (77.3%). In the remaining countries frequencies of these isolates 
ranged between 5.8 and 23.8%, with the exception of Spain and UK, in which no isolate 
with a WT CYP51p was detected. Isolates with a ~900 bp insert in CYP51p were found in 
each country tested. High frequencies ranging from 62.5 to 87.5% were detected across 
Czech Republic, France, Ireland, the Netherlands, Poland, Slovakia, and UK. In Spain, all 
tested isolates carried a ~900 bp insert. Compared to this, lower frequencies were identified 
in Bulgaria (5.9%), Russia (27.3%), and Ukraine (38.6%) as well as in Italy (26.7%). The 
121 bp insert was mainly detected in countries of Western and Central Europe, with the 
exception of Czech Republic and Slovakia. Frequency of isolates carrying this insert was 
highest in UK (37.5%), followed by Germany (27.1%) and Poland (24.4%). In France and 
Ireland, lower frequencies of 8.7% and 3.1%, respectively were identified. Two isolates with 
the 121 bp insert were found in Russia. No isolates with this insert were observed in all 
remaining countries. The 300 bp insert was only detected in a single isolate in Germany.  
Changes in the frequency of different CYP51p inserts between 2016 and 2017 can be 
evaluated for important cereal growing countries that were tested in both years. In UK, 
Germany and Poland, an increase about 9 to 15% in the frequency of the 121 bp insert was 
observed accompanied with a decrease in the frequency of the ~900 bp insert (UK: ~12%, 
DE: ~10%, PL:~ 4% ) and/or the WT CYP51p (PL: ~4%). A slight increase (~3%) of the 
121 bp insert and a slight decrease of the ~900 bp insert (~2%) as well as the WT CYP51p 
(~1%) was observed in France. In Ireland, frequencies of the inserts stayed relatively stable. 
In the Netherlands, frequencies of the 121 bp (~10%) and ~900 bp (~15%) inserts 
decreased, whereas frequency of the WT CYP51p increased (25%). However, it should be 
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noted that the sample size in the Netherlands was much smaller and single isolates can 
have a high impact on overall frequency of CYP51p inserts. All in all, results presented here 
indicate that in UK, Poland, and Germany, the frequency of CYP51 overexpression based 
on the 121 bp CYP51p insert increased in 2017, whereas in France only a slight increase 
of CYP51 overexpression was observed. No clear change in the frequency of CYP51 
overexpression was detected in Ireland.  
4.6 Increased efflux activity in Z. tritici  
The third mechanism that has been shown to affect DMI sensitivity of Z. tritici is an 
increased efflux activity of membrane bound transporters (Leroux and Walker, 2011). In 
Z. tritici, an increased efflux activity was shown to rely on overexpression of the MFS1 gene 
coding for an MFS1 transporter (Omrane et al., 2015). This overexpression was associated 
with different MFS1p inserts. Highest MFS1 overexpression was correlated to a 519 bp 
insert in MFS1p. Additionally, inserts with a length of 150, 338, and 369 bp were identified 
in MFS1p of Z. tritici field isolates leading to a lower MFS1 overexpression than the 519 bp 
insert (Omrane et al., 2015, 2017).  
In this work, all isolates from routine sensitivity monitoring were investigated for an 
increased efflux activity by identification of inserts in MFS1p. The effect of different inserts 
on an increased efflux activity of Z. tritici was investigated using tolnaftate. Additionally, the 
impact on epoxiconazole sensitivity of Z. tritici associated with different MFS1p inserts was 
evaluated. Finally, the occurrence and frequency of MFS1p inserts was analysed across 
Europe.  
4.6.1 Identification of an increased efflux activity in Z. tritici 
isolates 
The promotor region of all Z. tritici isolates obtained from routine sensitivity monitoring of 
2016 and 2017 was investigated for inserts based on PCR methods described by Omrane 
et al. (2015, 2017). In order to identify the exact size of inserts slightly differing in length, 
amplified fragments of the promotor region of these isolates were sequenced. Additionally, 
MFS1p fragments of a subset of isolates without an insert and for each insert were 
sequenced in order to check whether inserts identified in this work showed similar 
sequences compared to inserts already described in literature.  
PCR-amplification of MFS1p resulted in the identification of five different sizes of DNA 
fragments across all investigated isolates. Isolates without an insert showed a fragment size 
of ~600 bp (with oligonucleotide set 1: KES 2143 and KES 2144). Additionally, fragments 
of ~750, ~950, ~1000, or ~1100 bp were detected indicating the presence of inserts in these 
isolates. All isolates that produced no amplicon during the PCR with oligonucleotide set 1 
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were additionally tested in a PCR with another oligonucleotide set (oligonucleotide set 2: 
KES 2334 and KES 2335). Some of these isolates showed an MFS1p fragment after PCR 
with oligonucleotide set 2. The PCR with oligonucleotide set 2 resulted in MFS1p amplicon 
sizes of ~500 bp for isolates without an insert and ~800 as well as ~1000 bp for isolates 
with an insert. Nevertheless, some isolates still produced no amplicon during PCR with 
oligonucleotide set 2. 
Sequencing of different MFS1p fragments with or without an insert revealed a high 
polymorphism in MFS1p between Z. tritici isolates. Small insertions and deletions ranging 
from 3 to 42 bp were observed in each tested isolate compared to the reference sequence 
of IPO323 (shown in Figure 42 in the supplements). As described in the introduction 
(chapter 1.4.3), a high polymorphism and the occurrence of small MFS1p inserts has 
already been observed in previous studies, but MFS1 overexpression was mainly correlated 
to larger MFS1p inserts. Therefore, this work was focused on detection of inserts >50 bp 
with the remaining isolates regarded to carry a wild type MFS1p (WT MFS1p).  
Sequencing of MFS1p fragments revealed the occurrence of seven different inserts with a 
length of 150, 267, 308, 338, 369, 377, and 519 bp across all tested isolates. 
The complete sequence of the 150 bp insert is shown in the alignment in Figure 43 in 
supplementary material. Insertion of the 150 bp insert occurred -214 bp upstream of the 
MFS1 start codon (numbering based on WT MFS1p of St IPO323, Figure 20). As reported 
for inserts in CYP51p (shown in chapter 4.5.1), a sequence duplication (10 bp) was 
observed at both insertion sites in isolates carrying the 150 bp insert.  
 
Figure 20: Insertion sites of the 150 bp insert in MFS1p of Z. tritici. Extract of the complete DNA 
sequence alignment of an isolate carrying the WT MFS1p (St IPO323) and isolates carrying the 
150 bp insert is shown. Left and right insertion site of the insert is indicated by the arrows. 
Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are 
highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The 
insertion site is located -214 bp upstream of the MFS1 start codon (numbering based on WT MFS1p 
of St IPO323). A sequence duplication with a length of 10 bp (boxed) was observed in isolates 
carrying the 150 bp insert. The alignment was performed with MUSCLE algorithm. 
Complete sequences of the 267, 308, 338, 369, or 377 bp inserts are shown in 
supplementary material Figure 44. Inserts with a length of 267, 308, and 377 bp were 
identified for the first time in Z. tritici in this work. These three new inserts showed a high 
sequence identity between each other (between 66-80%) and to the already described 338 
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(sequence identity between 71-76%) and 369 bp inserts (sequence identity between 68-
97%). The 338 and 369 bp inserts showed a sequence identity of 77%. Differences in the 
sequences of these inserts mainly result from small insertions and deletions. If gaps 
between all sequences of the 267, 308, 338, 369, and 377 bp inserts were removed, a high 
sequence identity was observed across the remaining 252 bp (92-100%) in pairwise 
comparisons (data not shown).  
The insertion sites of the 267, 308, 338, 369, and 377 bp inserts are shown in Figure 21. 
Insertion of these inserts occurred at position -468 bp upstream of the MFS1 start codon 
(numbering based on WT MFS1p of St IPO323). A 3 bp sequence duplication was observed 
at the insertion sites in isolates carrying either the 267, 308, 369 or 377 bp inserts. Isolates 
carrying the 338 bp insert showed a 13 bp sequence duplication around the insertion sites 
of the insert. Based on this sequence duplication, the insertion site of the 338 bp insert could 
not be assigned with a high level of certainty in the alignment alone. Possibly, the insertion 
site has to be shifted by a few bases.  
 
Figure 21: Insertion sites of different inserts with a length of around 300 bp in MFS1p of 
Z. tritici. Extract of the complete DNA sequence alignment of an isolate carrying the WT MFS1p (St 
IPO323) and isolates carrying either the 267, 308, 338, 369 or 377 bp insert is shown. Left and right 
insertion site of the inserts is indicated by the arrows. Nucleobases of the reference sequence of St 
IPO323 and all disagreements to this sequence are highlighted in colour (adenine = red, guanine = 
yellow, thymine = green, cytosine = blue). The insertion site is located -468 bp upstream of the MFS1 
start codon (numbering based on WT MFS1p of St IPO323). A sequence duplication with a length of 
3 bp (boxed) was observed in isolates carrying either the 267, 308, 369 or 377 bp insert and a 12 bp 
sequence duplication (boxed) was observed in isolates carrying the 338 bp insert. The alignment 
was performed with MUSCLE algorithm. 
The complete sequence alignment of MFS1p of isolates carrying the 519 bp insert is 
depicted in Figure 45 in the supplements. Insertion of the 519 bp insert occurred at position 
-402 bp (numbering based on WT MFS1p of St IPO323) upstream of the MFS1 start codon 
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(Figure 22). A sequence duplication of 5 bp was observed at the insertion sites in isolates 
carrying the 519 bp insert. 
 
Figure 22: Insertion sites of the 519 bp insert in MFS1p of Z. tritici. Extract of the complete DNA 
sequence alignment of isolates carrying the WT MFS1p (St IPO323, St 6758) and isolates carrying 
the 519 bp insert is shown. A second isolate with a WT CYP51p was aligned for correct alignment. 
Left and right insertion site of the insert is indicated by the arrows. Nucleobases of the reference 
sequence of St IPO323 and all disagreements to this sequence are highlighted in colour (adenine = 
red, guanine = yellow, thymine = green, cytosine = blue). The insertion site is located -402 bp 
upstream of the MFS1 start codon (numbering based on WT MFS1p of St IPO323). A sequence 
duplication with a length of 5 bp (boxed) was observed in isolates carrying the 519 bp insert. The 
alignment was performed with MUSCLE algorithm.  
Besides inserts in MFS1p, a 148 and 165 bp deletion was found in one isolate, respectively. 
Deletion of the 148 bp sequence occurred -426 bp upstream of the MFS1 start codon, 
whereas the 165 bp deletion occurred -339 bp. Sequences of the deletions are shown in 
supplementary material Figure 46. 
Inserts in MFS1p were found in different frequencies across all investigated isolates (n=843) 
from routine sensitivity monitoring of 2016 and 2017 (Table 18).  
Table 18: Number of Z. tritici isolates carrying a wild type MFS1p (WT MFS1p) or an insert in 
MFS1p.  Isolates that did not produce an amplicon in PCR test are described with n.a.. 
Length of insert (bp) in MFS1p Number of isolates 
WT MFS1p   702 
 150  26 
 267  7 
 308  1 
 338  13 
 369  6 
 377  1 
 519  37 
 n.a.  48 
 
Across all investigated isolates, 702 isolates, thus the majority, carried a WT MFS1p. 
Among all isolates with an insertion, the 519 bp insert was found most frequently (n=37 
isolates), followed by the 150 bp insert (n=26 isolates) and the 338 bp insert (n=13 isolates). 
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The 267 bp insert was identified in 7 isolates and the 369 bp insert was detected in 6 
isolates. Only one isolate with a 308 or 377 bp insert was detected, respectively. For 48 
isolates no amplicon was observed after PCR, probably due to high sequence 
polymorphism in MFS1p region. MFS1p inserts were not observed to be correlated to a 
specific CYP51 haplotype (shown in supplementary material Table 26). 
4.6.2 Impact of inserts in MFS1p on an increased efflux activity of 
Z. tritici  
Microtiter tests with tolnaftate were performed to test whether inserts in MFS1p impact efflux 
activity of Z. tritici. These tests included isolates with a WT MFS1p and isolates carrying 
different MFS1p inserts. Increased EC50 values of the thiocarbamate tolnaftate indicate an 
increased efflux activity in Z. tritici isolates. Ten Z. tritici isolates, if available, were tested 
for each MFS1p insert identified in this work (except the 308 bp insert). If less than 10 
isolates were available, the total number of detected isolates with the respective MFS1p 
insert from 2016 and 2017 was used.  
EC50 values of Z. tritici isolates carrying different MFS1p inserts for tolnaftate are shown in 
Figure 23.  
 
Figure 23: Sensitivity of Z. tritici isolates carrying different inserts in MFS1p for tolnaftate. Box 
and Whisker of EC50 values of isolates carrying a wild type MFS1p (WT MFS1p) and of isolates 
carrying either the 150, 267, 338, 369, 377, or 519 bp insert for tolnaftate are shown. The number of 
tested isolates (n) is given in the diagram. Tolnaftate is used as an indicator for an increased efflux 
activity in Z. tritici. Different letters above the boxes indicate significant differences according to post-
hoc Nemenyi test (significance level: p= <0.05). The highest tolnaftate concentration tested in 
microtiter tests was 10 mg tolnaftate L-1. In Box and Whisker plots and statistics highest concentration 
of 10 mg tolnaftate L-1 was used for isolates with EC50 values larger than 10 mg tolnaftate L-1.  
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Increasing EC50 values for tolnaftate were observed for Z. tritici isolates with increasing 
length of MFS1p inserts (Figure 23). Compared to the sensitivity of isolates with a WT 
MFS1p, significant differences in tolnaftate sensitivity were observed for isolates carrying 
either the 369 or 519 bp insert. Significant differences between tolnaftate sensitivities were 
calculated with the Kruskall-Wallis-Test (significance level: p = <0.05), followed by the post-
hoc Nemenyi test (significance level: p = <0.05) across mean values of the same isolates 
from two independent experiments. As 10 mg tolnaftate L-1 was the highest tested 
concentration, an EC50 value of 10 mg tolnaftate L-1 was used for the calculation of statistical 
differences for isolates that showed a higher EC50 value than 10 mg a.i. L-1. Most isolates 
with the 150, 267, 338, and 377 bp insert showed higher EC50 values for tolnaftate than 
isolates with a WT MFS1p, but these differences were not significant. Compared to isolates 
with a WT MFS1p, these results indicate the highest increased efflux activity in isolates 
carrying the 369 or 519 bp insert, whereas the effects of the 150, 267, 338, and 377 bp 
inserts were lower. Nevertheless, compared to isolates with a WT MFS1p, an increased 
efflux is also indicated in isolates carrying the 150, 267, 338, and 377 bp inserts. Among all 
isolates with an MFS1p insert, significant differences in tolnaftate sensitivity were detected 
between isolates carrying the 150 and 519 bp insert, whereas across isolates with 
remaining inserts no significant differences were observed.  
One isolate with a WT MFS1p showed an increased EC50 value for tolnaftate compared to 
the remaining isolates with a WT MFS1p (Figure 23) indicating an increased efflux activity 
in this isolate. This isolate showed a small insert with a length of 42 bp in MFS1p (isolate St 
6781 shown in Figure 42 in the supplements). This finding indicates that for future studies 
it may be useful to also identify small inserts in MFS1p (smaller than <50 bp) and to analyse 
if they are correlated to an increased efflux.  
EC50 values of tolnaftate for isolates with the 148 or 165 bp deletion in MFS1p were located 
in the sensitivity range of isolates with a WT MFS1p (Figure 47 in supplementary material). 
These results indicate no effect of these deletions on efflux activity of Z. tritici.  
Altogether, an increased efflux activity is indicated in all isolates carrying an MFS1p insert. 
Highest impact on increased efflux was correlated to the 369 and 519 bp inserts. Further 
studies were carried out in the following chapter in order to test whether these effects can 
be confirmed with the sensitivity of isolates to epoxiconazole. 
4.6.3 DMI sensitivity of Z. tritici isolates correlated to inserts in 
MFS1p 
The EC50 values of epoxiconazole for Z. tritici isolates carrying the same CYP51 haplotype 
but differing in the presence or absence of an MFS1p insert were compared to analyse if 
the impact on tolnaftate sensitivity associated with different MFS1p inserts (previous 
chapter (4.6.2)) is similarly reflected in sensitivity towards epoxiconazole. All CYP51 
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haplotypes for which EC50 values of isolates with and without an insert in MFS1p were 
available from routine sensitivity monitoring of 2016 and 2017 were used. Only isolates 
without CYP51 overexpression based on the 121 bp insert in CYP51p were included in 
sensitivity evaluation of this chapter in order not to bias a possible effect of MFS1p inserts.  
Compared to isolates carrying the same CYP51 haplotype and a WT MFS1p, isolates with 
the 150 bp insert in MFS1p showed slightly higher EC50 or mean EC50 values (Figure 24). 
Nevertheless, only for 2 haplotypes (F8 and G1) a 2-fold higher adaptation to epoxiconazole 
was observed associated with the 150 bp insert, whereas isolates carrying remaining 
haplotypes and the 150 bp insert showed a lower adaptation. These results indicate that 
the 150 bp insert probably only confers a low effect on epoxiconazole sensitivity.  
Sensitivity of isolates carrying either the 267, 308, 338, 369, or 377 bp insert in MFS1p to 
epoxiconazole is presented in Figure 25. The EC50 or mean EC50 values of most isolates 
with the 267, 338, 369, or 377 bp insert were slightly higher compared to isolates carrying 
the same CYP51 haplotype and a WT MFS1p. Nevertheless, at most around a 2- to 2.5-
fold higher adaptation to epoxiconazole was observed to be associated with these inserts 
(in most cases for isolates carrying the 338 bp insert). Compared to this, in many cases the 
observed adaptation to epoxiconazole associated with these inserts was also lower. These 
results demonstrate that the 267, 338, 377, and 369 bp inserts probably only confer low 
impacts on epoxiconazole sensitivity of Z. tritici. One isolate with a 308 bp insert in MFS1p 
and a CYP51 haplotype E4 was identified. This isolate showed around a 2.5-fold higher 
adaptation to epoxiconazole than isolates with an E4 haplotype and a WT MFS1p. This 
isolate was not tested for tolnaftate sensitivity, however, results for epoxiconazole sensitivity 
indicate that this insert might exert similar effects than the remaining inserts around 300 bp. 
As across 2016 and 2017 only one isolate with a 308 bp insert in MFS1p was detected, 
evaluation of tolnaftate and DMI sensitivity of more isolates carrying this insert is 
recommended to confirm the results of this work.  
Single isolates with an insert in MFS1p (150 or 338 bp) showed a higher sensitivity to 
epoxiconazole than isolates with the same CYP51 haplotype but a WT MFS1p. Wild type 
isolates (CYP51 wild type, WT CYP51p, and WT MFS1p) investigated in this work already 
showed a 2.5-fold difference in epoxiconazole sensitivity (described in 4.3). These results 
may imply that natural variability in sensitivity of Z. tritici isolates to azoles, already 
described in previous studies (Gisi et al., 1997; Stergiopoulos et al., 2003; de Waard et al., 
2006), may interfere with the slight effects on epoxiconazole sensitivity associated with the 




Figure 24: Sensitivity of Z. tritici isolates carrying the 150 bp insert in MFS1p. EC50 values for epoxiconazole were determined in microtiter tests by 
EpiLogic and are shown for isolates carrying the same CYP51 haplotype but differing in the presence of a wild type MFS1 promotor (WT MFS1p) or the 
150 bp insert. As a reference, sensitivity of CYP51 wild type isolates (WT) is given. Single EC50 values are shown when only one isolate was detected, and 
mean EC50 values and standard deviations were calculated when more than one isolate was identified per CYP51 haplotype and with a WT MFS1p or an 
MFS1p insert. Mean EC50 and standard deviations were calculated over all isolates with the same CYP51 haplotype and a WT MFS1p or an MFS1p insert, 
respectively. Some standard deviations are smaller than the symbol itself. The number of tested isolates per CYP51 haplotype and with a WT MFS1p or an 




Figure 25: Sensitivity of Z. tritici isolates carrying an insert around 300 bp in MFS1p. EC50 values for epoxiconazole were determined in microtiter tests 
by EpiLogic and are shown for isolates carrying the same CYP51 haplotype but differing in the presence of a wild type MFS1 promotor (WT MFS1p) or the 
267, 308, 338, 369, or 377 bp insert. As a reference, sensitivity of CYP51 wild type isolates (WT) is given. Single EC50 values are shown when only one 
isolate was detected, and mean EC50 values and standard deviations were calculated when more than one isolate was identified per CYP51 haplotype and 
with a WT MFS1p or an MFS1p insert. Mean EC50 and standard deviations were calculated over all isolates with the same CYP51 haplotype and a WT 
MFS1p or an MFS1p insert, respectively. Some standard deviations are smaller than the symbol itself. The number of tested isolates per CYP51 haplotype 




Figure 26: Sensitivity of Z. tritici isolates carrying the 519 bp insert in MFS1p. EC50 values for epoxiconazole were determined in microtiter tests by 
EpiLogic and are shown for isolates carrying the same CYP51 haplotype but differing in the presence of a wild type MFS1 promotor (WT MFS1p) or the 519 
bp insert. As a reference, sensitivity of CYP51 wild type isolates (WT) is given. Single EC50 values are shown when only one isolate was detected, and mean 
EC50 values and standard deviations were calculated when more than one isolate was identified per CYP51 haplotype and with a WT MFS1p or an MFS1p 
insert. Mean EC50 and standard deviations were calculated over all isolates with the same CYP51 haplotype and a WT MFS1p or an MFS1p insert, 
respectively. Some standard deviations are smaller than the symbol itself. The number of tested isolates per CYP51 haplotype and with a WT MFS1p or an 
MFS1p insert is given in the diagram. 
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Sensitivity of isolates carrying the 519 bp insert in MFS1p for epoxiconazole is shown in 
Figure 26. Isolates carrying the 519 bp insert showed on average around 2- to 8- fold higher 
EC50 or mean EC50 values compared to isolates with the same CYP51 haplotype and a WT 
MFS1p, except isolates with haplotype H6 and I1. Isolates carrying haplotype H6 and the 
519 bp insert showed a smaller adaptation of less than 2-times. The isolate carrying 
haplotype I1 and the 519 bp insert showed a higher sensitivity than isolates carrying 
haplotype I1 and the WT MFS1p. These results indicate that in single cases the impact on 
epoxiconazole sensitivity associated with the 519 bp insert seems lower compared to 
previous results described here. On average, among all MFS1p inserts, the 519 bp insert 
was associated with highest effects on epoxiconazole sensitivity.  
Sensitivity of isolates for which MFS1p could not be characterised (described in chapter 
4.6.1) for epoxiconazole is shown in supplementary material in Figure 48. No clear trend in 
differences of epoxiconazole sensitivity was observed for these isolates compared to 
isolates with a WT MFS1p. In single cases a slightly higher adaptation to epoxiconazole 
was observed for isolates for which MFS1p could not be characterised. If this variation in 
sensitivity occurs due to natural variability in sensitivity of Z. tritici field isolates to azoles 
(Gisi et al., 1997; Stergiopoulos et al., 2003; de Waard et al., 2006) or due to a specific 
mechanism correlated to changes in MFS1p, needs to be clarified in future studies.  
Altogether, the impact on tolnaftate sensitivity conferred by different MFS1p inserts was 
reflected in most cases in the sensitivity to epoxiconazole. Highest impact on tolnaftate 
sensitivity associated with the 519 bp insert was confirmed for the sensitivity to 
epoxiconazole. Additionally, lower impacts on tolnaftate sensitivity correlated to the 267, 
338, and 377 bp inserts were confirmed for epoxiconazole sensitivity. Significant differences 
in the tolnaftate sensitivity between isolates that carry the 369 bp insert and isolates with a 
WT MFS1p suggested a strong enhanced efflux activity in these isolates (described in 
4.6.2). However, this finding was not reflected in the impact on epoxiconazole sensitivity 
associated with the 369 bp insert. The number of tested isolates carrying a 267, 369 or 377 
bp insert was relatively low, as these inserts were rarely identified in Z. tritici across 2016 
and 2017. Evaluating the impact associated with these inserts on triazole sensitivity in a 
higher number of isolates is recommended for future studies to confirm the results obtained 
here.  
Compared to the sensitivity of wild type isolates (WT CYP51, WT CYP51p and WT MFS1p), 
isolates carrying an altered CYP51 haplotype and the WT MFS1p used in this chapter for 
sensitivity comparisons (Figure 24, Figure 25, Figure 26) showed on average a 19- to 306-
fold higher adaptation to epoxiconazole (calculated with mean EC50 values). Additionally, 
as described in chapter 4.3, investigated wild type isolates showed a 2.5-fold difference in 
their sensitivity to epoxiconazole. Compared to these values, results presented here 
indicate that the impact on epoxiconazole sensitivity associated with the 150, 267, 308, 338, 
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369, and 377 bp inserts in MFS1p seems of minor relevance. Additionally, compared to 
resistance levels of CYP51 haplotypes alone, results imply that the impact on 
epoxiconazole sensitivity associated with inserts in MFS1p appears lower compared to 
combination of CYP51 alterations. Nevertheless, an additive effect of an increased efflux 
activity on adaptation of Z. tritici was observed in isolates carrying the 519 bp insert in 
MFS1p. Therefore, prevalence of an increased efflux was investigated for Z. tritici across 
Europe.  
4.6.4 Frequency and distribution of inserts in MFS1p of Z. tritici 
across Europe 
All isolates from routine sensitivity monitoring of 2016 and 2017 were analysed for inserts 
in MFS1p to identify the frequency of an increased efflux activity in regional populations of 
Z. tritici in Europe. The designation of Omrane et al. (2017) for different MFS1p inserts 
(described in 1.4.3) will be used hereafter in order to simplify description. As no major 
differences were observed for the impact on epoxiconazole sensitivity correlated to the 267, 
308, and 377 bp inserts compared to the 338 and 369 bp inserts and a high sequence 
similarity was observed between all of these inserts, the 267, 308, and 377 bp inserts were 
also designated as type II inserts. Consequently, the 150 bp insert is referred to as type III 
insert, the 267, 308, 338, 369, and 377 bp insert as type II and the 519 bp insert as type I.  
Figure 27 A shows that in 2016 a heterogenous frequency of the 150 bp insert (type III), 
267, 338, 369, and 377 bp inserts (type II) and 519 bp insert (type I) in MFS1p was observed 
across Europe. In Denmark, Czech Republic, and Sweden, only the WT MFS1p was 
detected. The type III insert was mainly detected in Ireland (9.7%) and UK (6.3%) as well 
as in one isolate in Poland. This insert was not found in any other investigated country. Type 
II inserts were mainly detected in UK. In this country, type II inserts with a length of 267 bp 
(6.3%), 338 bp (7.9%), and 369 bp (3.2%) were detected. In Ireland, only the type II insert 
with 338 bp was found and the frequency was low (2.2%). The type II insert with 377 bp 
was solely identified in one isolate in Poland. In no other country was a type II insert found. 
The type I insert was found in Ireland, the Netherlands, France, Germany, and Poland in 





Figure 27: Frequency and distribution of inserts in MFS1p of Z. tritici across Europe. Isolates 
were obtained from BASF routine sensitivity monitoring. Frequency of isolates carrying a wild type 
MFS1p (WT MFS1p) and frequencies of isolates with an insert in MFS1p are shown. For some 
isolates no amplicon was observed after PCR (n.a.). The colour code is given in the legend in the 
figure. The number of tested isolates is given under the respective pie chart and the size of the pie 
chart is increasing with the number of tested isolates per country. The 150 bp insert was designated 
as type III insert, the 267, 308, 338, 369, and 377 bp inserts as type II and the 519 bp insert as type I. 
A: Distribution and frequency of isolates with WT MFS1p or with the 150, 267, 338, 369, 377, or 
519 bp insert identified in 2016. B: Distribution and frequency of isolates with a WT MFS1p or with 
the 150, 267, 308, 338, 369, or 519 bp insert identified in 2017. These results have been previously 
published partially in Huf et al., 2020.  
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In 2017, the type III insert, type II inserts with a length of 267, 308, 338, and 369 bp, and 
the type I insert in MFS1p were detected in heterogenous frequencies in Z. tritici across 
Europe (Figure 27 B). In that year, the type II insert with a length of 377 bp was not detected 
anymore. In Russia, Ukraine, Bulgaria, Slovakia, Czech Republic, Italy, and Spain, only 
isolates with the WT MFS1p were identified. The type III insert was mainly detected in 
Ireland (34.4%) and only in one additional isolate in France. In no other country was the 
type III insert found. With the exception of the Netherlands, a low frequency of type II inserts 
was observed. In Ireland, respectively 3.1% of type II inserts with a length of 338 or 369 bp 
were detected, whereas in UK just the 338 bp type II insert was found (4.2%). Single isolates 
with a type II insert (267 and 369 bp) were detected in Poland. In contrast to 2016, single 
isolates with type II inserts were also found in Germany (338 bp) and France (308 bp). In 
the Netherlands, type II inserts with a length of 267, 338 and 369 bp were detected in a 
frequency of 16.7 %, respectively. The type I insert was found in Ireland, UK, the 
Netherlands, Germany, and France in frequencies ranging from 4.2 to 8.3%. In Poland, no 
isolate with this insert was found anymore. All in all, MFS1p inserts were only detected in 
Western Europe and in the Central European countries Germany and Poland but not in 
Czech Republic, Slovakia, the Eastern and Southern European countries.  
Two isolates with a deletion in MFS1p were identified. The 148 bp deletion was detected in 
an isolate from Ukraine and the deletion of 165 bp in an isolate from Poland (results not 
shown).  
Changes in the frequency of different MFS1p inserts between 2016 and 2017 were 
compared for important cereal growing countries that were tested in both years. An increase 
in the frequency of the type III insert (~25%) was observed in Ireland accompanied with a 
decrease of the WT MFS1p (~25%). Frequencies of type II inserts decreased in UK (in total 
~20%) and increased in the Netherlands (in total ~50%). A lower number of isolates was 
tested in 2017 from Ireland and UK compared to 2016. In the Netherlands, the number of 
tested isolates was relatively small in both years. In these cases, a small sample size may 
contribute to strong frequency changes of MFS1p inserts because single isolates cause a 
high change in overall frequency distribution. In other countries no strong changes in the 
frequency of type II inserts were observed. However, as single isolates with a type II insert 
were also detected in Germany and France in 2017, in contrast to 2016, a wider distribution 
of these inserts was detected. Nevertheless, the frequency of type II inserts was low in 
these countries. Overall, frequencies of the type I insert stayed relatively stable in Germany, 
France, and Ireland across both years. In Poland, this insert was not detected anymore, 
and an increase was detected in UK because this insert was absent in 2016. However, the 
type I insert was only detected in one isolate in UK in 2017. In conclusion, these results 
indicate no increase in the frequency of an increased efflux activity in 2017 compared to 
2016 based on the frequency of the 519 bp MFS1p insert. A wider spreading of isolates 
carrying inserts with lower impacts on tolnaftate and epoxiconazole sensitivity, thus 
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probably on increased efflux, was observed in 2017. However, frequencies were low, except 
for Ireland and the Netherlands.  
4.7 Sensitivity of Z. tritici isolates accumulating multiple 
resistance mechanisms to DMIs  
At the beginning of this work, the epoxiconazole sensitivity of isolates from the routine 
sensitivity monitoring was correlated to their CYP51 haplotypes (shown in chapter 4.3). 
Across all isolates within a CYP51 haplotype group, pronounced variation in the sensitivity 
was observed. This variation was assumed to be conferred by other DMI resistance 
mechanisms than CYP51 alteration such as CYP51 overexpression or an increased efflux. 
In order to prove this hypothesis, the sensitivity distribution of Z. tritici isolates for all 
‘frequently found CYP51 haplotypes’ was visualised based on EC50 values of single isolates 
and additional DMI resistance mechanisms were highlighted. In the course of this work, it 
was shown that CYP51 overexpression is mainly correlated to the 121 bp insert in CYP51p 
and increased efflux is mainly associated with the 519 bp insert in MFS1p. Therefore, only 
isolates carrying one of these two inserts were designated as isolates showing CYP51 
overexpression or an increased efflux. Other inserts in CYP51p and MFS1p will be not 
considered in this chapter due to their low impacts on epoxiconazole sensitivity.  
Figure 28 shows that in most cases the highest adaptation to epoxiconazole within a CYP51 
haplotype could be associated with CYP51 overexpression and/or an increased efflux 
activity. These results confirm an additive effect of CYP51 overexpression and an increased 
efflux on epoxiconazole adaptation of Z. tritici isolates which already show an adaptation 
based on CYP51 haplotypes. Isolates that combine all three mechanisms (only identified 
for haplotype F2) showed highest adaptation within the F2 haplotype group. Most of these 
isolates were less sensitive than isolates with a F2 haplotype and CYP51 overexpression 
alone. These results indicate an additive effect of increased efflux on epoxiconazole 
adaptation in isolates with CYP51 overexpression. Nevertheless, isolates combining all 






Figure 28: Sensitivity of Z. tritici isolates with multiple resistance mechanisms to DMIs. EC50 
values of epoxiconazole (gained in microtiter tests from EpiLogic) for each isolate carrying a 
‘frequently found CYP51 haplotype’ are shown. Isolates that show additional resistance mechanisms 
as an increased efflux activity and/or CYP51 overexpression are highlighted. The colour code is 
given in the legend. The number of tested isolates is given in the diagram.  
In some cases, the highest epoxiconazole adaptation of isolates within a CYP51 haplotype 
group could not be explained by CYP51 overexpression or an increased efflux activity 
based on identification of the 121 bp insert in CYP51p and 519 bp insert in MFS1p. In the 
H6 haplotype group, highest adaptation of isolates could be correlated to other MFS1p 
inserts that confer in most cases only low effects on an increased efflux (results not shown). 
Despite the highest adaptation that can be explained by an increased efflux activity or 
CYP51 overexpression, a broad range in sensitivity of the remaining isolates within a 
CYP51 haplotype group was still observed. These results indicate that high variability in 
epoxiconazole sensitivity may be observed based on natural variability in epoxiconazole 
sensitivity of Z. tritici field isolates or that other mechanisms may play a role in 
epoxiconazole adaptation. Further studies would be required to test these assumptions in 
future studies.  
After investigation of the epoxiconazole sensitivity of Z. tritici populations across Europe, 
cross-resistance between different DMIs was investigated in the next chapter.  
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4.8 Evaluation of cross-resistance between different 
DMIs of Z. tritici isolates  
The correlation of the sensitivity to different DMIs resulting from microtiter tests was 
analysed to identify if adapted Z. tritici isolates show cross-resistance for different DMIs. 
Moreover, the composition of CYP51 haplotypes in surviving Z. tritici populations after DMI 
treatment was examined based on isolates derived from field trials.  
4.8.1 Correlation of the sensitivity of Z. tritici isolates to DMIs 
Z. tritici isolates were tested for their sensitivity towards epoxiconazole, 
mefentrifluconazole, and prothioconazole-desthio in order to evaluate cross-resistance 
between different DMIs. EC50 values were determined in microtiter tests by EpiLogic with a 
commercial formulation of epoxiconazole and mefentrifluconazole and the technical a.i. for 
prothioconazole-desthio. The technical a.i. of prothioconazole-desthio was used as this 
metabolite is suggested to be responsible for fungicidal activity of prothioconazole (Parker 
et al., 2011, 2013). A subset of isolates of the routine sensitivity monitoring was tested and 
sensitivity of isolates carrying a ‘frequently found CYP51 haplotype’ (n=376) was analysed 
in this chapter. EC50 values for tested DMIs were plotted against each other and the linear 
correlation was analysed. The cross-resistance pattern of different ‘frequently found CYP51 
haplotypes’ was investigated based on resistance factors for each tested compound. 
Correlations of EC50 values of ‘frequently found CYP51 haplotypes’ for the three tested 
DMIs are shown in Figure 29, Figure 30, and Figure 31. Across all tested isolates, EC50 
values ranged from 0.004 to 4.630 mg epoxiconazole L-1, 0.003 to 1.736 mg 
prothioconazole-desthio L-1, and 0.001 to 1.609 mg mefentrifluconazole L-1. Most of the 
EC50 values of a respective CYP51 haplotype clustered in groups for all three compounds, 
but variation in sensitivity within CYP51 haplotypes was observed. In this chapter, isolates 
with similar CYP51 haplotypes were not separated for additional DMI resistance 
mechanisms (CYP51 overexpression, increased efflux) because in most cases only a single 
isolate with or without an additional mechanism was detected within a haplotype group. 
Therefore, in some isolates, variation in sensitivity may be correlated to additional 
resistance mechanisms. For example, within the F2 haplotype group, one isolate showed a 
higher sensitivity, whereas remaining isolates showed a lower sensitivity to all three 
compounds. This higher adaptation could be correlated to CYP51 overexpression in these 




Figure 29: Correlation of EC50 values of Z. tritici isolates with ‘frequently found CYP51 
haplotypes’ for epoxiconazole and prothioconazole-desthio. The log-transformed EC50 values 
were used to calculate linear regression and the coefficient of determination (R2 = 0.6801) over all 
isolates. Isolates for which EC50 values for all three tested DMIs (epoxiconazole, mefentrifluconazole 
and prothioconazole-desthio) were available, are plotted in the diagram and the number is shown. 
These results have been previously published partially in Huf et al., 2018. 
 
Figure 30: Correlation of EC50 values of Z. tritici isolates with ‘frequently found CYP51 
haplotypes’ for epoxiconazole and mefentrifluconazole. The log-transformed EC50 values were 
used to calculate linear regression and the coefficient of determination (R2 = 0.2075) over all isolates. 
Isolates for which EC50 values for all three tested DMIs (epoxiconazole, mefentrifluconazole and 




Figure 31: Correlation of EC50 values of Z. tritici isolates with ‘frequently found CYP51 
haplotypes’ for prothioconazole-desthio and mefentrifluconazole. The log-transformed EC50 
values were used to calculate linear regression and the coefficient of determination (R2 = 0.0435) 
over all isolates. Isolates for which EC50 values for all three tested DMIs (epoxiconazole, 
mefentrifluconazole and prothioconazole-desthio) were available, are plotted in the diagram and the 
number is shown. 
A high correlation of the EC50 values (R2=0.6801) for most of the isolates was observed for 
epoxiconazole and prothioconazole-desthio (Figure 29). In contrast to this, a weak 
correlation (R2=0.2075) of EC50 values for most of the isolates was observed for 
epoxiconazole and mefentrifluconazole (Figure 30). Almost no correlation was observed for 
the EC50 values (R2=0.0435) of most of the isolates for prothioconazole-desthio and 
mefentrifluconazole as shown in Figure 31.  
The cross-resistance pattern of ‘frequently found CYP51 haplotypes’ based on resistance 
factors for the tested DMIs is shown in Table 19. Resistance factors were calculated as the 
ratio of mean EC50 of an adapted CYP51 haplotype to mean EC50 of the CYP51 wild type. 
Resistance factors are dependent on the intrinsic activity of a compound for wild type 
isolates. Therefore, the mean EC50 values for wild type isolates (chosen for resistance factor 
calculation) are additionally depicted in Table 19. Compounds with a high intrinsic activity 
often lead to higher resistance factors than compounds with a lower intrinsic activity. 
Mefentrifluconazole showed highest activity for wild type isolates, followed by 
prothioconazole-desthio and epoxiconazole.  
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Table 19: Resistance factors (RF) of Z. tritici isolates with ‘frequently found CYP51 
haplotypes’ for different DMIs. Resistance factors (RF) were calculated for epoxiconazole, 
mefentrifluconazole and prothioconazole-desthio as ratio of the mean EC50 of an adapted CYP51 
haplotype to mean EC50 of sensitive isolates (CYP51 wild type). EC50 values of isolates analysed for 
their sensitivity to epoxiconazole, mefentrifluconazole and prothioconazole-desthio from routine 
sensitivity monitoring were used and additionally of five reference isolates from EpiLogic. EC50 values 
were determined in microtiter tests by EpiLogic. Resistance factors are coloured according to 
resistance levels: low RF: < 30 = bright yellow, moderate RF: 31-65 = dark yellow and 66-100 = 





 C8  22  26  9 
 D13  132  43  49 
 E3  189  33  143 
 E4  69  13  53 
 E5  183  36  176 
 F2  97  180  49 
 F3  37  23  6 
 F4  149  53  39 
 F8  206  58  224 
 G1  34  83  11 
 H4  240  61  235 
 H6  393  266  109 
Mean EC50 (mg a.i. L-1) 
sensitive isolates 
 0.006  0.001  0.002 
 
Resistance factors ranged from 6 to 393 across all haplotypes and DMIs. Different cross-
resistance patterns for some haplotypes were observed. In Table 19, low resistance factors 
are coloured bright yellow, moderate resistance factors dark yellow and orange, and high 
resistance factors were coloured red. It was observed that cross-resistance patterns were 
in most cases more similar for epoxiconazole and prothioconazole-desthio compared to 
mefentrifluconazole. For example, high resistance factors were observed for haplotypes E3, 
E5, F8, and H4 for epoxiconazole and prothioconazole-desthio, whereas they were 
moderate for mefentrifluconazole. In contrast, haplotype F2 showed a high resistance factor 
for mefentrifluconazole, whereas resistance factors for epoxiconazole and prothioconazole-
desthio were lower. Additionally, moderate resistance factors were observed for 
epoxiconazole and prothioconazole-desthio with haplotype E4, whereas 
mefentrifluconazole showed a low resistance factor. In contrast, haplotype G1 showed a 
moderate resistance factor for mefentrifluconazole, whereas resistance factors were lower 
for epoxiconazole and prothioconazole-desthio. Haplotype C8 showed low resistance 
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factors for all three compounds, whereas high resistance factors for all three DMIs were 
observed for haplotype H6.  
In conclusion, results of the in vitro studies indicate that across all ‘frequently found CYP51 
haplotypes’ the level of cross-resistance is higher for epoxiconazole and prothioconazole-
desthio compared to mefentrifluconazole. Dependent on specific CYP51 haplotypes limited 
cross-resistance as well as full cross-resistance could be detected for the three tested DMIs.  
4.8.2 Composition of CYP51 haplotypes in Z. tritici populations 
following DMI treatment  
Isolates generated from field samples taken after fungicide application were investigated 
for their CYP51 haplotypes. The aim was to identify if different cross-resistance patterns 
between DMIs, that were indicated in in vitro studies in the previous chapter, can be 
associated with differences in the composition of CYP51 haplotypes of Z. tritici after DMI 
application in the field. Four field trials were conducted across Ireland, Germany, UK and 
Denmark from BASF SE and samples were taken in untreated, mefentrifluconazole 
(Revysol®) and prothioconazole (Proline®) treated plots in each trial. EpiLogic generated 10 
isolates from each sample resulting in 120 isolates. Afterwards, CYP51 haplotypes of these 
isolates were identified in this work.  
CYP51 haplotypes and their relative frequencies identified per sample and country are 




Figure 32: CYP51 haplotypes of Z. tritici and their relative frequency in field trials after 
application of mefentrifluconazole (Revysol®) and prothioconazole (Proline®). Field trials were 
conducted in four different countries (Ireland, UK, Germany, Denmark). Samples were taken in 
untreated, mefentrifluconazole and prothioconazole treated plots and 10 isolates were generated per 
sample by EpiLogic. Isolates were investigated for their CYP51 haplotypes and relative frequency of 
CYP51 haplotypes per country and treatment is shown.  
Untreated plots showed different compositions and varying relative frequencies of CYP51 
haplotypes across all four investigated countries. Compared to untreated plots, changes in 
the composition and frequencies of CYP51 haplotypes were detected in all fungicide treated 
plots across all four countries. Over all trials, a different trend in the pattern of remaining 
CYP51 haplotypes after treatment with mefentrifluconazole or prothioconazole was 
observed. In plots treated with mefentrifluconazole often haplotypes F2 and H6 were 
identified among others that were found in lower frequencies. Compared to this, in Ireland 
and UK, the pattern of CYP51 haplotypes detected after prothioconazole treatment seems 
more variable. Except haplotype E4, all haplotypes found after prothioconazole treatment 
in UK and Ireland had in common that they carry the alteration S524T. In contrast to this, 
haplotypes E4 and F2 were frequently detected after prothioconazole treatment in 
Germany. Haplotype E4 was also frequently found in Denmark after treatment with 
prothioconazole. Although a different trend in the selection pattern of prothioconazole and 
mefentrifluconazole is indicated, it should be noted that in some cases similar haplotypes 
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were observed in surviving isolates such as H6 in Ireland, F2 in Germany, and G1 in 
Denmark.  
Similarities between resistance patterns observed in vitro in the previous chapter (4.8.1) 
and CYP51 haplotype patterns after DMI application in the field can be observed partially. 
High resistance factors of haplotype F2 and H6 in vitro correlate to frequent detection of 
these haplotypes after mefentrifluconazole treatment. In vitro, high resistance factors for 
prothioconazole were mainly detected for haplotypes carrying alteration S524T. These 
findings correlate to frequent detection of haplotypes with this alteration after 
prothioconazole treatment. Haplotype F2 and E4 that were frequently found in 
prothioconazole treated plots in Germany (F2 and E4) and Denmark (E4) showed moderate 
resistance factors to prothioconazole in vitro. An important point to mention is that the 
relative frequencies shown in results of this chapter does not provide information about 
absolute frequencies of these CYP51 haplotypes in the field. This fact is further evaluated 
in the discussion in chapter 5.3. 
All in all, results of this chapter indicate a different trend in the selection pattern of CYP51 
haplotypes after application of mefentrifluconazole and prothioconazole supporting the 
assumption of limited cross-resistance observed in vitro. Nevertheless, the same CYP51 
haplotypes can be detected after both treatments in some cases. Correlation of in vitro 
resistance patterns and emergence of CYP51 haplotypes after DMI treatment was 
observed. It should be noted, however, that relative frequencies of CYP51 haplotypes were 
analysed in this chapter and that resistance factors in vitro do not necessarily correlate to 
efficacy of fungicides in vivo. Therefore, efficacy of different DMIs was tested in the 
glasshouse (in vivo) in this work and results are shown in the next chapter. 
4.9 Efficacy of DMIs in glasshouse studies 
DMI efficacies were tested in the glasshouse to evaluate DMI efficacy for Z. tritici isolates 
under conditions that correspond more to realistic conditions in the field. Z. tritici isolates 
with different CYP51 haplotypes and different levels of CYP51 expression or increased 
efflux were used in these studies. CYP51 haplotypes were chosen based on the frequency 
of haplotypes identified in the routine sensitivity monitoring from 2016 and 2017 and/or due 
to a high adaptation in microtiter tests (EC50 values of microtiter tests are shown in 
supplementary material Table 27). Isolates were obtained from routine sensitivity monitoring 
of 2017 or were provided from isolate collection of BASF SE. The DMIs epoxiconazole 
(Opus®), mefentrifluconazole (Revysol®) and prothioconazole (Proline®) were applied in 
solo formulations one day preventatively. Visual assessment of the diseased leaf area was 
performed 21 dpi and the efficacy (inhibition %) of fungicides was calculated. Each isolate 
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was tested in two independent experiments (except the isolate carrying haplotype E1 that 
was tested three times due to methodological split of all tested isolates).  
In Figure 33, efficacy of epoxiconazole, mefentrifluconazole, and prothioconazole in the 
glasshouse for the tested isolates is shown. The isolate carrying haplotype E1 was used as 
an internal control (reference isolate). This isolate showed a low DMI adaptation in microtiter 
tests. In glasshouse tests it was fully controlled (99-100%) by epoxiconazole and 
mefentrifluconazole and a high efficacy was observed for prothioconazole (93%). Across all 
other isolates, a variable efficacy was observed dependent on the tested DMI and isolate. 
Statistical differences between the efficacy for the reference isolate and the grouped 
efficacies across all remaining haplotypes were calculated with the Kruskal-Wallis-Test 
(significance level: p<0.05). Compared to the reference, a significantly reduced efficacy of 
epoxiconazole and prothioconazole was observed across all remaining haplotypes, 
whereas no significantly reduced efficacy was observed for mefentrifluconazole. Efficacy of 
epoxiconazole was lowest for isolates with haplotype H6, which additionally exert an 
increased efflux activity, and haplotype I2 with mean inhibition levels of around 75%, 
respectively. Inhibition of remaining haplotypes was higher (> 80%). Efficacy of 
mefentrifluconazole was slightly reduced (85%) only for the isolate carrying haplotype G2 
and additionally exerting slight CYP51 overexpression and slight efflux. For all remaining 
haplotypes mean inhibition of mefentrifluconazole was high with at least 90%. Mean 
inhibition levels of prothioconazole ranged between 44-67%. Highest reduction in efficacy 
was observed for isolates carrying haplotypes H6 (with increased efflux) and I2. 
Methodological issues may interfere with lower and more variable efficacies of 
prothioconazole compared to epoxiconazole. With regard to Z. tritici on wheat, in BASF SE, 
it is experienced that prothioconazole often performs more poorly under controlled 
conditions in the glasshouse compared to the field.  
Isolates carrying the F2 haplotype additionally showed CYP51 overexpression. A high 
efficacy of epoxiconazole (89-93%) and mefentrifluconazole (93-99%) was observed for 





Figure 33: Efficacy of epoxiconazole (Opus®), mefentrifluconazole (Revysol®), and prothioconazole (Proline®) for Z. tritici isolates in glasshouse 
experiments. Fungicides at full registered field rate (epoxiconazole: 125 g a.i. ha-1, mefentrifluconazole: 150 g a.i. ha-1, prothioconazole: 200 g a.i. ha-1) were 
applied one day preventative in three replicates. Isolates with different CYP51 haplotypes and with or without different levels of CYP51 expression (indicated 
by sign Δ) and/or an increased efflux activity (indicated by sign +) were tested (explanation of signs is given in the diagram). An isolate (n=1) with a low DMI 
adapted CYP51 haplotype (E1) was used as internal control (reference isolate). Respectively one isolate (n=1) was tested for haplotype E4 (Δ), E4 (Δ;++), 
F2 (ΔΔ), F2 (ΔΔ;++), G2 (Δ), G2 (Δ;+) and two isolates (n=2) for H6 (Δ;++) and I2 (Δ). Each isolate was tested in two independent experiments (except for 
haplotype E1 that was tested three times due to methodological split of all tested isolates). Mean values of inhibition (%) of the applied DMIs and standard 
deviations are shown. Mean values and standard deviations were calculated across independent experiments. Statistical differences between the efficacy 
for the reference and grouped efficacies across all haplotypes were calculated with Kruskal-Wallis-Test (significance level: p= <0.05). In comparison to the 
reference isolate, statistical differences for grouped efficacies across all remaining haplotypes were observed in the efficacy of epoxiconazole (p=0.0106) 
and prothioconazole (p=0.0062) but not for mefentrifluconazole (p=0.0802).  
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In glasshouse tests, isolates with the same CYP51 haplotype but differing in the absence 
or presence of an increased efflux were tested. In the case of haplotype E4 no decrease in 
efficacy of all DMIs was observed for the isolate with an increased efflux compared to the 
isolate carrying haplotype E4 and no increased efflux. In case of haplotype F2 and G2 a 
slight decrease (4-8%) in the efficacy of epoxiconazole and mefentrifluconazole was 
observed for the isolate with an increased efflux. Among all CYP51 haplotypes, 
prothioconazole only showed a slight reduced efficacy (4%) for the isolate with haplotype 
F2 and increased efflux. As isolates with haplotype F2 additionally show CYP51 
overexpression and varying impacts associated with CYP51 overexpression were observed 
(shown in 4.5.2), it cannot be clarified if lower efficacy for the isolate carrying CYP51 
overexpression and an increased efflux is driven by an increased efflux or by a stronger 
CYP51 overexpression. Additionally, as no isolate carrying haplotype H6 without an 
additional increased efflux was tested, it cannot be clarified if an increased efflux contributes 
to lower efficacy of epoxiconazole and prothioconazole for these isolates compared to 
remaining isolates. Altogether, no clear conclusion about the impact of an increased efflux 
on efficacy of DMIs in vivo could be drawn. A contribution to a slight reduction in DMI 
efficacy seems possible in single cases. Nevertheless, this reduction was observed to be 
low and in cases in which a reduction was observed, efficacy of epoxiconazole and 
mefentrifluconazole was still at a high level.  
Resistance factors observed in in vitro studies for haplotypes E4, F2, and H6 (described in 
chapter 4.8.1) could only be correlated partly to efficacies of different DMIs in the 
glasshouse. High resistance factors for haplotype H6 were observed for epoxiconazole and 
prothioconazole-desthio, whereas the resistance factors for the E4 and F2 haplotype were 
moderate. These results correlate to lowest efficacy of epoxiconazole and prothioconazole 
for haplotype H6 (mean inhibition) in glasshouse tests, whereas efficacy for haplotype E4 
and F2 (mean inhibition) was higher. In contrast, high resistance factors were detected for 
mefentrifluconazole for haplotypes F2 and H6 in vitro. Efficacies of mefentrifluconazole in 
glasshouse tests for isolates carrying a F2 or H6 haplotype were on average high with at 
least 90% inhibition. These results indicate that high resistance factors in vitro do not 
necessarily imply a low efficacy of DMIs in the glasshouse and that the correlation between 
resistance factors observed in vitro and the efficacy of DMIs in the glasshouse (in vivo) may 





5 Discussion  
During the last few decades, DMIs have been the most widely used fungicides and still 
represent an important tool in disease management of wheat, including STB (Parker et al., 
2011; Cools and Fraaije, 2013; Jørgensen et al., 2018; Heick et al., 2017a; Kildea et al., 
2019; Jørgensen et al., 2019). Over many years, intensive application of DMIs has resulted 
in the evolution of DMI adaptation and a gradual shift towards a reduced sensitivity of the 
Z. tritici population in Europe (Cools et al., 2011; Lucas et al., 2015; FRAC, 2019). Molecular 
mechanisms conferring DMI resistance in Z. tritici include alteration of the CYP51 target 
enzyme, CYP51 overexpression and an increased efflux activity of membrane transporters. 
The most studied and reported mechanism is the alteration of CYP51, whereas contribution 
of CYP51 overexpression and an increased efflux activity in Z. tritici across Europe is less 
intensively studied so far (Stammler et al., 2008b; Stammler and Semar, 2011; Leroux and 
Walker, 2011; Cools and Fraaije, 2013; Jørgensen et al., 2019).  
In this work, an overview about the occurrence of different DMI resistance mechanisms in 
Z. tritici across Europe and their impact on DMI sensitivity has been shown. In the following 
chapter the emergence, distribution, and impact of these mechanisms is discussed. 
Combination of different DMI resistance mechanisms and further evolution of these 
mechanisms is considered. Furthermore, cross-resistance patterns of different DMIs are 
debated with regard to future DMI usage and resistance management approaches. The 
impact of different DMI resistance mechanisms on field performance and possible 
consequences for future DMI application for STB control are also discussed.  
5.1 Emergence of DMI resistance in Z. tritici  
5.1.1 Alteration of CYP51: Ongoing evolution after 30 years of 
changes?  
Since the first detection of a CYP51 alteration in isolates from 1988, new alterations in 
CYP51 of Z. tritici emerged successively over time and space and the sequential 
accumulation of these alterations has led to the emergence of increasingly more complex 
CYP51 haplotypes (Cools and Fraaije, 2013; Lucas et al., 2015). In this work, sequencing 
of the CYP51 gene of Z. tritici isolates from routine sensitivity monitoring programmes for 
2016 and 2017 revealed the prevalence of 23 CYP51 alterations that have already been 
described in literature (Stammler et al., 2008b; Cools and Fraaije, 2013). Previously, 
deletions in CYP51 of Z. tritici were shown to occur in amino acid region YGYG at positions 
459-462 coded by nucleotides TAT/GGC/TAC/GGC (Stammler et al., 2008b). With the 
exception of two isolates, all investigated isolates that showed a deletion in CYP51 showed 
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missing codons for Y459 (TAT) and Y460 (GGC) with remaining codons in this region 
observed to be TAC/GGC (data not shown). Consequently, isolates carrying a CYP51 
haplotype with a deletion frequently showed a combination of deletions Y459 and Y460. 
Seldomly a single amino acid deletion was detected (only found in one isolate with 
haplotype E26). Additionally, only one isolate showed a remaining DNA sequence of 
TAT/GGC at codon positions 459-462 (data not shown). In this isolate the amino acid at 
position Y461 was deleted and either G460 or G462 (haplotype E21). It could not be clarified 
in this work if amino acid position G460 or G462 was deleted based on sequence 
alignments. Occurrence of such isolates was already reported before (Stammler et al., 
2008b), but clarification if amino acid G460 or G462 is deleted, would need further 
investigations.  
Besides the 23 existing alterations, 11 new CYP51 alterations that were not described so 
far were identified. Molecular characterisation of the location of these new alterations within 
the CYP51 enzyme and phenotypical assessment of the sensitivity of isolates carrying 
these new alterations gave information about their potential impact on DMI binding and DMI 
sensitivity.  
Amino acid alterations in CYP51 can affect binding of triazoles in different ways. In their 
work, Mullins et al. (2011) and Becher and Wirsel (2012) described that an alteration may 
lead to conformational changes that confer a loss of interaction between the triazole and a 
specific residue (or residues). Another possibility is the direct substitution of such a key 
residue. Both can lead to a disturbed accommodation of the triazole within the binding cavity 
that may lead to a hindered interaction of the triazole with the haem. A third possibility is 
the disturbed access of the triazole to the active site (Mullins et al., 2011; Becher and Wirsel, 
2012). In Figure 34, binding of the triazole triadimenol to the wild type CYP51 is shown. 
Amino acid positions V136, Y137, I381, Y459, G460, and Y461 known to be the subject of 
existing alterations associated to DMI adaptation were localised at the border of the binding 
pocket (Mullins et al., 2011). In contrast, amino acids L50 and A379 were not observed to 
be directly bordering the binding pocket but form parts of the secondary structure adjacent 
to the binding cavity. Amino acids S188 and N513 are located far away from the binding 
region (Mullins et al., 2011). This modelling is in accordance with the observation that 
alterations L50S, S188N, and N513K are not associated with DMI adaptation, whereas 
alterations of amino acids V136, Y137, I381, Y459, G460, and Y461 drive DMI adaptation 
or compensatory effects enabling DMI adaptation (Cools et al., 2010, 2011; Mullins et al., 





Figure 34: Protein model of CYP51 wild type with bound triadimenol (orange) and location of 
amino acids subject to alterations. Picture was extracted from Mullins et al., 2011. Amino acids 
L50, V136, Y137, S188, A379, I381, and N513 labelled in grey, region of Y459, G460, Y461 labelled 
in yellow, haem group labelled white. Amino acids L50 and A379 form parts of secondary structure 
directly adjacent to the binding cavity but do not border it. Amino acid S188 and N513 are located far 
away from the binding cavity at the outside of the protein. Amino acids V136 and Y137 are located 
at the end of the access channel of the binding pocket, whereas I381, Y459, G460, and G461 are 
located at the end of the binding pocket at haem site (Mullins et al., 2011).  
As positions of amino acids K95, I452, and N507, that were observed to be subject of new 
CYP51 alterations, are located far away from the haem group, and thus from the binding 
pocket, the relevance of these residues in triazole binding may be considered to be minor. 
Mullins et al. (2011) identified 86 specific residues lining the binding pocket of the wild type 
protein and additionally several residues, among them V136, Y137, I381, Y459, G460, and 
Y461, in close proximity to different bound triazoles. Although compared to position of amino 
acids K95, I452, and N507, the remaining amino acids that were observed to be subject of 
new alterations were located in closer proximity to the haem, only positions L197, E457, 
D458, and Y461 represent residues lining the binding pocket according to Mullins et al. 
(2011). Among those four amino acid residues, E457, D458, and Y461 were observed 
additionally to be located in close proximity to the docked triazoles but not L197 (Mullins et 
al., 2011). Based on these results it may be deduced that across all new alterations probably 
only the deletion of E457 and D458 as well as alteration Y461N may affect DMI binding. 
This assumption may be supported by findings for neighbouring residues in the region 
Y459-Y461. Deletions or alterations in this region result in severe structural rearrangements 
of CYP51 and/or in the loss of residues that confer a disturbed interaction to triazoles 
(Mullins et al., 2011). 
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The effect of new CYP51 alterations on DMI sensitivity was tested by comparing the 
sensitivity of CYP51 haplotypes that differ in the presence or absence of new alterations or 
to the CYP51 wild type. As CYP51 alterations almost always occur in combinations, this is 
a commonly applied method to assess the effect of single alterations (Cools et al., 2011; 
Leroux and Walker, 2011). Depending on the alteration and test method around a 2- to 8-
fold higher epoxiconazole adaptation was correlated to the individual impact of alterations 
V136A, I381V, and S524T, known as key alterations in DMI resistance evolution (Cools et 
al., 2011; Leroux and Walker, 2011; Lucas et al., 2015). Compared to this, no strong effects 
on epoxiconazole sensitivity could be associated with a high level of certainty to new CYP51 
alterations identified in this work. It should be clarified in future studies, whether the 2.5-fold 
higher adaptation in the isolate carrying alteration A318G is driven by this alteration or a 
slight increased efflux. However, such a study would require an isolate with alteration 
A318G but no additional resistance mechanism or, for example, heterologous expression 
studies with this alteration in S. cerevisiae (Cools et al., 2010) which are currently not 
available. Furthermore, future studies would be required to assess the individual effect of 
alteration L197V and deletion of amino acids K456, E457, D458, and L463. As these 
alterations occur together with deletion of Y459, G460, Y461, and G462, already known for 
their relevant role in DMI adaptation (Mullins et al., 2011; Cools and Fraaije, 2013), it may 
be speculated that these latter alterations contribute to the 3-fold higher epoxiconazole 
adaptation in isolates carrying haplotype I4 (L197V, Del K456-L463). Resistance levels of 
isolates carrying haplotype I4, however, were observed to be very low compared to isolates 
carrying more adapted CYP51 haplotypes that are frequently found in Z. tritici (this work; 
Leroux and Walker, 2011; Stammler et al., 2008b; Cools et al., 2011; Buitrago et al., 2014). 
Therefore, no further studies were conducted to investigate haplotype I4. Nevertheless, it 
cannot be excluded that deletion of the whole amino acid region from K456 to L463 
becomes relevant when combined with other CYP51 haplotypes. As most of the new 
alterations were only found in a single isolate, it is recommended to confirm results of this 
work in future studies when new isolates with these alterations are found. In addition, 
molecular techniques such as CRISPR-Cas9 may be used to explore the individual effect 
of new target site alterations. Compared to traditional genetic approaches, CRISPR-Cas9 
was shown to be a simple as well as precise system that facilitates the introduction of 
desired mutations (reviewed in Deng et al., 2017; reviewed in Schuster and Kahmann, 
2019). Introduction of the new CYP51 mutations into the CYP51 wild type would enable 
investigation of their individual effect on DMI sensitivity without the interference of the effect 
of other mutations.  
Alterations with no clear effect on DMI sensitivity of Z. tritici such as L50S, S188N, and 
N513K were commonly identified in modern Z. tritici populations (this work; Leroux et al., 
2007; Cools and Fraaije, 2013). The widespread occurrence of these alterations is 
suggested to rely on the emergence of amino acid alterations that affect DMI sensitivity in 
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CYP51 haplotype backgrounds that already carry either L50S, S188N, or N513K alone or 
in combination (Cools and Fraaije, 2013). Additionally, it was shown that CYP51 alterations 
with or without an impact on DMI sensitivity may confer conformational changes in the 
enzyme that increase selective pressure of triazoles on individual amino acid residues or 
enable the emergence of other alterations that were otherwise lethal (e.g. alteration I381V) 
(Mullins et al., 2011; Cools et al., 2010, 2011; Lucas et al., 2015). Consequently, it cannot 
be excluded that new alterations observed in this work may drive such conformational 
changes of CYP51 and may enable emergence of new alterations in the future. This 
assumption, however, was not proven in this work and would require further elucidation 
using protein modelling studies of CYP51 proteins carrying the new alterations. Although 
there was no strong impact of the new alterations on epoxiconazole sensitivity in this work, 
their occurrence indicates that CYP51 can still accept changes in the protein structure 
without losing its enzymatic function. In addition, it confirms the high level of flexibility of the 
protein which was already suggested after the emergence of various amino acid alterations 
in the past (Becher and Wirsel, 2012). Lucas et al. (2015) suggested that the occurrence of 
alterations in CYP51 is a dynamic process in Z. tritici that was expected to continue at the 
time of publication. This assumption was confirmed in this work based on the identification 
of newly emerged CYP51 alterations in Z. tritici isolates and thus confirm the ongoing 
evolution of CYP51 which is likely to continue in the future.  
Most of the CYP51 alterations were found in different combinations leading to distinct 
CYP51 haplotypes. An ongoing emergence of new CYP51 haplotypes was described for 
Z. tritici over three decades (Stammler et al., 2008b; Brunner et al., 2008; Stammler and 
Semar, 2011; Leroux and Walker, 2011; Lucas et al., 2013; Buitrago et al., 2014). The 
occurrence of new CYP51 alteration has led simultaneously to the emergence of new 
CYP51 haplotypes. Additionally, so far not described CYP51 haplotypes based on new 
combinations of already existing alterations were identified during the current work. New 
combinations of already existing alterations were shown probably to occur due to intragenic 
recombination (Brunner et al., 2008). The occurrence of new CYP51 haplotypes confirms 
the assumption above that CYP51 evolution is still ongoing and that new combinations of 
new and/or already existing amino acid alterations continue to occur. This finding was 
additionally confirmed by studies of Kildea et al. (2019) who also identified new CYP51 
haplotypes based on new combinations of already existing alterations. In total, 57 CYP51 
haplotypes were identified across all investigated isolates from 2016 and 2017, but only 13 
haplotypes were identified more frequently (‘frequently found CYP51 haplotypes’). The 13 
‘frequently found CYP51 haplotypes’ represented the majority (~89%) of all investigated 
isolates from routine sensitivity monitoring of 2016 and 2017, whereas the remaining 44 
‘rarely found CYP51 haplotypes’ only accounted for around 11%. Therefore, the main focus 
in this discussion is on these ‘frequently found CYP51 haplotypes’. In the course of this 
work, a new nomenclature was proposed to describe CYP51 haplotypes of Z. tritici. Due to 
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the complex evolution and occurrence of different evolutionary pathways for various CYP51 
haplotypes (Lucas et al., 2013) the proposed approach is not intended to reflect CYP51 
evolution. Instead, it is intended to give a more systematic and sustainable description of 
CYP51 haplotypes enabling a description of haplotypes in the ongoing evolution of CYP51 
because it can be used and amended continuously in the future. An assignment of the new 
nomenclature to CYP51 haplotypes that were detected in the past was published in the 
course of this work in Huf et al. (2018) and the nomenclature was already used and 
amended by different authors (Kildea et al., 2019; McDonald et al., 2019) during the time of 
this work.  
5.1.2 Emergence and identification of CYP51 overexpression and 
increased efflux activity in Z. tritici  
CYP51 overexpression has been reported as a mechanism contributing to DMI resistance 
in plant and human pathogens (Ma and Michailides, 2005; Cools and Fraaije, 2013; 
reviewed in Ziogas and Malandrakis, 2015). Increased CYP51 expression was shown to 
rely either on an increased CYP51 copy number (Marichal et al., 1997; Coste et al., 2007) 
or on inserts in the CYP51 regulatory region (Cools et al., 2013; Ziogas and Malandrakis, 
2015). A possible contribution of an increased CYP51 expression in DMI adaptation of 
Z. tritici was already suggested in 2003 (Stergiopoulos et al., 2003). In 2012, a 120 bp insert 
in CYP51p was identified and shown to be correlated to an increased CYP51 expression of 
Z. tritici (Cools et al., 2012).  
An increased efflux activity in fungal pathogens, commonly referred to as multi-drug-
resistance (MDR) in literature, is based on the overexpression of membrane bound efflux 
transporters and known to reduce sensitivity to unrelated fungicides (reviewed in Gulshan 
and Moye-Rowley, 2007; Morschhäuser, 2010; Hahn and Leroch, 2015). In 2011, Z. tritici 
isolates were detected that were highly resistant to DMIs but also to other unrelated 
fungicides suggesting that an active efflux of membrane bound transporters contribute to 
DMI resistance of Z. tritici (Leroux and Walker, 2011). In 2015, RNA sequencing revealed 
that the overexpression of the MFS1 transporter is responsible for an increased efflux 
activity in Z. tritici. This overexpression was conferred by different insertions in MFS1p 
(Omrane et al., 2015, 2017).  
In the current study, the CYP51p and MFS1p of all isolates was investigated for the 
presence of inserts in order to identify the occurrence and frequency of CYP51 
overexpression and an increased efflux activity in Z. tritici across Europe.  
Across all isolates, four different CYP51p inserts and seven different MFS1p inserts were 
identified. Length of inserts in comparison to inserts described in literature are summarised 
in Table 20.  
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Table 20: Summary of inserts and insertion sites identified in CYP51p and MFS1p of Z. tritici 
in this work and comparison to inserts in the literature, when available.  The sign ‘-‘ shows that 
this insert was identified for the first time in the current work. 
Promotor region  Length of insert (bp) / insertion 
site (bp upstream of start codon 
in IPO323) in this work  
Length of insert (bp) / 
insertion site in literature 
(Source) 
CYP51 
121 / -83 120 / -83 (1) 
863 / - 207 862 / -205 (4) 
868 / -184 866 / -184 (2) 
300 / -118 - 
MFS1 
150 / -214 150 / -201 (3) 
267 / -468 - 
308 / -468 - 
338 / -468 338 / -455 (3) 
369 / -468 369 / -455 (3) 
377 / -468 - 
519 / -402 519 / -401 (2) 
1Cools et al., 2012; 2Omrane et al., 2015; 3Omrane et al., 2017; 4Kildea et al., 2019 
 
MFS1p inserts identified in this work showed similar sequences and length compared to 
MFS1p inserts described by Omrane et al. (2015, 2017). CYP51p inserts were almost 
identical in length and sequence compared to the 120 (Cools et al., 2012), 862 (Kildea et 
al., 2019), and 866 bp inserts (Omrane et al., 2015) described in literature. Nevertheless, 
small differences of one or two nucleobases in length were observed. Additionally, for some 
inserts, differences in the insertion sites between inserts of this work and inserts in literature 
were observed. Sequence duplications (target site duplications) were observed in all 
isolates carrying an insert in MFS1p or CYP51p except for the 121 bp CYP51p insert. In 
contrast to most parts of this work, the term target site is not restricted to a gene in this 
chapter but can also refer to a promotor. Emergence of target site duplications in association 
with insertions will be discussed later in this chapter. However, at this point it should be 
mentioned that based on the sequence alignment alone, insertion sites of the MFS1p or 
CYP51p inserts could not be determined with a high level of certainty from this work. It was 
not clarified if insertion of the inserts occurred left- or right-hand site of the duplicated 
sequence upon insertion in the native gene. Therefore, it is possible that insertion sites 
shown here have to be shifted by the number of nucleobases of the respective sequence 
duplication. Especially in the case of the 338 bp MFS1p insert, insertion sites may have to 
be shifted by a couple of nucleobases. However, precise assignment of these insertion sites 
was no issue in this work and would need further bioinformatical investigations in the future. 
Nevertheless, these circumstances may explain differences between insertion sites of 
inserts in this work and published in literature. Small differences in length or position of 
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insertion sites between inserts identified in this work and already published ones may also 
result from a high genetic variability known for Z. tritici field isolates (Schnieder et al., 2001; 
reviewed in Simón et al., 2012). Furthermore, as sequencing was performed based on PCR 
products, methodological issues during sequencing or afterwards during sequence 
alignment may contribute to these small differences, because alignment of sequences is 
highly dependent on the algorithm used and on the number of aligned sequences. Due to 
these reasons, it was assumed that small differences between inserts identified in this work 
and described in literature are negligible and that inserts identified in this work are equal to 
inserts identified in literature. Therefore, the CYP51p inserts with a length of 121, 863, and 
868 bp identified in this work will be described hereafter in the discussion as 120, 862, and 
866 bp inserts. 
Compared to the WT CYP51p, the 120 bp insert in CYP51p was correlated to a 10- to 40-
fold constitutive overexpression of CYP51 that was not induced by addition of 
epoxiconazole (Cools et al., 2012; Kildea et al., 2019). CYP51p inserts associated with 
CYP51 overexpression were identified also in other plant pathogens. For example, a 126 bp 
tandem repeated sequence or a 199 bp insert confer a higher PdCYP51 expression in 
P.  digitatum (Hamamoto et al., 2000; Sun et al., 2013). A 533 bp insert confers a 18-fold 
constitutive ViCYP51 overexpression in V. inaequalis (Schnabel and Jones, 2001) and a 
65 bp repetitive element (named mona) in Monilinia fructicola results in a 5- to 11-fold higher 
increased constitutive MfCYP51 expression (Luo and Schnabel, 2008). In contrast to the 
120 bp insert, it is assumed that the 862 and 866 bp inserts alone do not alter CYP51 
expression of Z. tritici (Omrane et al., 2015; Kildea et al., 2019). A slight increase in CYP51 
expression of isolates carrying either the 862 or 866 bp insert was observed upon addition 
of epoxiconazole, however, expression levels were still at a low level compared to the wild 
type (Kildea et al., 2019). The molecular effect of the newly identified 300 bp insert on 
CYP51 expression has not been tested during this work and analysing CYP51 mRNA levels 
in isolates carrying the 300 bp insert is recommended for future research. 
Molecular studies revealed that the 150, 338, 369, and 519 bp inserts in MFS1p are 
correlated to an increased expression of MFS1 with highest effect exerted by the 519 bp 
insert (Omrane et al., 2017). In Z. tritici, overexpression of MFS1 varied between 28- to 50-
times in strains showing an MDR profile compared to sensitive strains (Omrane et al., 2015). 
A comparison to the effect of MFS1p inserts on MFS1 expression in other fungal plant 
pathogens is critical because increased efflux based on MFS1 overexpression is not a 
widespread phenomenon so far. Besides Z. tritici, only in B. cinerea, one of the best studied 
fungal plant pathogens concerning increased efflux activity, overexpression of an MFS 
transporter was reported. In B. cinerea, two types of a promotor insert lead to an over 600-
times increased constitutive BcMFSM2 expression (Kretschmer et al., 2009; Mernke et al., 
2011). Molecular examination of the MFS1 expression level in Z. tritici isolates carrying the 
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newly described 267, 369, and 377 bp inserts was not performed in this work but is 
recommended for future studies.  
As described above, target site duplications directly adjacent to all inserts in CYP51p 
(except the 120 bp insert) and MFS1p were identified. These target site duplications may 
yield information about the origin of these inserts. Insertion of transposable elements (TEs) 
almost always results in short target site duplications based on the process of transposition. 
This process includes cleavage of the target molecule that results in cohesive (sticky) ends 
and subsequent filling of unpaired oligonucleotides after insertion of the TE (Shapiro, 1979; 
Kleckner, 1981; Kempken and Kück, 1998; Wicker et al., 2007). In filamentous fungi it was 
observed that these target site duplications can vary between 2 to 17 bp dependent on the 
organism and the type of transposon (reviewed in Kempken and Kück, 1998). Therefore, 
target site duplications identified at insertion sites of CYP51p and MFS1p inserts may 
indicate that these inserts derive from transposition of transposable elements (or parts of 
those). This assumption is supported by the fact that BLASTn searches with the 120, 862, 
and 866 bp inserts of CYP51p and with the 150 and 519 bp insert of MFS1p revealed 
multiple regions showing high sequence similarities throughout the Z. tritici genome (Cools 
et al., 2012, Omrane et al., 2015, 2017; Kildea et al., 2019). Indeed, the 519 bp insert in 
MFS1p region was described to be a relic of a Class 1 Ty1/Copia retrotransposon that is 
still active in Z. tritici (Omrane et al., 2015). Additionally, a high number of sequence 
similarities between the 338 and 369 bp inserts to other sequences of IPO323 were 
identified and consequently it was suggested that these inserts may also derive from a 
repeated element or part of it (Omrane et al., 2017). As the newly identified inserts of MFS1p 
(267, 308, and 377 bp) showed a high identity to each other and to the 338 and 369 bp 
insert, it may be speculated that they derive from the same repeated element. Interestingly, 
these type II inserts from MFS1p showed a high sequence identity to the newly identified 
300 bp insert in CYP51p (results not shown). This finding supports the suggestion that these 
inserts represent repetitive elements derived from a TE. In many other plant pathogens it 
was already described that inserts in CYP51p conferring CYP51 overexpression often 
belong to TEs and contain strong promotor sequences (Schnabel and Jones, 2001; Luo 
and Schnabel, 2008; Cools et al., 2013; Sun et al., 2013; Ziogas and Malandrakis, 2015). 
In Z. tritici, at least 17% of the genome were estimated to be repetitive and 70% of the total 
repetitive content was shown to be represented by Class I TEs (amplify via RNA 
intermediate) (Dhillon et al., 2014). TEs contribute to genomic rearrangements, relocation 
of genes, generation of new genes and can alter regulation of gene expression. Therefore, 
TEs are suggested to play a relevant role in the evolutionary adaptation of living organisms 
as they are the main source of genome plasticity (reviewed in Gozukirmizi, 2019). Further 
clarification about the role of TEs in gene and genome evolution may help to understand 
genome plasticity and its effect on the adaptation of organisms, among them Z. tritici, to 
changing environments (Kempken and Kück, 1998; Dhillon et al., 2014; Gozukirmizi, 2019). 
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Therefore, future research about the origin of CYP51p and MFS1p inserts and analysing if 
they derive from transposable elements may be helpful to understand evolutionary 
adaptation of Z. tritici.  
The insertion of TEs inside or outside of the promotor may introduce regulatory elements 
that impact gene expression (reviewed in Girard and Freeling, 1999; Rebollo et al., 2012; 
Krishnan et al., 2018). Different effects of inserts in MFS1p on gene expression were 
suggested to occur due to different upstream activation sequences (UAAs) that may recruit 
transcription activators or coactivators and thus increase transcription (Hahn and Young, 
2011; Omrane et al., 2017). In fact, different regulatory elements were identified in the 519 
and 338/369 bp inserts, whereas no regulatory elements were found in the 150 bp insert. 
Consequently, it was speculated that the 519 and 338/369 bp inserts induce overexpression 
on their own, whereas the 150 bp insert may function through the release of inhibition of 
MFS1 transcription (Omrane et al., 2017). Research on how inserts in MFS1p drive 
overexpression, however, is just at its beginning and further studies are needed to fully 
understand this phenomenon as well as different levels of overexpression. Additionally, 
CYP51p inserts were not investigated for regulatory elements so far. Such studies may help 
to understand why the 120 bp insert is responsible for CYP51 overexpression (Cools et al., 
2012), whereas the inserts around ~900 bp do not alter CYP51 expression (Kildea et al., 
2019).  
5.2 DMI resistance mechanisms of Z. tritici: Impact on 
DMI sensitivity, evolution, and prevalence across 
Europe 
5.2.1 CYP51 haplotypes of Z. tritici 
In vitro sensitivity studies (microtiter tests) revealed that all isolates with ‘frequently found 
CYP51 haplotypes’ showed a reduced sensitivity to epoxiconazole compared to wild type 
isolates. A 20- to 350-fold higher adaptation dependent on the CYP51 haplotype was 
observed. Differences in epoxiconazole sensitivity between isolates with these CYP51 
haplotypes in this work confirm effects of CYP51 alterations that have been reported before 
(Leroux and Walker, 2011; Cools et al., 2011, 2013; Cools and Fraaije, 2013). An additive 
effect of alteration D134G and V136A on adaptation to epoxiconazole was observed in this 
work. As alteration D134G always occurs in combination with other alterations, the 
individual effect of this alteration is still unclear (Cools and Fraaije, 2013). However, the 
effect of alteration V136A on a reduced DMI sensitivity has been proven before (Leroux and 
Walker, 2011; Cools et al., 2011; Cools and Fraaije, 2013) and it is likely that higher 
adaptation of haplotype E4 compared to haplotype C8 (only differing in alteration D134G 
Discussion 113 
 
and V136A) is driven by alteration V136A. In this work, the highest adaptation to 
epoxiconazole was correlated to alteration S524T. This finding confirms previous results 
which demonstrate that alteration S524T further affects sensitivity to all triazoles, among 
them epoxiconazole and prothioconazole, the two most effective and widely used triazoles 
in the past years (Cools et al., 2011; Lucas et al., 2015; Kirikyali et al., 2017; Kildea et al., 
2019). In general, different CYP51 haplotypes were shown to affect DMI sensitivity to some 
triazoles differently (Leroux et al., 2007; Fraaije et al., 2007; Leroux and Walker, 2011; 
Buitrago et al., 2014) and sensitivity of ‘frequently found CYP51 haplotypes’ to different 
triazoles will be discussed at a later point in this work (see chapter 5.3). 
A large sensitivity range for epoxiconazole was identified across all isolates with ‘rarely 
found CYP51 haplotypes’. Their low frequency identified in 2016 and 2017 indicate a minor 
importance of these haplotypes in DMI adaptation of Z. tritici compared to ‘frequently found 
CYP51 haplotypes’. Nevertheless, as some of these CYP51 haplotypes also express high 
adaptation towards epoxiconazole, especially those carrying alteration S524T, their 
frequency may increase in the future under continued DMI selection pressure.  
A selective replacement in the occurrence and frequency of increasingly DMI adapted 
CYP51 haplotypes was observed in Z. tritici over time and space during the last three 
decades based on widespread use of different DMI fungicides (Gisi et al., 2005; Leroux et 
al., 2007; Brunner et al., 2008; Stammler et al., 2008b; Stammler and Semar, 2011; Leroux 
and Walker, 2011; Lucas et al., 2013; Buitrago et al., 2014; Lucas et al., 2015). A 
heterogenous frequency and distribution of ‘frequently found CYP51 haplotypes’ was 
observed across Europe in 2016 and 2017. Some of these haplotypes were detected in 
each investigated country, whereas others were only found in a few countries. Isolates 
carrying the wild type CYP51 were only detected in the Eastern European countries 
Bulgaria, Russia, and Slovakia. In previous studies it was shown that already in 2004 and 
2007 no CYP51 wild type isolates were detected anymore in Central and Western European 
countries such as France, Germany, and UK and that they were only found in Eastern 
European countries as well as in Sweden (Chassot et al., 2008; Stammler et al., 2008b). 
Since 2002, an increase in the frequency of isolates carrying alterations L50S, I381V and 
Y461H, as found in the C8 haplotype, or isolates with L50S, S188N, A379G, I381V, 
DelG460 and DelY461, as observed in haplotype G1 (except positions of deletions that are 
DelY459 and DelG460), were found. The Z. tritici populations of 2006 were mainly 
composed of these isolates and isolates carrying alterations at position V136 and/or 
alterations at position Y459, G460, and Y461. From 2007 to 2010, the Z. tritici populations 
across Europe (except for Ireland) were dominated by isolates carrying alteration I381V in 
combination with alteration of Y461 (as found in C8) or alterations A379G, I381V, DelY459, 
and DelG460 (as found in G1) (Stammler et al., 2008b; Stammler and Semar, 2011; 
Buitrago et al., 2014). From 2009 to 2011, a slow decrease in the frequency of CYP51 
haplotype C8 was observed, whereas the frequency of isolates with haplotype E4 (L50S, 
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D134G, V13A, I381V, Y461H) increased (Buitrago et al., 2014). In 2015, haplotypes E4 and 
F2 were most frequently found in an isolate collection across UK, Germany, and France, 
followed by haplotype C8 (Kirikyali et al., 2017). During the present study, it was shown that 
haplotype E4, expressing moderate adaptation to epoxiconazole, was identified most 
frequently across all tested isolates and was detected in almost every country of Central 
(except for Czech Republic and Slovakia) and Western Europe (except for Ireland in 2017). 
This finding confirms the increasing importance of haplotype E4. Additionally, a high 
frequency of haplotype F2 and C8 was confirmed, but haplotype C8 was mainly detected in 
France, in Central European countries, and especially in Southern and Eastern European 
countries.  
A west-to-east gradient in the DMI adaptation of Z. tritici across Europe has been reported 
previously in several studies (Strobel et al., 2017; Heick et al., 2017a; Jørgensen et al., 
2018) and was also confirmed in this work for 2016 and 2017. The Eastern European 
countries were mainly composed of isolates with haplotypes C8 and G1 exerting highest 
sensitivity to epoxiconazole among all ‘frequently found CYP51 haplotypes’. Based on 
historical data about CYP51 haplotype occurrence described above, the composition of the 
Z. tritici populations in Eastern European countries in 2016 and 2017 is comparable to the 
composition of the Z. tritici populations in Central Europe around 10 years ago. In 2016 and 
2017, Z. tritici populations of France, Germany, and Poland were mainly composed of 
haplotypes C8 and G1, together with moderately adapted haplotypes E4 and F2. The 
frequency of isolates that carry haplotypes with alteration S524T, showing highest 
adaptation towards epoxiconazole, is higher in France and Germany in 2016 and 2017 
compared to previous studies (Stammler et al., 2008b; Stammler and Semar, 2011). The 
higher frequency of haplotypes with moderate adaptation and higher frequency of 
haplotypes with alteration S524T in France and some countries of Central Europe 
demonstrates that evolution towards a reduced DMI sensitivity of Z. tritici is still ongoing. A 
further increase in the adaptation of the Z. tritici populations was observed in the Western 
European countries, Ireland, UK, and the Netherlands compared to France, Germany, and 
Poland. In Ireland, UK, and the Netherlands, a higher frequency of CYP51 haplotypes with 
alteration S524T was found. This alteration was described for the first time in an isolate 
from UK from 2007 (Stammler et al., 2008b). Afterwards, a high frequency of isolates with 
alteration S524T was observed in Ireland in 2010, whereas it was lower in the UK (Stammler 
and Semar, 2011). In the current study, Z. tritici populations in Ireland, UK, and the 
Netherlands were mainly composed of haplotypes conferring moderate or high 
epoxiconazole adaptation indicating a further shift in DMI sensitivity in these countries 
compared to previous studies (Stammler et al., 2008b; Stammler and Semar, 2011).  
On one side, the west-to-east gradient in DMI adaptation of Z. tritici may be explained based 
on the historical origin of DMI resistance. Brunner et al. (2008) proposed that CYP51 
alterations or new combinations of those alterations conferring DMI resistance arose locally 
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in North-West Europe and were then disseminated eastwards through wind-dispersed 
ascospores. A selective replacement of CYP51 haplotypes by CYP51 haplotypes with 
higher adaptation to DMIs followed (Brunner et al., 2008). On the other side, variability in 
disease prevalence and fungicide use intensity may also play a role in the west-east 
adaptation gradient (Stammler et al., 2008b; Strobel et al., 2017; Jørgensen et al., 2018). 
Intensive wheat production and a high disease prevalence is known for Northern France, 
Germany, and UK (Jørgensen et al., 2014; Fones and Gurr, 2015). Among these countries, 
fungicide input in winter wheat is highest in UK with often 3 to 4 fungicide applications 
(Jørgensen et al., 2014). Both together, the intensive use of fungicides and high disease 
prevalence most probably drives higher adaptation of Z. tritici populations to DMIs in 
countries as UK and Ireland. In contrast, agricultural production is more extensive in Eastern 
European countries and fungicide selection pressure is not as high as in Western European 
countries and some countries of Central Europe. A west-to-east gradient was already 
observed in the resistance emergence of Z. tritici to QoIs and SDHIs (Torriani et al., 2009; 
Jørgensen et al., 2017a; FRAC, 2019). Alteration G143A conferring QoI-resistance of 
Z. tritici was shown to have evolved independently through at least four mutational events 
and was subsequently distributed from West to East Europe through wind dispersal of 
ascospores (Torriani et al., 2009). These patterns support the assumption that increasingly 
adapted CYP51 haplotypes emerge in countries with a high fungicide selection pressure 
and high disease prevalence and subsequently spread across Europe.  
Compared to the development of QoI resistance in Z. tritici, evolution of DMI resistance 
proceeded much more slowly and gradually (reviewed in Jørgensen et al., 2019). As 
described previously in this chapter, a stepwise replacement of CYP51 haplotypes was 
observed over many years until the distribution of CYP51 haplotypes presently described 
for 2016 and 2017. In this work, to test whether changes continue to emerge slowly over a 
short period of time, the composition of CYP51 haplotypes and their frequency between 
2016 and 2017 was compared for chosen countries that were tested in both years. Results 
demonstrated that development in occurrence and frequency of CYP51 haplotypes 
between 2016 and 2017 was dependent on the country and no general pattern was 
observed across all countries. In Ireland, a further shift towards a reduced epoxiconazole 
sensitivity was indicated in 2017. This finding confirms the gradual shift in the sensitivity of 
the Irish Z. tritici population reported steadily during the past years (Stammler and Semar, 
2011; Kildea et al., 2019). In Germany and France, at least a slight further shift towards a 
reduced DMI sensitivity was indicated, whereas in Poland and UK no clear further shift was 
observed. An important point to mention here is the fact that in 2016 not all isolates from 
the European sensitivity monitoring were tested for their CYP51 haplotypes during this work 
but rather a selection of isolates. In contrast to this, all isolates from the European sensitivity 
monitoring were investigated for their CYP51 haplotypes in 2017. Therefore, results of 2017 
may be more representative and differences in sample size between both years may 
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partially explain why no further shift could be detected at molecular basis for Poland and 
UK. Such a shift could be expected based on CYP51 haplotype evolution in past years. 
Analysing a comparable number of isolates from the same locations within a country is 
recommended for future studies, if it is intended to compare changes in CYP51 haplotype 
frequency over a short period of time between individual consecutive years.  
In the past, recurring phases of shifts in sensitivity and a stabilised situation, that often lasted 
two to three years, were observed for Z. tritici (FRAC, 2019). Taking all results of this work 
into account compared to previous studies (Stammler et al., 2008b; Stammler and Semar, 
2011; Buitrago et al., 2014), a further evolution in the frequency and distribution of 
increasingly adapted CYP51 haplotypes was observed. This demonstrates an ongoing shift 
towards a reduced DMI sensitivity in regional populations of Z. tritici across Europe, 
especially in intensive wheat growing areas. The previously reported west-to-east gradient 
in DMI adaptation of Z. tritici was confirmed across Europe in this work. At a worldwide scale 
DMI adaptation in Z. tritici is most advanced in Europe. Compared to Europe, DMI 
resistance development is less advanced in other countries such as Tunisia (Taher et al., 
2014) as well as USA and Australia in which beginning emergence of CYP51 haplotypes 
that affect DMI sensitivity was reported (Estep et al., 2015; Milgate et al., 2016). These 
differences may result from different intensities in the use of DMIs (Estep et al., 2015) and 
different disease severities of Z. tritici (Goodwin, 2019). 
5.2.2 CYP51 overexpression in Z. tritici  
The epoxiconazole sensitivity of Z. tritici isolates carrying the same CYP51 haplotype but 
differing in the presence or absence of a CYP51p insert was compared in order to analyse 
the impact of the 120, 862, and 866 bp inserts in CYP51p on DMI sensitivity. On average, 
a 5- to 8-fold reduction in sensitivity was associated with the 120 bp insert. Compared to 
isolates with CYP51 haplotype F2 and a WT CYP51p, isolates carrying haplotype F2 and 
the 120 bp insert in CYP51p showed on average a 7-fold higher epoxiconazole adaptation. 
Adaptation across all of these isolates varied between 2- to 16-fold. These results reflect 
the findings of Cools et al. (2012) who reported that the 120 bp insert confers CYP51 
overexpression. In their studies, isolates carrying a F2 haplotype and the 120 bp insert 
showed a 7- to 16-fold reduction in sensitivity to four different triazoles. Additionally, it was 
found that for most triazoles tested there was an increasing reduction in sensitivity with 
increasing levels of CYP51 expression which varied between a 10- to 40-fold 
overexpression (Cools et al., 2012). Although this finding was based on only 3 isolates, the 
results may indicate a positive correlation of CYP51 quantity and a lower DMI sensitivity. 
This in turn may account for the variation in sensitivity of isolates carrying haplotype F2 and 
the 120 bp insert in CYP51p. On the other hand, natural variability in azole sensitivity of 
Z. tritici (Gisi et al., 1997; Stergiopoulos et al., 2003) may contribute to sensitivity variation 
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of these isolates. Moreover, it cannot be excluded that other mechanisms not investigated 
in the current work, as for example an increased efflux activity due to membrane 
transporters other than MFS1, may play a role. Determining the quantity of CYP51 mRNA 
in several F2 haplotypes expressing varying adaptation to epoxiconazole could help to 
further elucidate the relationship between CYP51 quantity and DMI adaptation.  
Across all investigated isolates carrying a ~900 bp insert in CYP51p, no clear trend in the 
impact on epoxiconazole sensitivity of Z. tritici was observed compared to isolates carrying 
the same CYP51 haplotype and a WT CYP51p. The effect correlated to the ~900 bp insert 
was either negligible or low (1.5- to 3.5-fold reduction in sensitivity). A low impact on 
epoxiconazole adaptation (~3-fold reduction in sensitivity) was also observed for the 300 bp 
insert in CYP51p. A 2.5-fold difference in sensitivity was observed across wild type isolates 
investigated in this work (described in chapter 4.3). Moreover, a high variability in azole 
sensitivity of Z. tritici has been reported before (Gisi et al., 1997; Stergiopoulos et al., 2003). 
Therefore, it is challenging to determine whether such minor differences in sensitivity can 
be attributed to natural variation in triazole sensitivity or to the ~900 bp or 300 bp inserts in 
CYP51p. Based on molecular studies that showed no or only slight alteration of CYP51 
expression conferred by ~900 bp inserts (Heick Wieczorek, 2017; Kildea et al., 2019), no 
or only slight effects on epoxiconazole sensitivity would be expected. Quantification of 
CYP51 mRNA levels in isolates with a ~900 bp insert in CYP51p showing slightly higher 
adaptation in comparison to isolates carrying the same insert but without increased 
adaptation could help to clarify if increased CYP51 expression drives an adaptation in these 
isolates. Nevertheless, compared to the impact correlated to the 120 bp insert, the previous 
assumption, that the ~900 bp inserts alone only confer a low impact (if at all) on triazole 
sensitivity (Leroux and Walker, 2011; Lucas et al., 2015; Heick Wieczorek, 2017; Kildea et 
al., 2019) was confirmed. Determining CYP51 mRNA levels in isolates carrying the 300 bp 
insert would help to correlate the impact of this insert to epoxiconazole sensitivity. In 
general, further sensitivity studies with a higher number of isolates are recommended for 
CYP51 haplotypes for which only single isolates with a CYP51p insert were available and 
could be tested (e.g. the 120 bp insert combined to haplotype C2, D7, or G1, or the 300 bp 
insert). The prerequisite for this, however, is an increase in the frequency of these isolates 
in field populations of Z. tritici. Additionally, introduction of promotor inserts into the wild type 
promotor with molecular techniques such as CRISPR-Cas9 (reviewed in Deng et al., 2017; 
reviewed in Schuster and Kahmann, 2019) would be helpful. Based on this method, isolates 
with similar genetic background that only differ in the presence or absence of a promotor 
insert could be used to determine the individual effect of promotor inserts on CYP51 
overexpression and DMI sensitivity. Thereby, interference of other resistance mechanisms 
or natural variation between field isolates would be excluded.  
Compared to some target site alterations, CYP51 overexpression in several pathogens was 
shown to reduce sensitivity to all DMIs tested at the time of publication, thus to confer cross-
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resistance (Cools et al., 2012, 2013; Ziogas and Malandrakis, 2015). Therefore, it can be 
assumed that results obtained for epoxiconazole in this work would most likely also account 
for other common DMIs. As described in chapter 4.5.2, in comparison to resistance levels 
of isolates carrying different CYP51 haplotypes and no CYP51 overexpression (9- to 166-
fold higher adaptation compared to CYP51 wild type), the impact on epoxiconazole 
sensitivity of the ~900 and 300 bp inserts appears of minor relevance. Additionally, as 
epoxiconazole adaptation associated with the 120 bp insert was shown to be on average 
5- to 8-fold higher compared to isolates with the same CYP51 haplotype and a WT CYP51p, 
the potential impact associated with inserts in CYP51p seems lower than the combination 
of CYP51 alterations. This assumption is confirmed by previous authors who reported for 
several pathogens that resistance levels conferred by CYP51 overexpression were lower 
compared to resistance levels correlated to target site alterations (Cools et al., 2013; Ziogas 
and Malandrakis, 2015). Nevertheless, as CYP51 overexpression based on the 120 bp 
insert in CYP51p exhibits an additive effect on DMI adaptation (this work; Cools et al., 2012; 
Kildea et al., 2019) and confers cross-resistance between most common DMIs (Cools et 
al., 2012, 2013; Ziogas and Malandrakis, 2015; Kildea et al., 2019), monitoring of the 
occurrence and frequency of this mechanism in field populations of Z. tritici is required.  
Occurrence and frequency of CYP51 overexpression in Z. tritici was investigated in this 
study across Europe in 2016 and 2017. Isolates overexpressing CYP51 associated with the 
120 bp insert in CYP51p were identified in almost every country of Central and Western 
Europe in 2016 and 2017. In 2016, frequencies of isolates exhibiting CYP51 overexpression 
were low to moderate (~4 to 25%) in these countries. In UK, the 120 bp insert in CYP51p 
was detected for the first time in isolates from 2009 (Cools et al., 2012). Afterwards, this 
insert was detected in two isolates from UK in 2010 and 2011 (Buitrago et al., 2014) as well 
as in isolates from the Nordic-Baltic area in 2014 (Heick et al., 2017a). The frequency of the 
120 bp insert across Europe now observed in 2016 has therefore increased compared with 
earlier findings. A higher number of isolates carrying the 120 bp insert compared to previous 
studies described above was already reported for France, Germany and UK in 2015 
(Kirikyali et al., 2017) and an increase in the frequency of this insert of up to 14% was 
reported in Ireland in 2015 compared to 2011 (Kildea et al., 2019). In addition, a further 
increase in the frequency of the 120 bp insert was detected in 2017 compared to 2016 in 
this work. An increase was observed in the UK, Poland, and Germany and slightly in France. 
Although most isolates carrying the 120 bp insert only express moderate DMI adaptation in 
vitro among all isolates with ‘frequently found CYP51 haplotypes’, this increase supports 
the previous assumption of Kildea et al. (2019) that CYP51 overexpression confers a 
selective advantage for Z. tritici isolates upon DMI treatment in the field. It may be 
speculated that the main driver of this selective advantage is cross-resistance for most 
common DMIs conferred by CYP51 overexpression (Leroux et al., 2007; Fraaije et al., 2007; 
Leroux and Walker, 2011; Buitrago et al., 2014). In contrast to the 120 bp insert, the majority 
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of countries showed high frequencies of the ~900 bp inserts in Z. tritici populations from 
2016 and 2017 investigated in this work. These results confirm an increase in the frequency 
and now widespread distribution of these inserts in Europe that was reported before for 
Ireland and the Nordic-Baltic area compared to previous years (Heick et al., 2017a; Kildea 
et al., 2019).  
Interestingly, as observed for the distribution of CYP51 haplotypes across Europe (lower 
adaptation in the East) (this work; Strobel et al., 2017; Heick et al., 2017a; Jørgensen et al., 
2018), lower frequencies of CYP51p inserts were identified in Eastern European countries 
and Italy compared to Western and two Central European countries (Germany and Poland). 
In this work, as in previous studies (Cools et al., 2012; Buitrago et al., 2014; Kildea et al., 
2019) the occurrence of the 120 bp insert was generally restricted to isolates carrying 
CYP51 haplotype F2. In contrast, a ~900 bp insert was combined to several CYP51 
haplotypes. As described for the emergence and distribution of CYP51 alterations from 
West to East Europe (Brunner et al., 2008), the fact that the 120 bp insert in CYP51p is 
mostly restricted to the F2 haplotype, may indicate that this insertion occurred once in the 
evolution of Z. tritici and then was spread within the population. It may be speculated that 
the same holds true for the 862 and 866 bp inserts. Although combinations of these inserts 
with different CYP51 haplotypes were observed, a pattern still seems to exist. Sequencing 
results for promotor fragments with a ~900 bp insert in this work confirmed results from 
Kildea et al. (2019) who reported that the 866 bp insert is always combined to CYP51 
haplotypes with alterations Y461S/H. In contrast, the 862 bp insert is always combined to 
CYP51 haplotypes with deletion of Y459 and G460 (except for one isolate). It was 
suggested that the evolutionary history of both groups is slightly different (Kildea et al., 
2019) indicating that insertion occurred once. The pattern of CYP51 alterations of 
haplotypes that have either the 862 or 866 bp CYP51p insert in common are more similar 
to each other compared to the contrasting group (results not shown). From this finding it 
may be deduced that new alterations evolved in CYP51 haplotypes which were already 
combined to one of these CYP51p inserts. In contrast to the 120 bp insert, combination of 
a ~900 bp insert was detected with almost all ‘frequently found CYP51 haplotypes’ (with 
exception of F3) in this work. This indicates that development of alterations in CYP51 
already combined to a CYP51p insert has happened more frequently for CYP51 haplotypes 
previously combined with a ~900 bp insert compared to the 120 bp insert. Combinations of 
a ~900 bp insert with almost all ‘frequently found CYP51’ haplotypes may explain the wider 
distribution and higher frequencies of these inserts compared to the 120 bp insert. As ~900 
bp inserts were not correlated to substantial impacts on DMI sensitivity (this work; Kildea et 
al., 2019), selection occurred probably in parallel with the corresponding CYP51 haplotypes. 
High frequency of the WT CYP51p in Eastern Europe may support the assumption that 
combination of CYP51p inserts to CYP51 haplotypes emerged in Western Europe and 
afterwards distribution of these genotypes occurred from West to East associated with the 
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distribution of the CYP51 haplotypes. Differences in fungicide use patterns and disease 
severity, however, as described for the distribution of CYP51 haplotypes (see chapter 
5.2.1), may have also contributed to regional differences and distribution of CYP51p inserts 
observed between Western or Central Europe and Eastern Europe.  
In this work, for the first time the 120 bp insert was identified in single isolates in combination 
to CYP51 haplotypes other than F2. These CYP51 haplotypes and their CYP51 alterations 
are shown in Table 21. 
Table 21: CYP51 haplotypes combined to the 120 bp insert in CYP51p. 
CYP51 haplotype Amino acid alterations 
C2 L50S, I381V, Y459S 
D7 L50S, V136A, Y461S, S524T 
F2 L50S, S188N, I381V, Del Y459, Del G460, N513K 
F6 L50S, V136A, S188N, Del Y459, Del G460, S524T 
G1 L50S, S188N, A379G, I381V, Del Y459, Del G460, N513K 
H3 L50S, S188N, N284H, A379G, I381V, Del Y459, Del G460, N513K  
 
Only two of these CYP51 haplotypes (G1 and H3) share an evolutionary pathway with the 
haplotype F2 (Lucas et al., 2013) and may have evolved through the emergence of new 
alterations in the F2 CYP51 haplotype background already combined to the 120 bp insert 
in the promotor. The other CYP51 haplotypes combined to the 120 bp insert in CYP51p 
(C2, D7, and F6) do not show similarities in their evolution (Lucas et al., 2013). Therefore, 
emergence of these genotypes through successive emergence of alterations in a CYP51 
haplotype background already combined to the promotor insert seems unlikely. The 
emergence of the 120 bp insert combined to these CYP51 haplotypes may be explained 
due to intragenic recombination that has been previously described by Brunner et al. (2008) 
for the combination of alterations in CYP51.  
Previous authors predicted that if frequency of CYP51 overexpression increases in Z. tritici 
populations, probability of recombination of the overexpression trait with more evolved 
CYP51 haplotypes or emergence of new alterations in the overexpression background may 
increase (Lucas et al., 2015; Kildea et al., 2019). This assumption can be supported based 
on results of the current work. It is possible that further selection of isolates with CYP51 
overexpression (based on 120 bp insert in CYP51p) in combination with more evolved 
CYP51 haplotypes may lead to a further reduction in sensitivity of Z. tritici to DMIs (this 
work; Lucas et al., 2015; Kildea et al., 2019). Therefore, it is important that further monitoring 
studies should be carried out to monitor whether the frequency of the 120 bp insert 
combined to the F2 haplotype or to other CYP51 haplotypes increases. The possible impact 
of CYP51 overexpression on field performance of DMIs will be discussed in chapter 5.4.  
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5.2.3 Increased efflux activity in Z. tritici  
In many studies (Kretschmer et al., 2009; Leroux and Walker, 2011; Heick et al., 2017a), 
tolnaftate, a squalene-epoxidase inhibitor used in dermatophytes (Barrett-Bee et al., 1986) 
has been used as a common indicator for the phenotypical identification of an increased 
efflux activity. Tolnaftate has no role in agriculture and therefore is not linked to specific 
resistances of Z. tritici (Omrane et al., 2017). The designation for MFS1p inserts of Omrane 
et al. (2017) was accepted and amended in order to describe MFS1p inserts in the course 
of this work. The 150 bp insert was designated as type III, the 267, 308, 338, 369, 377 bp 
inserts as type II and the 519 bp insert as type I. Tolnaftate sensitivity of Z. tritici isolates 
carrying different inserts in MFS1p was tested to identify their impact on an increased efflux 
activity. In comparison to isolates with a WT MFS1p a reduced tolnaftate sensitivity was 
observed for all isolates carrying an MFS1p insert (except for the 308 bp insert that was not 
tested). Based on tolnaftate adaptation, the highest increased efflux was associated with 
the 519 and 369 bp inserts, with a lower effect correlated to the 150, 267, 338, and 377 bp 
inserts. These results partially confirm molecular results from Omrane et al. (2017) who 
reported that all tested MFS1p inserts were correlated to MFS1 overexpression. However, 
expression levels conferred by the 519 bp insert were significantly higher than by the 150, 
338, or 369 bp inserts (Omrane et al., 2017). Based on these results, it would not be 
expected that isolates with a 369 bp insert would behave differentially than isolates carrying 
another type II insert. Unexpectedly however, across all isolates carrying a 369 bp insert in 
the current work, significant differences in tolnaftate sensitivity were observed compared to 
isolates with a WT MFS1p, whereas no significant differences were observed for isolates 
with remaining type II inserts (267, 338, 377 bp). It is possible that the low number of tested 
isolates with the 369 bp insert resulted in a high impact of the sensitivity of outliers which 
may contribute to these differences in significance. It is not always possible to obtain a 
representative number of isolates to investigate all effects under consideration. Analysing 
tolnaftate sensitivity of more isolates carrying a type II insert, especially the 369, 377, or 
308 bp insert, would help to further characterise the effect of those inserts. A combination 
of these analyses with the molecular determination of MFS1 expression level could help to 
further correlate increased MFS1 expression to phenotypical sensitivity. Such studies would 
be especially valuable for characterisation of the 267, 308 and 377 bp inserts as their effect 
on MFS1 expression has not been investigated via molecular studies to date.  
The epoxiconazole sensitivity of isolates carrying the same CYP51 haplotype but differing 
in the presence or absence of an insert in MFS1p was compared in order to analyse if and 
to which extend higher tolnaftate adaptation implying increased efflux activity is reflected in 
DMI sensitivity of Z. tritici. Impacts associated with different MFS1p inserts based on 
tolnaftate sensitivity were correlated with epoxiconazole sensitivity of isolates in most cases. 
Across all MFS1p inserts, the highest impact on epoxiconazole sensitivity (~2- to 8-fold 
reduction in sensitivity) was correlated to the 519 bp insert (type I). In single cases a low 
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impact was correlated to the 519 bp insert. As this low impact was observed for isolates 
carrying highly adapted CYP51 haplotypes, it may be speculated that the impact of the 
519 bp insert is “masked” by the already high adaptation driven by CYP51 alterations. 
Type III (150 bp) and type II (267, 308, 338, 369, or 377 bp) inserts were associated with 
lower effects on epoxiconazole sensitivity (<2- to 2.5-fold reduction in sensitivity). These 
results support the molecular impact of different inserts on MFS1 expression observed by 
Omrane et al. (2015, 2017). They reported highest MFS1 expression driven by the 519 bp 
insert, whereas type III and type II inserts lead to lower levels of MFS1 overexpression. 
Furthermore, results shown here are consistent with the findings of Kildea et al. (2019), who 
reported a minor effect on DMI sensitivity correlated to the type III (150 bp) insert. Distinct 
differences in the impact on epoxiconazole sensitivity correlated to type II inserts were not 
observed in this work. This supports the assumption that differences described previously 
for tolnaftate sensitivity may result from methodological issues due to a low sample size. 
Consequently, results for epoxiconazole sensitivity indicate that all type II inserts confer 
more or less similar impacts on sensitivity. This is in line with the molecular results from 
Omrane et al. (2017), who reported that type II inserts exert similar effect on MFS1 
expression. So far, only a few studies exist that investigate correlation of MFS1p inserts on 
increased efflux and consequently on DMI sensitivity in Z. tritici. For this reason, further 
studies on DMI sensitivity of isolates carrying MFS1p inserts would be helpful to confirm the 
results of this work. Increased efflux activity of Z. tritici was shown to reduce sensitivity to 
common DMIs tested at the time of publication and even to fungicides with unrelated MOAs 
(Leroux and Walker, 2011; Omrane et al., 2015, 2017). Therefore, it may be assumed that 
effects of an increased efflux shown here by means of epoxiconazole would most likely also 
account for other DMIs.  
Characterisation of MFS1p was not achieved in all investigated isolates as several isolates 
produced no amplicon during PCR. Evaluation of epoxiconazole sensitivity indicated no 
specific mechanisms across all of these isolates. Nevertheless, single isolates with 
uncharacterised MFS1p showed slightly higher adaptation to epoxiconazole compared to 
isolates with a WT MFS1p. Therefore, further studies are recommended in order to 
characterise MFS1p in these isolates and to clarify if this sensitivity variation occurred due 
to natural variation in sensitivity of Z. tritici to azoles (Gisi et al., 1997; Stergiopoulos et al., 
2003) or whether alteration of MFS1p and increased efflux plays a role.  
Compared to resistance levels of isolates carrying different CYP51 haplotypes but no other 
additional resistance mechanism (19- to 306- fold reduction in sensitivity compared to 
CYP51 wild type) described in chapter 4.6.3, potential impact of an increased efflux was 
assumed to be lower compared to combination of CYP51 alterations. This assumption is 
supported by previous studies for Z. tritici that reported moderate resistance factors due to 
an increased efflux activity (Leroux and Walker, 2011; Omrane et al., 2015). Comparison to 
other fungal plant pathogens is challenging. An increased efflux has only been reported in 
Discussion 123 
 
a few fungal plant pathogens, for example, in B. cinerea (Kretschmer et al., 2009) and in 
eyespot on wheat, O. yallundae (Leroux et al., 2013). For B. cinerea comparable results 
were published. Resistance levels towards fungicides due to an increased efflux were 
observed to be low to moderate (10- to 20-fold) while high resistance factors were conferred 
by target site alterations (up to several hundredfold) (Hahn and Leroch, 2015). 
Nevertheless, as an increased efflux activity based on the 519 bp insert in MFS1p was 
associated with an additive effect on DMI adaptation of Z. tritici (this work; Leroux and 
Walker, 2011; Omrane et al., 2015, 2017) and potentially can affect sensitivity to several 
fungicides with unrelated MOA (Roohparvar et al., 2007, 2008; Leroux and Walker, 2011; 
Omrane et al., 2015, 2017), monitoring of the occurrence and frequency of this mechanism 
in Z. tritici is recommended and of value.  
Across all investigated isolates from 2016 and 2017, the frequency of inserts in MFS1p was 
relatively low (around 10%). Across both years, the type I insert associated with the highest 
impacts on DMI adaptation (this work; Omrane et al., 2017) was only found in countries of 
Central Europe (Germany and Poland) and Western Europe in a relatively low frequency of 
around 5 to 10%, respectively. Only single isolates carrying the type I insert in MFS1p were 
detected in isolate collections from Ireland from 2006 to 2015 (Kildea et al., 2019), from 
Germany, France, and UK from 2015 (Kirikyali et al., 2017), and a very low frequency (1.5%) 
of MFS1p inserts was observed in isolate collections from 2006 to 2011 from Europe and 
New Zealand (Buitrago et al., 2014). Compared to these earlier studies (Buitrago et al., 
2014; Kirikyali et al., 2017; Kildea et al., 2019), a slight increase in the frequency and 
distribution of the type I insert in MFS1p was observed across Europe. Among all MFS1p 
inserts identified in isolates of this work, the type I insert was identified most frequently. This 
finding is in line with results from a population survey which revealed that among all isolates 
with increased efflux activity, the type I insert in MFS1p was found most frequently and was 
detected since 2009. This was followed by the type II inserts (338 and 369 bp), detected 
since 2012 and the least frequent type III insert which was only found since 2015 (reviewed 
in Omrane et al., 2017). In the current work the type III and type II inserts were mainly 
detected in Ireland and UK and only in single isolates from other countries in 2016. In 2017, 
there was a wider distribution of type II inserts in the Netherlands, Germany, and France, 
although still at a low level (with exception of the Netherlands). In addition, there was an 
increase in the frequency of the type III insert in Ireland. This finding is supported by Kildea 
et al. (2019), who already observed that the type III insert was detected most frequently in 
MFS1p in Z. tritici from 2015 in Ireland. Together, these results indicate a selective 
advantage of isolates carrying one of the type III or type II inserts and it may be speculated 
that frequency of the smaller inserts may increase in the future. The frequency of the type I 
insert has not increased between 2016 and 2017 with exception of UK. As mentioned 
before, sample size in UK was limited in 2017 and single isolates gained higher impact on 
changes in frequency of MFS1p inserts. The fact, that despite the first isolates with a 519 bp 
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insert in MFS1p being detected 10 years ago (Omrane et al., 2017) and that no widespread 
distribution of these isolates has occurred may indicate a reduced fitness of isolates exerting 
increased efflux activity. Fitness aspects correlated to DMI resistance mechanisms will be 
discussed in the next chapter (5.2.4). 
Inserts in MFS1p were mainly restricted to isolates found in Central European countries, 
Germany and Poland, and to Western European countries. MFS1p inserts were not 
detected in isolates from Slovakia, Czech Republic, the Eastern, Northern, and Southern 
European countries. A higher frequency of MFS1p inserts in Western and some Central 
European countries compared to Eastern European countries was observed as was already 
seen for inserts in CYP51p and increasingly adapted CYP51 haplotypes. As already 
hypothesized for CYP51 haplotypes and CYP51p inserts, distribution of MFS1p inserts is 
likely to be influenced by the geographic emergence of DMI resistance mechanisms, 
differences in fungicide use patterns and disease prevalence (Brunner et al., 2008; 
Stammler et al., 2008b; Strobel et al., 2017; Jørgensen et al., 2018). It may be speculated 
again that insertions in MFS1p arose under high fungicide selection pressure in Western 
European countries and were then distributed to the East via windborne ascospores. A 
contrasting argument to this is the fact that the 308 and 377 bp inserts were detected in 
France and Poland. These two inserts were detected for the first time during this work and 
only in a single isolate, respectively. These results may indicate that fungicide selection 
pressure in these countries is sufficient for the selection of new MFS1p inserts. Practical 
relevance of an increased efflux for DMI field performance will be discussed at later point in 
this discussion (chapter 5.4). 
5.2.4 Combination of DMI resistance mechanisms and 
possibilities for future evolution  
Different DMI resistance mechanisms have evolved in several human and plant pathogenic 
fungi. Nevertheless so far, Z. tritici seems to be one of the only plant pathogens which 
combined all three described resistance mechanisms in individual isolates (this work; Cools 
et al., 2013; Ziogas and Malandrakis, 2015; Kirikyali et al., 2017). Four isolates combining 
CYP51 alterations, CYP51 overexpression (based on 120 bp CYP51p insert) and increased 
efflux (based on 519 bp MFS1p insert) were found in 2015 (Kirikyali et al., 2017). 
Occurrence of such isolates was confirmed at a very low frequency (<1%) in isolates 
investigated from 2016 and 2017 in the current work. In the further discussion, these isolates 
are described as isolates with an additional resistance mechanism, that combine target site 
alterations, CYP51 overexpression (based on 120 bp insert in CYP51p), and/or an 
increased efflux (based on 519 bp insert in MFS1p). As has already been suggested here 
and in previous studies (Omrane et al., 2017; Kildea et al., 2019) the remaining CYP51p 
and MFS1p inserts are probably of minor relevance for DMI adaptation. Therefore, isolates 
carrying one of these inserts were not designated as isolates carrying CYP51 
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overexpression or an increased efflux in this chapter. It should be mentioned that the impact 
of different inserts in MFS1p or CYP51p was only tested based on the sensitivity 
comparison of isolates carrying the same CYP51 haplotype but differing in the presence or 
absence of an insert because all inserts were detected in combination to CYP51 alterations. 
In order to investigate the individual impact of MFS1p and CYP51p inserts on DMI sensitivity 
and to exclude the factor of natural variation in azole sensitivity between field isolates of 
Z. tritici (this work; Gisi et al., 1997; Stergiopoulos et al., 2003), future studies are 
recommended that comprise the introduction of promotor inserts in sensitive parental 
strains via transformation, as for example performed for the 519 bp insert in MFS1p 
(Omrane et al., 2017), and subsequent analyses of DMI sensitivity.  
In vitro sensitivity studies described in the current work showed that highest adaptation to 
epoxiconazole within a CYP51 haplotype group could be associated with CYP51 
overexpression and/or increased efflux. Kirikyali et al. (2017) reported that isolates 
combining all three resistance mechanisms showed highest sensitivity reduction to 
triazoles. These results were confirmed within haplotype group F2 for epoxiconazole 
sensitivity in this work demonstrating the additive effect of an increased efflux and CYP51 
overexpression on DMI adaptation. Nevertheless, a high variability in epoxiconazole 
sensitivity of isolates within a CYP51 haplotype group, which could not be explained by 
CYP51 overexpression or an increased efflux, was observed (chapter 4.7). In some cases, 
natural variation in azole sensitivity of Z. tritici (Gisi et al., 1997; Stergiopoulos et al., 2003; 
de Waard et al., 2006) probably contributes to this variation in sensitivity. In other cases, 
transporters other than the MFS1 and/or other mechanisms leading to an increased efflux 
or CYP51 overexpression could be responsible for this sensitivity variation although have 
not been elucidated. One isolate was defined to carry the WT MFS1p but showed an 
adaptation towards tolnaftate indicating an increased efflux activity (shown in chapter 4.6.2). 
As this isolate showed a small insertion in MFS1p (<50 bp, described in chapter 4.6.2), it 
may be useful to investigate whether individual small insertions can confer an effect on an 
increased efflux. Single isolates without the 519 bp insert in MFS1p but displaying an MDR 
phenotype were also identified previously by Omrane et al. (2015). They suggested that 
transporters other than the MFS1 transporter may contribute to an increased efflux in 
Z. tritici. Furthermore, Z. tritici isolates exerting CYP51 overexpression independently from 
the 120 or ~900 bp insert were detected (Omrane et al., 2015). In C. beticola, it was 
observed that CbCYP51 overexpression was not caused by promotor alterations or by copy 
number variation and it was proposed that trans-acting factors may contribute to CbCYP51 
overexpression (Bolton et al., 2012). Further studies are needed to clarify if other 
transporters or CYP51 overexpression mediated by mechanisms other than the 120 bp 
promotor insert play a role in variation of epoxiconazole sensitivity in isolates of this work. 
Omrane et al. (2015) already identified candidate transporters which may be involved in an 
increased efflux activity in addition to the MFS1 transporter. They claimed that studies 
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including mutagenesis of these transporters are necessary to define their contribution to an 
increased efflux activity in Z. tritici.  
So far, combination of all three DMI resistance mechanisms have only been found in 
association with the F2 haplotype (this work; Kirikyali et al., 2017). CYP51 overexpression 
is mainly restricted to isolates carrying the F2 CYP51 haplotype (this work; Cools et al., 
2012; Buitrago et al., 2014; Kildea et al., 2019). Therefore, combination of CYP51 
overexpression and an increased efflux to other CYP51 haplotypes is probably mainly 
dependent on the emergence of CYP51 overexpression combined to other CYP51 
haplotypes than F2. As described in chapter 5.2.2, combination of CYP51 overexpression 
to CYP51 haplotypes other than F2 was detected in isolates from 2016 and 2017. It may be 
speculated that if the frequency of these isolates increases in field populations of Z. tritici, 
the likelihood of combination of all three DMI resistance mechanisms including other CYP51 
haplotypes than F2 will also increase.  
Predictions about further evolution, increase and spread of individual DMI resistance 
mechanisms or combinations of those in Z. tritici is challenging due to its high complexity. 
Factors such as fungicide use intensity, disease pressure, anti-resistance-strategies, and 
fitness of a resistant isolate determine the increase and spread of resistances in fungal 
populations (van den Bosch et al., 2011, 2014; Ma and Michailides, 2005; Mikaberidze and 
McDonald, 2015). Due to fungicide selection pressure, frequency of isolates carrying a 
resistance mechanism that confers a selective advantage increases (van den Bosch et al., 
2014; Oliver and Hewitt, 2014). Mutations conferring fungicide resistance, however, may 
disturb efficiency of physiological and biochemical processes that lead to a lower pathogen 
fitness (Anderson, 2005; Mikaberidze and McDonald, 2015). The fitness of resistant isolates 
determines if they persist or decrease in fungal populations in the absence of fungicide 
selection pressure and fitness costs may delay resistance development (Ma and 
Michailides, 2005; Mikaberidze and McDonald, 2015). The frequency of resistant individuals 
may decline in the absence of fungicide selection pressure when resistant populations show 
a lower fitness compared to the sensitive one (Ma and Michailides, 2005; Ishii, 2015). 
Fitness costs associated with different DMI resistance mechanisms may therefore impact 
further evolution, spread, and persistence of those mechanisms in field populations of 
Z. tritici. In this work, fitness of isolates with different DMI resistance mechanisms or 
combination of those was not investigated. However, information about fitness costs 
associated with CYP51 alterations in Z. tritici and with increased efflux or CYP51 
overexpression in other pathogens is available in literature.  
Some alterations or combinations of alterations in CYP51 of Z. tritici have been correlated 
to negative impacts on enzymatic activity and consequently to potentially lower pathogen 
fitness (Bean et al., 2009; Cools et al., 2010, 2011; Mullins et al., 2011; Becher and Wirsel, 
2012; Oliver and Hewitt, 2014). Yet, some alterations were shown to destroy CYP51 
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function completely, but it was observed that compensatory alterations in other parts of the 
gene partially restored CYP51 function (Brunner et al., 2008; Mullins et al., 2011; Cools et 
al., 2010). Therefore, the sequence and frequency by which CYP51 alterations have 
occurred was probably driven by differential effects on enzyme activity (Cools et al., 2013). 
The requirement for multiple alterations to confer DMI resistance is one factor suggested to 
be responsible for the slow emergence of DMI resistance in Z. tritici (Cools et al., 2013) 
compared, for example, to QoI resistance. Regarding QoI resistance, the single alteration 
G143A, which is claimed not to affect enzyme activity of CYTB, was enough to confer a 
highly resistant phenotype that rapidly predominated the pathogen population (Gisi et al., 
2002; Fraaije et al., 2005; Lucas and Fraaije, 2008; Jørgensen et al., 2019). Although 
detection of new CYP51 alterations in this work confirms the high level of flexibility of the 
CYP51 protein (Becher and Wirsel, 2012), it was predicted that the scope for changing the 
gross architecture of the haem pocket is limited, because native function of the enzyme has 
to be restored (Mullins et al., 2011). It may be speculated that the possibility for the 
development of new alterations with strong effects on the haem environment and 
consequently on DMI binding is now less likely because of the high number of already 
existing alterations. Nevertheless, occurrence of compensatory alterations may facilitate the 
ongoing evolution of new alterations and it remains to be seen if new alterations that affect 
DMI sensitivity will occur in the future. Due to the ongoing evolution in the frequency and 
distribution of existing increasingly adapted CYP51 haplotypes described in chapter 5.2.1, 
a further increase of these haplotypes may be expected in the future.  
Whether constitutive overexpression of CYP51 and MFS1 (increased efflux) reduces the 
fitness of Z. tritici is not clear to date. However, energy dependent increased efflux (MDR) 
is often associated with fitness penalties in plant pathogenic fungi in the absence of 
fungicide selection pressure (de Waard et al., 2006). It is conceivable that resource 
allocation for overexpression of CYP51 or increased efflux is associated with fitness costs 
(Hawkins and Fraaije, 2018). Among other factors, this may contribute to the fact that 
widespread occurrence of these mechanisms in plant pathogens do not seem to have 
occurred so far (Cools et al., 2013; Leroux et al., 2013). Nevertheless, it was observed that 
fitness costs associated for example with MDR phenotypes can be compensated for in 
C. albicans (Cowen et al., 2001). Moreover, it was observed that MDR strains of B. cinerea 
did not show any differences in fitness parameters compared to non-MDR strains and seem 
to compete efficiently under field conditions (Hahn and Leroch, 2015). In addition, Cools et 
al. (2013) suggested that additional resistance mechanisms leading to cross-resistance 
between DMIs may increase in Z. tritici in the future despite any fitness costs associated 
with them. This prediction is supported in findings reported in the current work as an 
increase in the frequency of additional resistance mechanisms was observed compared to 
past years. However, as first isolates with increased CYP51 or MFS1 expression already 
appeared in 2009, the relatively long period until their increase in frequency and still low 
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levels of strong MFS1 overexpression in 2016 and 2017 may support the assumption of 
fitness penalties associated with these mechanisms. Fitness tests such as, for example, 
competition studies commonly used to assess pathogen fitness (Karaoglanidis et al., 2001; 
Ma and Uddin, 2009; Rehfus, 2018; Graf, 2018; Hawkins and Fraaije, 2018) are 
recommended for future research. Such studies should incorporate Z. tritici isolates that 
carry the same CYP51 haplotype and only differ in the presence or absence of an additional 
resistance mechanism or in combination of different mechanisms. Thereby, information 
about fitness aspects associated with CYP51 overexpression and an increased efflux or 
combination of those may be gained. Knowledge about fitness costs may help to establish 
efficient resistance management strategies (Mikaberidze and McDonald, 2015; Hawkins 
and Fraaije, 2018) and may support predictions about further evolution of CYP51 
overexpression and increased efflux in Z. tritici.  
5.3 Cross-resistance of Z. tritici to different DMIs  
As all DMIs show the same mode of action, they are generally considered to be cross-
resistant with each other (FRAC, 2019). Indeed, CYP51 overexpression and an increased 
efflux activity was shown to affect sensitivity of Z. tritici to most common DMIs on the market 
at the time of publication (Cools et al., 2012, 2013; Ziogas and Malandrakis, 2015; Omrane 
et al., 2015, 2017; Kildea et al., 2019). Nevertheless, incomplete cross-resistance was 
observed between individual DMIs or a subset of DMIs for specific CYP51 haplotypes based 
on specific CYP51 alterations (this work; Cools et al., 2011; Leroux and Walker, 2011; Cools 
et al., 2013; Lucas et al., 2015; Strobel et al., 2017; Jørgensen et al., 2018).  
Isolates obtained from field trials of 2015 and 2016 showed a high correlation with the in 
vitro sensitivity between epoxiconazole, prothioconazole, and metconazole, whereas 
correlation to tebuconazole was lower (Jørgensen et al., 2018). Differences in the sensitivity 
profile of DMIs result in different cross-resistance patterns with epoxiconazole, 
prothioconazole, and cyproconazole belonging to one group and difenoconazole and 
tebuconazole to another (Leroux and Walker, 2011; Buitrago et al., 2014). Correlations of 
the in vitro sensitivity of all ‘frequently found CYP51 haplotypes’ during this work confirmed 
a high correlation between epoxiconazole and prothioconazole-desthio, while correlation to 
the new DMI compound mefentrifluconazole was weaker or almost absent. As expected 
from overall sensitivity correlations across all ‘frequently found CYP51 haplotypes’, the 
cross-resistance patterns, based on resistance factors of individual CYP51 haplotypes, 
between epoxiconazole and prothioconazole-desthio were more similar compared to 
mefentrifluconazole. These findings indicate a limited cross-resistance of epoxiconazole as 
well as prothioconazole-desthio to mefentrifluconazole in vitro. In the past, efficacy data for 
STB control from field trials confirmed that cross-resistance relationships observed in vitro 
could also be seen in vivo (Jørgensen et al., 2018). A higher correlation of epoxiconazole 
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and prothioconazole efficacy compared to correlation of prothioconazole and tebuconazole 
was observed (Jørgensen et al., 2018). In addition, different selection patterns after DMI 
treatment seem to occur in the field (Heick et al., 2017b). A different trend in the pattern of 
CYP51 haplotypes of Z. tritici after solo treatment of prothioconazole or mefentrifluconazole 
was also observed among isolates from field trials in this work. This result supports the 
assumption of limited cross-resistance from in vitro results. Relative frequencies of CYP51 
haplotypes after DMI treatment showed that CYP51 haplotypes expressing high resistance 
factors in vitro (in case of prothioconazole also moderate RF values) preferentially survived 
DMI treatment in the field. Nevertheless, an important point to mention is that results 
presented in chapter 4.8.2 represent relative frequencies of different CYP51 haplotypes 
gained from a defined number of investigated isolates. Therefore, they do not reflect 
absolute number of isolates with these haplotypes in the field. For example, in Ireland, a 
relative frequency of 70% of all investigated isolates from the mefentrifluconazole treated 
plot showed haplotype H6, whereas only 30% were identified among isolates after 
prothioconazole treatment (Figure 32). An important aspect contributing to the absolute 
number of Z. tritici isolates in the field is the field efficacy conferred by different DMIs. 
Quantification of Z. tritici DNA in a field sample with real-time PCR would help to correlate 
the relative frequency of CYP51 haplotypes to the absolute occurrence of Z. tritici with these 
CYP51 haplotypes in the field. In this work, quantification of Z. tritici in field samples was 
not performed. Therefore, assessment data of STB infection were used here in order to give 
an estimation about the absolute occurrence of isolates with specific CYP51 haplotypes in 
the field. In Figure 35, the relative frequency of CYP51 haplotypes was visualised in relation 
to the STB infection in untreated plots and after DMI treatment. For this evaluation mean 
STB infection (%) on the second- and flag leaf detected at the final assessment date of the 
respective field trial was used. 
Results shown in Figure 35 illustrate that a large difference between the relative frequency 
of CYP51 haplotypes (described in Figure 32) does not result in same differences in the 
absolute frequency of these CYP51 haplotypes in the field when regarded in relation to STB 
infection. For example, based on Figure 35, it could be assumed that the absolute frequency 
of isolates with haplotype H6, was more similar in mefentrifluconazole and prothioconazole 
treated plots in the field in Ireland than expected from differences in relative frequencies 
described above. A higher level of STB infection in the prothioconazole treated plot 
compared to the mefentrifluconazole treated plot in Ireland results in the approximation of 
absolute frequencies of this haplotype. Across all locations, efficacy of mefentrifluconazole 
was higher compared to prothioconazole resulting in a lower level of Z. tritici infection after 
mefentrifluconazole treatment. Except for Denmark, a higher proportion of the STB 
population was composed of a single CYP51 haplotype following treatment with 
mefentrifluconazole compared to prothioconazole. A higher level of Z. tritici infection was 
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observed in the prothioconazole treated plots, but composition of Z. tritici in these plots 
tended to be more variable. 
 
Figure 35: CYP51 haplotypes of Z. tritici and their frequency in field trials after application of 
mefentrifluconazole (Revysol®) and prothioconazole (Proline®) in relation to Z. tritici infection 
(%). Field trials were conducted in four different countries (Ireland, UK, Germany, Denmark). 
Samples were taken in untreated, mefentrifluconazole and prothioconazole treated plots and 10 
isolates were generated per sample by EpiLogic. Relative frequency of CYP51 haplotypes (shown 
in Figure 32) in relation to Z. tritici infection is presented per country and treatment. 
The importance of these findings for further resistance evolution can be considered in 
different ways. For example, in the absence of any fitness penalty associated with different 
CYP51 haplotypes a low absolute frequency of STB, independently from any proportions of 
different CYP51 haplotypes, may help to slow down further resistance evolution because 
future build-up of the STB population would start at a lower level. On the other hand, van 
den Bosch et al. (2014) suggested that selection for fungicide resistance can only be 
reduced when the increase of both, the sensitive and resistant strain is reduced or when 
the increase of the resistant strain is reduced relative to that of the sensitive one. It is 
assumed that the probability of a resistant strain to build a population is higher when the 
density of the sensitive population is low (van den Bosch et al., 2011). As the CYP51 wild 
type can no longer be found in Western and Central Europe (described in chapter 5.2.1), 
this hypothesis could only be transferred to less adapted and highly adapted CYP51 
haplotypes. A higher absolute frequency of STB with varying CYP51 haplotypes may help 
Discussion 131 
 
to slow down resistance evolution if fitness penalties are associated with highly adapted 
CYP51 haplotypes. If the higher absolute STB frequency is composed of moderately and 
highly adapted CYP51 haplotypes, further increase of highly adapted CYP51 haplotypes 
may be slower as they have to compete in future STB build-up with eventually more fit 
moderately adapted CYP51 haplotypes. Under this assumption, in the long-run, resistance 
build-up may be slower compared to the scenario of population build-up after a low absolute 
STB frequency with high proportions of single CYP51 haplotypes. In the end, no final 
conclusion can easily be drawn about these hypotheses here and further studies are 
recommended for clarification. Additionally, as this is the first report of selection studies for 
mefentrifluconazole and only a limited number of isolates in a limited number of trials was 
tested, results of this work need confirmation in future studies. Moreover, quantification of 
Z. tritici DNA in field samples and subsequent determination of CYP51 haplotypes is 
recommended for future studies when relative frequencies in vitro should be correlated to 
absolute frequency of a haplotype in the field.  
Taken all results from in vivo studies and from field trials into account, a limited cross-
resistance between epoxiconazole as well as prothioconazole compared to 
mefentrifluconazole was demonstrated. Protein modelling in combination with azole 
docking studies revealed that limited cross-resistance between existing DMIs probably 
occurs due to different binding specificities of different triazoles and consequently due to 
different effects of alterations on triazole binding (Mullins et al., 2011). Such studies may 
clarify if different binding properties of mefentrifluconazole compared to other triazoles are 
responsible for limited cross-resistance for specific CYP51 haplotypes and are 
recommended.  
Application of DMIs that differ in their cross-resistance pattern and differentially select for 
DMI resistance (CYP51 haplotypes) in mixtures or alternation is suggested to be a suitable 
strategy of anti-resistance management and has been proven in field trials (Cools and 
Fraaije, 2008; Heick et al., 2017b; Jørgensen et al., 2018). In field trials of 2015 and 2016, 
a high variability in tebuconazole sensitivity was observed (Jørgensen et al., 2018). High 
efficacy of this triazole was correlated to high proportions of alteration V136A that exert 
different effects to different triazoles (Cools et al., 2011; Leroux and Walker, 2011; Buitrago 
et al., 2014; Jørgensen et al., 2018). Heick et al. (2017b) demonstrated in field trials of 2015 
and 2016 that selection for CYP51 alterations conferring DMI adaptation was reduced when 
spray strategies were applied consisting of DMIs of different cross-resistance groups 
compared to spray strategies consisting of DMIs of the same cross-resistance group. 
Therefore, maintenance of DMI diversity in the fungicide market and registration of new 
DMIs that show a different cross-resistance pattern to existing DMIs is considered to be an 
important aspect of disease management of STB. Nevertheless, in the long-run as 
suggested before (Heick et al., 2017b; Jørgensen et al., 2018), application of DMI mixtures 
may select for CYP51 haplotypes that show cross-resistance to all common DMIs or for 
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additional resistance mechanisms conferring cross-resistance, such as CYP51 
overexpression or an increased efflux. Therefore, application of DMIs in mixtures with 
fungicides with different MOAs is also recommended in order to counteract this selection 
(Hobbelen et al., 2013; van den Bosch et al., 2014; Heick et al., 2017b).  
5.4 Impact of in vitro DMI adaptation on in vivo DMI 
efficacy and implications for field performance of 
DMIs  
Detection of resistant isolates in fungal field populations is not necessarily associated with 
sudden and direct disease control problems under field conditions (Brent and Hollomon, 
2007a). Therefore, it is important to distinguish between ‘field resistance’ that describes the 
presence of resistant isolates in field populations and ‘practical resistance’ that indicates 
losses in disease control based on fungicide resistance (Brent and Hollomon, 2007a). 
‘Practical resistance’ arises when the resistance levels of isolates are high enough to 
survive application rates in the field and the prevalence of these isolates is also high enough 
to dominate the population (Oliver and Hewitt, 2014). Resistance factors determined in in 
vitro studies do not necessarily correlate linearly to fungicide efficacies in the glasshouse 
(this work; Rehfus, 2018) and consequently probably not to field performance. Monitoring 
of field performance of fungicides is therefore an important issue of fungicide resistance 
monitoring, alongside the identification and characterisation of resistances in the laboratory 
(Brent and Hollomon, 2007a).  
Although adapted CYP51 haplotypes were detected in field populations of Z. tritici and a 
shift in sensitivity was observed in vitro, field performance of registered field rates of 
epoxiconazole was not significantly affected until 2008 (Stammler et al., 2008b). Across 26 
field trials in 2015 and 2016, triazoles provided significant control of STB (50-70%) with 
highest levels of control associated with triazole mixtures, epoxiconazole+metconazole 
(Osiris®) and prothioconazole+tebuconazole (Prosaro®) (Jørgensen et al., 2018). Highly 
variable field performance across Europe was observed and correlated at least to some 
extend to varying DMI adaptation of the Z. tritici populations and different impacts on 
triazoles (see chapter 5.3) (Jørgensen et al., 2018). In glasshouse studies in this work, it 
was observed that epoxiconazole showed substantial efficacy (on average around 75% or 
higher) even for isolates carrying CYP51 haplotypes that showed high adaptation in vitro. 
Additionally, mefentrifluconazole showed high efficacy for all tested CYP51 haplotypes (on 
average at least around 85% and in most cases higher) including haplotype F2 and H6, 
which showed high resistance factors in vitro. Limited correlation of in vitro and in vivo 
results may result from the interaction of metabolic processes in plant cells with fungicides. 
For example, in case of mefentrifluconazole, a high CYP51 binding affinity has been 
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observed indicating a lower concentration required for an effective binding of CYP51 
compared to currently registered DMIs. Furthermore, mefentrifluconazole showed a lower 
solubility and consequently lower translocation within the plant compared to reference 
triazoles (depot effect). Interaction of these two properties may lead to lower degradation of 
free mefentrifluconazole by plant metabolism over time compared to older triazoles 
(personal communication Dieter Strobel, technical manager BASF SE). All in all, results of 
the glasshouse tests imply that DMIs still contribute to STB control in the field despite the 
occurrence of isolates that show high adaptation in vitro. In glasshouse trials, a high spore 
density of individual highly in vitro adapted isolates with a specific CYP51 haplotype was 
tested and conditions for fungal growth optimised. These conditions would not occur in 
nature. The assumption that DMIs can still contribute to the control of the tested CYP51 
haplotypes in the field is supported by these facts, because under natural conditions a lower 
frequency of these CYP51 haplotypes occur (this work). Under natural conditions a high 
variation of different CYP51 haplotypes is prevalent, even within a single field (Stammler et 
al., 2008b; Stammler and Semar, 2011). In glasshouse studies in this work, only a limited 
number of CYP51 haplotypes was tested. Therefore, additional glasshouse studies with an 
extended number of CYP51 haplotypes are recommended for further predictions about field 
efficacy of triazoles.  
In field studies of 2015 and 2016, efficacy of triazoles could not always be correlated to the 
frequency of CYP51 mutations and to in vitro adaptation of regional Z. tritici populations 
across different countries (Jørgensen et al., 2018). It was suggested that disease pressure, 
weather conditions, leaf emergence, and application timing may be crucial factors 
determining field performance of triazoles (Paveley et al., 2000; Strobel et al., 2017; Blake 
et al., 2018). It may be speculated that under suboptimal application conditions (e.g. high 
disease pressure, unfavourable application timing, lower doses) the impact of DMI 
adaptation measured in vitro on field performance of triazoles is more severe than indicated 
by glasshouse studies of this work. This fact may contribute to overall decline in the field 
performance of triazoles reported in the past (Kildea, 2016; Heick et al., 2017a; Strobel et 
al., 2017; Blake et al., 2018; Jørgensen et al., 2018). Although, in glasshouse studies 
epoxiconazole showed substantial control for isolates that showed highest adaptation in 
vitro, a reduced efficacy was observed compared to isolates that showed lower adaptation 
in vitro. Ongoing evolution of CYP51 haplotypes and an ongoing shift in sensitivity identified 
in this work across Europe may consequently reduce field efficacy of individual triazoles 
further if no resistance management strategies would be applied. Therefore, constant 
monitoring of field performance of existing and new DMIs entering the market is 
recommended.  
In vitro studies of this work and previous studies (Cools et al., 2012) revealed that CYP51 
overexpression confers an additive effect on DMI adaptation, but the decrease in sensitivity 
based on CYP51 overexpression is lower compared to the potential impact of combination 
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of CYP51 alterations (see chapter 5.2.2). In glasshouse studies of this work, epoxiconazole 
and mefentrifluconazole showed a high efficacy for isolates with CYP51 overexpression 
which supports findings from Cools et al. (2012). They reported that isolates with CYP51 
overexpression were completely controlled in the glasshouse when fungicides were applied 
at full rates. Resistance levels correlated to CYP51 overexpression in the laboratory may 
not be high enough to impact efficacy at field dose rates (Oliver and Hewitt, 2014; Blake et 
al., 2018). Consequently, it was suggested that disease control of STB is not affected due 
to CYP51 overexpression under field conditions when triazoles are used at full 
recommended rates, optimal application timing and uniform coverage of the crop is ensured 
(Cools et al., 2012). However, the increase of CYP51 overexpression in countries of 
Western Europe and in Poland as well as in Germany (this work; Kildea et al., 2019) may 
be interpreted as a contrasting argument. It may allow the assumption that under suboptimal 
application conditions and reduced application rates the impact of CYP51 overexpression 
on DMI sensitivity measured in vitro may be high enough to affect field performance of 
DMIs. It was reported that isolates overexpressing CYP51 grew at higher fungicide doses 
in the glasshouse compared to isolates with the same CYP51 haplotype but without CYP51 
overexpression indicating that these isolates will be selected in the field (Cools et al., 2012). 
Furthermore, the selective advantage of isolates with CYP51 overexpression may rely on 
cross-resistance to most common DMIs associated with CYP51 overexpression (Cools et 
al., 2012, 2013; Ziogas and Malandrakis, 2015; Kildea et al., 2019). Finally, however, it 
remains to be tested for example in the glasshouse or in field trials if these hypotheses play 
a role in the increase of CYP51 overexpression. In this work, CYP51 overexpression was 
identified in combination with CYP51 haplotypes other than the F2 haplotype. Therefore, 
the assumption from previous authors (Lucas et al., 2015; Kildea et al., 2019) that it cannot 
be ruled out that combination of CYP51 overexpression with highly evolved CYP51 
haplotypes will lead to further reduction in sensitivity and may contribute to reduced 
fungicide efficacy in the field is supported.  
The practical relevance of an increased efflux activity for fungicide performance in the field 
was not investigated so far. As for CYP51 overexpression, in this work and previous studies 
(Leroux and Walker, 2011; Omrane et al., 2015, 2017), it was demonstrated that an 
increased efflux is correlated to an additive effect on DMI adaptation, but this effect is 
smaller compared to the potential impact of combination of CYP51 alterations. In this work, 
in vivo results for isolates exerting increased efflux were presented for the first time for 
Z. tritici. Overall, epoxiconazole and mefentrifluconazole showed high efficacies for isolates 
with an increased efflux. If at all, only a slight decrease in efficacy (4-8%) was observed for 
all tested compounds for isolates with increased efflux (compared to isolates with the same 
CYP51 haplotype but without increased efflux). For one isolate, it could not be clarified if 
lower efficacy is conferred by an increased efflux or CYP51 overexpression. Additionally, a 
high variability of Z. tritici field isolates in general, makes it hard to predict if slight differences 
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in efficacy are conferred by an increased efflux. Moreover, it could not be clarified if an 
increased efflux has contributed to the lowest efficacy of epoxiconazole and 
prothioconazole for isolates carrying haplotype H6 with increased efflux, because no 
isolates with a H6 haplotype and without increased efflux were tested. However, in vitro 
results (Figure 26) showed that CYP51 haplotype H6 alone confers high adaptation to 
epoxiconazole and an increased efflux only has a slight additive effect on DMI adaptation 
of this haplotype (around 1.5-fold). Based on these results, it may be assumed that lower 
efficacy for the H6 haplotype in glasshouse is mainly driven by combination of CYP51 
alterations.  
All in all, no clear conclusion could be drawn for the impact of an increased efflux on in vivo 
efficacy of different DMIs, but a contribution to a slightly lower efficacy seems possible. 
Nevertheless, efficacy of epoxiconazole and prothioconazole for isolates that only carry 
haplotype I2 and no additional resistance mechanism was lower compared to isolates 
carrying other haplotypes and an increased efflux and/or CYP51 overexpression (except 
haplotype H6). Based on this fact, it may be speculated that combination of CYP51 
alterations has higher relevance for epoxiconazole and prothioconazole efficacy in vivo 
compared to additional resistance mechanisms. Due to the high variability of Z. tritici field 
isolates and the low number of tested isolates in glasshouse studies of this work, further 
studies with a higher number of isolates that carry the same CYP51 haplotype and only 
differ in the presence or absence of an increased efflux are recommended. These studies 
would help to gain further information about the impact of an increased efflux on DMI 
efficacy in vivo. As assumed for CYP51 overexpression and CYP51 haplotypes, it may be 
speculated that the impact associated with an increased efflux on DMI sensitivity in vitro, 
may be high enough to affect field performance of DMIs under suboptimal application 
conditions. Additionally, it cannot be excluded that combination of an increased efflux 
activity with highly evolved CYP51 haplotypes will lead to further reduction in sensitivity and 
field efficacy of DMIs will be affected. An increase in the frequency of these isolates, 
however, would still be required in order to constrain field performance of triazoles for STB. 
Such an example was found for another pathogen, where for B. cinerea an increase in the 
frequency of such isolates was detected (Hahn and Leroch, 2015). For B. cinerea in 
strawberries, an additive effect on adaptation to some fungicides was shown to be due to a 
combination of target site mutations and MDR (Grabke and Stammler, 2015). Combination 
of multiple target site resistances and MDR1, an MDR type that relies on overexpression of 
ABC transporters (Kretschmer et al., 2009), seems to have practical relevance (Hahn and 
Leroch, 2015). Nevertheless, it was stated that a complete failure of fungicide efficacy due 
to MDR is unlikely in B. cinerea, but combination with multiple target site resistances makes 
disease control increasingly difficult (Hahn and Leroch, 2015). The role of multiple target 
site resistances to fungicides with different MOAs combined to an increased efflux for future 
control of STB has not been investigated so far and seems a relevant issue based on the 
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example of B. cinerea. Nevertheless, for B. cinerea in strawberries a different situation 
exists compared to Z. tritici in wheat, since several fungicide treatments are applied in 
strawberries for B. cinerea control within a couple of weeks. Additionally, in this 
crop/pathogen system, MDR is mainly driven by fludioxonil applications for which no target 
site alterations occur in field isolates. MDR is the only resistance mechanism of field isolates 
of B. cinerea against fludioxonil since more than 20 years of product launch. This fungicide, 
however, is not registered and applied in cereals (Leroch et al., 2013; Grabke and 
Stammler, 2015; personal communication Dr. Gerd Stammler, fungicide resistance 
monitoring BASF SE).  
In summary, the combination of CYP51 alterations in Z. tritici and an increase of the 
frequency of these CYP51 haplotypes were associated with a reduced field performance of 
DMIs (Heick et al., 2017a; Jørgensen et al., 2018). Nevertheless, it was shown that existing 
DMIs still contribute to STB control under glasshouse- or field conditions (this work; 
Jørgensen et al., 2018) and the new DMI probably will provide good STB control for some 
time (this work). Glasshouse studies indicate up to now, that the impact of CYP51 
overexpression and an increased efflux activity on field performance of DMIs is relatively 
low under optimal application conditions. If conditions are not ideal, then the effect of an 
increased efflux or CYP51 overexpression may be high enough to contribute to a reduced 
field performance and selection of these mechanisms under field conditions may be 
possible. Additionally, due to the possible combination of additional resistance mechanisms 
with increasingly adapted CYP51 haplotypes, and cross-resistance between triazoles 
conferred by an increased efflux and CYP51 overexpression, these mechanisms may be 
selected in the future. These assumptions, however, need to be confirmed experimentally 
in future studies.  
5.5 Prospects for future DMI application 
DMI resistance in Z. tritici has been intensively studied since many years. Making 
predictions about further development of DMI efficacy in the control of STB is difficult due 
to a high level of complexity. Different DMI resistance mechanisms exert different effects 
on DMI sensitivity (this work; Leroux and Walker, 2011; Cools and Fraaije, 2013). A 
heterogenous distribution of these mechanisms across Europe exist (this work), meaning 
that resistance development is spatially variable. In addition, limited cross-resistance of 
CYP51 haplotypes to different DMIs was shown at one site (this work; Cools et al., 2011; 
Leroux and Walker, 2011; Cools et al., 2013; Lucas et al., 2015; Strobel et al., 2017; 
Jørgensen et al., 2018), but cross-resistance conferred by CYP51 overexpression as well 
as an increased efflux on the other site (Leroux and Walker, 2011; Cools et al., 2012, 2013; 
Ziogas and Malandrakis, 2015; Omrane et al., 2015; Kildea et al., 2019).  
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Currently, despite the emergence of DMI resistance over many years, triazoles still play a 
crucial role in STB control (Strobel et al., 2017; Jørgensen et al., 2018; Kildea et al., 2019). 
This crucial role is based on direct STB control but also on the importance to have DMIs as 
mixing partners for other fungicides with different MOAs as option for anti-resistance 
management (Jørgensen et al., 2018). A heterogenous distribution of CYP51 haplotypes 
with varying resistance levels, occurrence of CYP51 overexpression and an increased efflux 
across Europe demonstrated that resistance in Western and in the Central European 
countries, Germany and Poland, is more advanced than in Eastern Europe. As described 
in the previous chapter, ongoing spread and increase of increasingly adapted CYP51 
haplotypes probably will affect field performance of individual DMIs further. Nevertheless, 
results of this work supported the assumption made before (Cools and Fraaije, 2008; Heick 
et al., 2017b; Jørgensen et al., 2018; Kildea et al., 2019), that incomplete cross-resistance 
between existing DMIs as well as to new DMIs entering the market may be exploited for 
anti-resistance management by alternation or mixing of different DMIs and consequently 
could help to maintain STB control.  
Although the impact conferred by CYP51 overexpression and an increased efflux in Z. tritici 
seems lower than the potential impact of combinations of CYP51 alterations, they further 
reduce triazole sensitivity of Z. tritici in vitro (this work; Cools et al., 2012; Omrane et al., 
2015, 2017). As assumed in the previous chapter, a potential impact of these additional 
mechanisms on field performance of DMIs under suboptimal application conditions 
(including application timing, disease pressure, weather conditions) could not be excluded. 
Furthermore, CYP51 overexpression or an increased efflux may contribute to a reduced 
field performance in STB control when combined with increasingly adapted CYP51 
haplotypes in the future. The same is assumed when all three mechanisms will be combined 
involving highly adapted CYP51 haplotypes. Therefore, further distribution and increase of 
isolates with additional DMI resistance mechanisms in Z. tritici should be prevented. As 
described in chapter 5.2.4, fitness aspects correlated to additional resistance mechanisms 
may affect distribution and increase of these mechanisms in Z. tritici. Investigation of such 
fitness aspects is recommended in order to establish appropriate anti-resistance 
management strategies. As CYP51 overexpression and an increased efflux confer cross-
resistance between DMIs (Cools et al., 2012, 2013; Ziogas and Malandrakis, 2015; Omrane 
et al., 2015; Kildea et al., 2019), principal resistance management strategies that aim to 
reduce fungicide resistance build-up should be applied (Jørgensen et al., 2019). Alternation 
or especially mixtures of fungicides with different effective MOAs or multi-site inhibitors have 
been shown to delay the evolution of fungicide resistance (Hobbelen et al., 2013; van den 
Bosch et al., 2014; Heick et al., 2017b) and are recommended. Moreover, an optimal 
application timing, rather preventive than curative, can provide anti-resistance management 
(van den Berg et al., 2013; Jørgensen et al., 2019). Additionally, limiting the number of 
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fungicide applications according to their requirement is also an important tool in anti-
resistance management (van den Bosch et al., 2014; Jørgensen et al., 2019).  
A relevant aspect that has to be considered for anti-resistance management strategies and 
future disease control of STB is the occurrence of multiple resistances to different MOAs. 
Multiple resistances were not investigated in this work, but as frequency of QoI resistance 
is generally high in Western Europe (Fraaije et al., 2005; Lucas and Fraaije, 2008; 
Jørgensen et al., 2019), the combination of DMI adaptation and QoI resistance in the 
majority of isolates in Western Europe is likely. Moreover, field isolates that exhibit SDHI 
resistance, QoI resistance, benzimidazole resistance and that carry an evolved CYP51 
haplotype have been already detected (Rehfus, 2018). Availability of different active MOAs 
for effective anti-resistance management strategies has therefore been suggested to be at 
risk (Jørgensen et al., 2019). Moreover, a stricter regulation approach in the EU is likely to 
reduce the availability of different MOAs on the European fungicide market in the future 
(Hollomon, 2015; Bryson and Brix, 2019). Consequently, future resistance management 
strategies should incorporate integrated disease management approaches such as host 
plant resistance and the combined application of biopesticides with conventional fungicides. 
These strategies aim to keep disease pressure, and consequently the requirement for 
fungicide applications, low (reviewed in Hollomon, 2015; Jørgensen et al., 2019). Thereby, 
they may help to protect active ingredients entering the market as well as existing DMIs and 
the important role of DMIs in control of STB may be maintained.  
5.6 Proposal for future research on DMI resistance 
Monitoring of DMI resistance in Z. tritici, as performed in this work, is recommended for 
future studies in order to determine future evolution, spread, and frequency of CYP51 
haplotypes and additional DMI resistance mechanisms across Europe. For a better 
understanding of DMI resistance and for prediction about further evolution, future studies 
could also comprise:  
• Protein modelling studies with new CYP51 alterations identified in this work could 
help to predict if they bear evolutionary potential for the emergence of other 
alterations that may affect DMI sensitivity. 
• Characterisation of inserts in CYP51p and MFS1p with respect to their origin and 
how they drive overexpression could help to understand evolution of adaptation in 
Z. tritici.  
• Introduction of CYP51p and MFS1p inserts in sensitive isolates, for example, via 
molecular techniques as CRISPR-Cas9 in order to investigate their individual effect 
on DMI sensitivity of Z. tritici. 
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• Investigation if other transporters or mechanisms play a role in increased efflux 
activity or CYP51 overexpression of Z. tritici. 
• Extension of glasshouse studies with more isolates with different CYP51 haplotypes 
carrying CYP51 overexpression and/or increased efflux or not (preventive as well 
as curative application) for better estimation of their impact on DMI field 
performance.  
• Assessment of the fitness of isolates, for example, via competition studies in the 
glasshouse with isolates that show the same CYP51 haplotypes but differ in the 
presence or absence of CYP51 overexpression and/or increased efflux.  
• Establishment of a method for absolute quantification of Z. tritici in field samples that 
are subsequently analysed for CYP51 haplotypes after solo DMI treatment in order 
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Table 22: Z. tritici isolates from European sensitivity monitoring of 2016 and 2017 used in this 
work and their origin. All isolates were tested for their sensitivity to epoxiconazole. Isolates marked 
in bold were additionally tested for their sensitivity to prothioconazole-desthio and 
mefentrifluconazole. Microtiter tests were performed by the company EpiLogic. 







Jihocesky kraj 6871, 6872, 6873 
Olomoucky kraj 6874 
DE 
Baden-Württemberg 6460, 6461, 6813, 6814, 6815, 6816, 6817, 6818, 
6819 
Bayern 6439, 6446 
Niedersachsen 6472, 6473, 6811  
Rheinland-Pfalz 6466, 6468, 6812 
Schleswig-Holstein 6498, 6500, 6809, 6501, 6810 
DK 
Midtjylland 6802, 6803, 6804 
Sjæland 6805, 6806, 6807, 6808 
FR 
Aquitaine 6787, 6788 
Bourgogne 6445, 6448, 6773, 6774, 6775, 6776, 6777, 6778, 
6779 
Bretagne 6452, 6453, 6757, 6758, 6759, 6760, 6761, 6762 
Centre 6467, 6769, 6770, 6771, 6772 
Champagne-Ardenne 6436, 6447, 6755, 6756 
Haute Normandie 6443, 6444, 6741, 6742, 6743 
Île de France 6752, 6753 
Midi-Pyrenees 6789, 6790, 6791, 6792 
Nord-Pas de Calais 6438, 6454, 6455, 6456, 6735, 6736, 6737, 6738, 
6739, 6740 
Pays de Loire 6442, 6763, 6764, 6765, 6766, 6767, 6768 
Picardie 6437, 6459, 6744, 6745, 6746, 6747, 6748, 6749, 
6750, 6751 
Poitou-Charente 6780, 6781, 6782 
Rhône-Alpes 6783, 6784, 6785, 6786 
IE 
Leinster 6410, 6412, 6413, 6415, 6416, 6435, 6476, 6477, 
6478, 6479, 6480, 6481, 6482, 6484, 6485, 6486, 
6487, 6488, 6489, 6628, 6629, 6630, 6631, 6632, 
6633, 6634, 6635, 6636, 6637, 6638, 6639, 6640, 
6641, 6642, 6643, 6644, 6645, 6646, 6647, 6648, 
6649, 6650, 6651, 6652, 6653, 6654, 6655, 6656, 
6657, 6658, 6659, 6660, 6661, 6662, 6663, 6664, 
6665, 6666, 6667, 6668 
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IE Munster 6417, 6418, 6419, 6420, 6421, 6440, 6474, 6475, 
6490, 6492, 6493, 6494, 6669, 6670, 6671, 6672, 
6673, 6674, 6675, 6676, 6677, 6678, 6679, 6680, 
6681, 6682, 6683, 6684, 6685, 6686, 6687, 6688, 
6689 
NL 
Flevoland 6425, 6426, 6505 
Groningen 6422, 6423, 6424, 6427, 6428, 6429, 6502, 6504 
PL 
Dolnośląskie 6853, 6854, 6855 
Kujawsko-Pomorskie 6846, 6847, 6848, 6849, 6850, 6851,  
Łódzkie 6852 
Lubelskie 6868 
Lubuskie 6827, 6828, 6829, 6830, 6831, 6832 
Mazowieckie 6867 
Opolskie 6856, 6857, 6858, 6859, 6860, 6861, 6862 
Podkarpackie 6869, 6870 
Pomorskie 6823, 6824, 6825, 6826 
Slaskie 6863 
Warminsko-Mazurskie 6864, 6865, 6866 
Wielkopolskie 6834, 6835, 6836, 6837, 6838, 6839, 6840, 6841, 
6842, 6843, 6844, 6845 
Zachodniopomorskie 6821, 6822 
SE 
Blekinge 6793 
Östergötland 6794, 6795, 6796, 6797 
Skåne 6798, 6799, 6800 
Västra Götaland 6801 
UK 
East Anglia 6462, 6469, 6730, 6731, 6732, 6733 
East Midlands 6407, 6430, 6431, 6434, 6464, 6720, 6721, 6722, 
6723, 6724, 6725, 6726, 6727, 6728, 6729 
North West 6470, 6471, 6716, 6717 
Scotland 6450, 6451, 6457, 6458, 6690, 6691, 6692, 6693, 
6694, 6695, 6696, 6697, 6698, 6699, 6700, 6701, 
6702, 6703, 6704, 6705, 6706, 6707, 6708, 6709, 
6710, 6711, 6712, 6713, 6714, 6715 
South West 6432, 6433, 6465, 6734 








Severozapaden 7676, 7677, 7678 
Yuzhen tsentralen 7662, 7663, 7664, 7665, 7666, 7667, 7668, 7669, 
7670, 7671, 7672, 7673, 7674, 7675 
CZ Jihocesky kraj 7572, 7573, 7574, 7575, 7576, 7577 
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Olomoucky kraj 7581, 7582, 7583 
Pardubicky kraj 7578, 7579, 7580 
DE 
Baden-Württemberg 7458, 7459, 7460, 7461, 7462, 7463, 7464, 7465, 
7466 
Bayern 7467, 7468, 7469, 7470, 7471, 7472, 7473, 7474, 




7436, 7438, 7439, 7440, 7441 
Niedersachsen 7442, 7443, 7444, 7445, 7446, 7447, 7448, 7449, 
7450, 7451 
Rheinland-Pfalz 7455, 7456, 7457 
Sachsen 7452, 7453, 7454 
ES Andalucía 7679, 7680, 7681, 7682, 7683, 7684 
FR 
Aquitaine 7420, 7421, 7422, 7423, 7424, 7425, 7426, 7427, 
7428, 7429, 7430, 7431, 7432, 7433, 7434 
Basse Normandie 7306, 7307, 7308 
Bourgogne 7388, 7389, 7390, 7391, 7392, 7393, 7394, 7395, 
7396, 7397, 7398, 7399, 7400, 7401, 7402, 7403, 
7404 
Bretagne 7341, 7342, 7343, 7344, 7345, 7346, 7347, 7348, 
7349, 7350, 7351, 7352 
Centre 7367, 7368, 7369, 7370, 7371, 7372, 7373, 7374, 
7375, 7376, 7377, 7378, 7379, 7380, 7381, 7382, 
7383, 7384, 7385, 7386, 7387 
Champagne-Ardenne 7332, 7333, 7334, 7335, 7336, 7337, 7338, 7339, 
7340 
Haute Normandie 7309, 7310, 7311, 7312, 7313, 7314, 7315, 7316, 
7317, 7318, 7319, 7320 
Île de France 7329, 7330, 7331 
Midi-Pyrenees 7435 
Nord-Pas de Calais 7288, 7289, 7290, 7291, 7292, 7293, 7294, 7295, 
7296, 7297, 7298, 7299, 7300, 7301, 7302, 7303, 
7304, 7305 
Pays de Loire 7353, 7354, 7355, 7356, 7357, 7358, 7359, 7360, 
7361, 7362, 7363, 7364, 7365, 7366, 7863 
Picardie 7321, 7322, 7323, 7324, 7325, 7326, 7327, 7328,  
Poitou-Charente 7405, 7406, 7407, 7408, 7409, 7410, 7411, 7412, 
7413, 7414, 7415, 7416, 7417, 7418, 7419 
IE 
Leinster 6999, 7000, 7001, 7002, 7003, 7235, 7236, 7237, 
7238, 7239, 7240, 7241, 7242, 7243, 7244, 7245, 
7246, 7247, 7248, 7249, 7250, 7251, 7252, 7253, 
7254, 7255 
Munster 7256, 7257, 7258, 7259, 7260, 7261 
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Emilia Romagna 7694, 7695, 7696, 7697, 7698 
Lombardia 7685, 7686, 7687, 7688, 7689, 7690, 7691, 7692 
Toscana 7699, 7700 
NL 
Flevoland 7285, 7286, 7287 
Groningen 7276, 7277, 7278, 7279, 7280, 7281, 7282, 7283, 
7284 
PL 
Dolnośląskie 7532, 7533, 7534, 7535, 7536, 7537, 7538 
Kujawsko-Pomorskie 7523, 7524, 7525, 7526 
Łódzkie 7527, 7528, 7529, 7530, 7531 
Lubelskie 7563, 7564, 7565 
Lubuskie 7498, 7499 
Małopolskie 7566, 7567, 7568, 7569, 7570, 7571 
Opolskie 7539, 7540, 7541, 7542, 7543, 7544, 7545, 7547, 
7548, 7549, 7550, 7551, 7552, 7553, 7554, 7555, 
7556 
Pomorskie 7488, 7489, 7490, 7491, 7492, 7493, 7494, 7495, 
7496, 7497 
Warminsko-Mazurskie 7557, 7558, 7559, 7560, 7561, 7562 
Wielkopolskie 7500, 7501, 7502, 7503, 7504, 7505, 7506, 7507, 
7508, 7509, 7510, 7511, 7512, 7513, 7514, 7515, 
7516, 7517, 7518, 7519, 7520, 7521, 7522 
Zachodniopomorskie 7485, 7486, 7487 
RU 
Juschny 7848, 7849, 7850, 7851, 7852, 7853, 7854 
Sewero-kavkaskyi 7855, 7856, 7857, 7858, 7859, 7860, 7861, 7862 
Sewero-sapadny 7829, 7830, 7831, 7832, 7833, 7834 
Zentralny 7835, 7837, 7838, 7839, 7840, 7841, 7842, 7843, 
7844, 7845, 7846, 7847 
SK 
Banskobystrický kraj 7584, 7585, 7586, 7587, 7588, 7589, 7590, 7591, 
7592 
Košický kraj 7599, 7600, 7601, 7602, 7603, 7604 
Prešovský kraj 7593, 7594, 7595, 7596, 7597, 7598 
UA 
Chersonska 7656, 7657, 7658, 7659, 7660, 7661 
Chmelnyzka 7623, 7624, 7625, 7626, 7627, 7628, 7629, 7630, 
7631 
Kyjiwska 7644, 7645, 7646 
Lwiwska 7620, 7621, 7622 
Mykolajiwska 7653, 7654, 7655 
Odeska 7638, 7639, 7640, 7641, 7642, 7643 
Riwnska 7611, 7612, 7613, 7614, 7615, 7616, 7617, 7618, 
7619 
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Sumska 7647, 7648, 7649 
Tscherkaska 7650, 7651, 7652 
Tschernihiw 7635, 7636, 7637 
Winnyzka 7632, 7633, 7634 
Wolynska 7605, 7606, 7607, 7608, 7609, 7610 
UK 
East Anglia 7077, 7078, 7079, 7080, 7081, 7262, 7263, 7264 
South East 7158, 7159, 7160, 7161, 7162, 7271, 7272, 7273, 
7274, 7275 
South West 7265, 7266, 7267, 7268, 7269, 7270 
 
Table 23: Z. tritici isolates obtained from trial sites used in this work. Leave samples from trial 
sites were sent to EpiLogic and they generated single pycnidia isolates. 
Country Region Treatment  Isolates  
DE Niedersachsen  
Untreated  6598, 6599, 6600, 6601, 6602, 6603, 
6604, 6605, 6606, 6607 
Mefentrifluconazole 6608, 6609, 6610, 6611, 6612, 6613, 
6614, 6615, 6616, 6617 
Prothioconazole 6618, 6619, 6620, 6621, 6622, 6623, 
6624, 6625, 6626, 6627 
DK Sjæland 
Untreated  6568, 6569, 6570, 6571, 6572, 6573, 
6574, 6575, 6576, 6577 
Mefentrifluconazole 6578, 6579, 6580, 6581, 6582, 6583, 
6584, 6585, 6586, 6587 
Prothioconazole 6588, 6589, 6590, 6591, 6592, 6593, 
6594, 6595, 6596, 6597 
IE Munster 
Untreated  6508, 6509, 6510, 6511, 6512, 6513, 
6514, 6515, 6516, 6517 
Mefentrifluconazole 6518, 6519, 6520, 6521, 6522, 6523, 
6524, 6525, 6526, 6527 
Prothioconazole 6528, 6529, 6530, 6531, 6532, 6533, 
6534, 6535, 6536, 6537 
UK East Anglia 
Untreated  6538, 6539, 6540, 6541, 6542, 6543, 
6544, 6545, 6546, 6547 
Mefentrifluconazole 6548, 6549, 6550, 6551, 6552, 6553, 
6554, 6555, 6556, 6557 
Prothioconazole 6558, 6559, 6560, 6561, 6562, 6563, 
6564, 6565, 6566, 6567 
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Table 24: Distances (Å) from wild type amino acids observed as position of alteration to the 
haem group in the CYP51 enzyme. Distances were calculated from the iron atom of the haem to 
the alpha carbon on the protein backbone for each alteration. Amino acids that were observed as 
subject of alterations already described for Z. tritici were designated as ‘existing’. Amino acids that 
were observed as subject of new alterations identified in this work were designated as ‘new’.  
Position of wild type 
amino acid observed 
as subject of alteration 
Status of occurrence Distance to haem 
group (Å) 
L50 Existing 37.0 
D134 Existing 19.3 
V136 Existing 12.3 
Y137 Existing 14.1 
S188 Existing 34.4 
N284 Existing 19.2 
A379 Existing 11.1 
I381 Existing 9.8 
A410 Existing 14.8 
Y459 Existing 16.0 
G460 Existing 16.3 
Y461 Existing 13.6 
G462 Existing 15.0 
N513 Existing 28.3 
S524 Existing 14.0 
K95 New 25.4 
L197 New 17.6 
A318 New 12.9 
I377 New 16.7 
I452 New 20.1 
K456 New 18.5 
E457 New 19.4 
D458 New 17.2 
L463 New 16.2 
N507 New 30.1 
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Figure 36-Part 1: Amino acid sequence of all CYP51 haplotypes identified in Z. tritici isolates of this work. Further information is given on page 175. 
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Figure 36-Part 2: Amino acid sequence of all CYP51 haplotypes identified in Z. tritici isolates of this work. Further information is given on page 175. 
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Figure 36-Part 3: Amino acid sequence of all CYP51 haplotypes identified in Z. tritici isolates of this work. Further information is given on page 175. 
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Figure 36-Part 4: Amino acid sequence of all CYP51 haplotypes identified in Z. tritici isolates of this work. Further information is given on page 175. 
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Figure 36-Part 5: Amino acid sequence of all CYP51 haplotypes identified in Z. tritici isolates of this 
work. Alignment was performed with one Z. tritici isolate for each identified CYP51 haplotype (including the 
WT CYP51 of St IPO323). For some CYP51 haplotypes the beginning and end of the amino acid sequences 
are missing. However, it is known that in these regions resistance alterations are less likely. Amino acids of 
the reference sequence of St IPO323 and all disagreements to this sequence are highlighted in colour. 
CYP51 haplotypes that carry new CYP51 alterations are shown. Following isolates (CYP51 haplotypes) 
carry a new alteration: St 7636 (A15): I452V, St 6803 (C9): Y461N, St 7259 (D26): A318G, St 7342 (D27): 
I377V, St 7362 (E28): K95M, St 7578 (F20): N507S, St 7854 (I4): L197V, Del K456, Del E457, Del D458, 
Del L463. Alignment was performed with MUSCLE algorithm and manually corrected for positions of 
deletions. 
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Figure 37: Alignment of Z. tritici isolates carrying the wild type CY51p (WT CYP51p). Nucleobases of the reference sequence of St IPO323 and all 
disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The CYP51 start codon is 
indicated by the asterisk. Compared to reference sequence of St IPO323, all isolates showed small insertions ranging between 8 and <30 bp. Nevertheless, 
these isolates were regarded in this work to carry a WT CYP51p (described in 4.6.1). Alignment was performed with MUSCLE algorithm. 
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Figure 38: Alignment of Z. tritici isolates carrying the 121 bp insert in CYP51p. Isolates carrying the 121 bp insert in CYP51p were aligned to the WT 
CYP51p (St IPO323). Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are highlighted in colour (adenine = red, 
guanine = yellow, thymine = green, cytosine = blue). The alignment is only shown until the beginning of the CYP51 gene and the start codon is indicated by 
the asterisk. The insertion site of the 121 bp insert is located -83 bp upstream of the start codon (based on WT CYP51p of St IPO323). Alignment was 
performed with MUSCLE algorithm. 
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Figure 39: Alignment of Z. tritici isolates carrying the 300 bp insert in CYP51p. Isolates carrying the 300 bp insert in CYP51p were aligned to the WT 
CYP51p (St IPO323). Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are highlighted in colour (adenine = red, 
guanine = yellow, thymine = green, cytosine = blue). The CYP51 start codon is indicated by the asterisk. The insertion site of the 300 bp insert is located  
-118 bp upstream of the start codon (based on WT CYP51p of St IPO323). Alignment was performed with MUSCLE algorithm.  
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Figure 40-Part 1: Alignment of Z. tritici isolates carrying the 863 bp insert in CYP51p. Further information is given on page 181. 
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Figure 40-Part 2: Alignment of Z. tritici isolates carrying the 863 bp insert in CYP51p. Further information is given on page 181. 
Supplementary material 181 
 
 
Figure 40-Part 3: Alignment of Z. tritici isolates carrying the 863 bp insert in CYP51p. Isolates carrying the 863 bp insert in CYP51p were aligned to 
the WT CYP51p (St IPO323, St 6631). The second WT CYP51p sequence was aligned for correct alignment. Nucleobases of the reference sequence of St 
IPO323 and all disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The CYP51 
start codon is indicated by the asterisk. The insertion site of the 863 bp insert is located -207 bp upstream of the start codon (based on WT CYP51p of St 
IPO323). Alignment was performed with MUSCLE algorithm. 
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Figure 41-Part 1: Alignment of Z. tritici isolates carrying the 868 bp insert in CYP51p. Further information is given on page 184. 
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Figure 41-Part 2: Alignment of Z. tritici isolates carrying the 868 bp insert in CYP51p. Further information is given on page 184. 
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Figure 41-Part 3: Alignment of Z. tritici isolates carrying the 868 bp insert in CYP51p. Isolates carrying the 868 bp insert in CYP51p were aligned to 
the WT CYP51p (St IPO323, St 6631). The second WT CYP51p sequence was aligned for correct alignment. Nucleobases of the reference sequence of St 
IPO323 and all disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The CYP51 
start codon is indicated by the asterisk. The insertion site of the 868 bp insert is located -184 bp upstream of the start codon (based on WT CYP51p of St 
IPO323). Alignment was performed with MUSCLE algorithm. 
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Table 25: Number of Z. tritici isolates carrying a wild type CYP51p (WT CYP51p) or a CYP51p 
insert shown separately for ‘rarely found CYP51 haplotypes’. Isolates that did not produce a 




Length of CYP51p insert 
(bp) n.a. 
121 300 ~900 
A2 - - - - 1 
A3 1 - - - - 
A14 2 - - - - 
A15 1 - - - - 
B8 3 - - - - 
B15 1 - - - - 
C2 4 1 - - - 
C4 4 - - - - 
C6 1 - - - - 
C7 1 - - 1 - 
C9 - - 1 - - 
C18 1 - - - - 
D2 1 - - - - 
D7 3 1 - - - 
D9 1 - - 1 - 
D10 - - - 1 - 
D26 - - - 1 - 
D27 - - - 1 - 
E7 - - - 2 - 
E8 - - - 1 - 
E9 1 - - - - 
E21 1 - - - - 
E25 1 - - - - 
E26 - - - 1 - 
E27 1 - - - - 
E28 1 - - - - 
E29 1 - - - - 
F1 - - - 1 - 
F5 2 - - 2 - 
F6 - 1 - 8 - 
F7 4 - - 1 - 
F9 1 - - - - 
F10 - - - 5 - 





Length of CYP51p insert 
(bp) n.a. 
121 300 ~900 
F19  - - 1 - 
F20  - - 1 - 
G2 - - - 2 - 
G6 - - - 2 - 
G7 3 - - - - 
H3 1 1 - - - 
H5 2 - - 1 - 
H9 - - 1 - - 
I1 - - - 5 - 
I2  - - 2 - 
I4 5 - - - - 
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Figure 42-Part 1: Alignment of Z. tritici isolates carrying the wild type MFS1p (WT MFS1p). Further information is given on the next page.  
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Figure 42-Part 2: Alignment of Z. tritici isolates carrying the wild type MFS1p (WT MFS1p). Nucleobases of the reference sequence of St IPO323 and 
all disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The MFS1 start codon is 
indicated by the asterisk. Compared to the reference sequence of St IPO323, all isolates showed small insertions ranging between 3 and ≤42 bp. 
Nevertheless, these isolates were regarded in this work to carry a WT MFS1p (described in 4.6.1). Alignment was performed with MUSCLE algorithm. 
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Figure 43-Part 1: Alignment of Z. tritici isolates carrying the 150 bp insert in MFS1p. Further information is given on the next page.  
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Figure 43-Part 2: Alignment of Z. tritici isolates carrying the 150 bp insert in MFS1p. Isolates carrying the 150 bp insert in MFS1p were aligned to the 
WT MFS1p (St IPO323). Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are highlighted in colour (adenine = 
red, guanine = yellow, thymine = green, cytosine = blue). The MFS1 start codon is indicated by the asterisk. The insertion site of the 150 bp insert is located 
-214 bp upstream of the MFS1 start codon (based on WT MFS1p of St IPO323). Alignment was performed with MUSCLE algorithm 
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Figure 44-Part 1: Alignment of Z. tritici isolates carrying different inserts with a length of around 300 bp in MFS1p. Further information is given on 
page 194.  
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Figure 44-Part 2: Alignment of Z. tritici isolates carrying different inserts with a length of around 300 bp in MFS1p. Further information is given on 
page 194.  
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Figure 44-Part 3: Alignment of Z. tritici isolates carrying different inserts with a length of around 300 bp in MFS1p. Further information is given on 
page 194.  
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Figure 44-Part 4: Alignment of Z. tritici isolates carrying different inserts with a length of around 300 bp in MFS1p. Isolates carrying either the 267, 
308, 338, 369, or 377 bp insert in MFS1p were aligned to the WT MFS1p (St IPO323). Nucleobases of the reference sequence of St IPO323 and all 
disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The MFS1 start codon is 
indicated by the asterisk. The insertion site is located -468 bp upstream of the MFS1 start codon (based on WT MFS1p of St IPO323). Alignment was 
performed with MUSCLE algorithm. 
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Figure 45-Part 1: Alignment of Z. tritici isolates carrying the 519 bp insert in MFS1p. Further information is given on page 197. 
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Figure 45-Part 2: Alignment of Z. tritici isolates carrying the 519 bp insert in MFS1p. Further information is given on page 197. 
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Figure 45-Part 3: Alignment of Z. tritici isolates carrying the 519 bp insert in MFS1p. Isolates carrying the 519 bp insert in MFS1p were aligned to the 
WT MFS1p (St IPO323, St 6758). The second WT MFS1p fragment was aligned for correct alignment. Nucleobases of the reference sequence of St IPO323 
and all disagreements to this sequence are highlighted in colour (adenine = red, guanine = yellow, thymine = green, cytosine = blue). The MFS1 start codon 
is indicated by the asterisk. The insertion site of the 519 bp insert is located -402 bp upstream of the MFS1 start codon (based on WT MFS1p of St IPO323). 
Alignment was performed with MUSCLE algorithm.  
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Figure 46: Alignment of Z. tritici isolates carrying a 148 or 165 bp deletion in MFS1p. Isolates carrying a WT MFS1p (St IPO323, St 6830) were aligned 
to isolate St 7622 carrying a 148 bp deletion in MFS1p and to isolate St 7536 with a 165 bp deletion. The second WT MFS1p fragment was aligned for correct 
alignment. Nucleobases of the reference sequence of St IPO323 and all disagreements to this sequence are highlighted in colour (adenine = red, guanine = 
yellow, thymine = green, cytosine = blue). The MFS1 start codon is indicated by the asterisk. The site of the 148 bp deletion is located -426 bp upstream of 
the MFS1 start codon (based on WT MFS1p of St IPO323), whereas the site of the 165 bp deletion is located -339 bp upstream of the MFS1 start codon. 
Alignment was performed with MUSCLE algorithm.  
Supplementary material 199 
 
Table 26: Number of Z. tritici isolates carrying a wild type MFS1p (WT MFS1p) or an MFS1p 





Length of MFS1p insert (bp) 
 n.a. 
 150  267  308  338  369  377  519 
WT  14  -  -  -  -  -  -  -  - 
A2  1  -  -  -  -  -  -  -  - 
A3  1  -  -  -  -  -  -  -  - 
A14  2  -  -  -  -  -  -  -  - 
A15  1  -  -  -  -  -  -  -  - 
B8  3  -  -  -  -  -  -  -  - 
B15  1  -  -  -  -  -  -  -  - 
C2  5  -  -  -  -  -  -  -  - 
C4  4  -  -  -  -  -  -  -  - 
C6  1  -  -  -  -  -  -  -  - 
C7  2  -  -  -  -  -  -  -  - 
C8  131  1  -  -  -  -  -  2  5 
C9  1  -  -  -  -  -  -  -  - 
C18  1  -  -  -  -  -  -  -  - 
D2  1  -  -  -  -  -  -  -  - 
D7  3  -  -  -  -  -  -  -  1 
D9  2  -  -  -  -  -  -  -  - 
D10  1  -  -  -  -  -  -  -  - 
D13  10  1  -  -  1  -  -  -  - 
D26  -  1  -  -  -  -  -  -  - 
D27  1  -  -  -  -  -  -  -  - 
E3  7  4  -  -  -  -  -  1  3 
E4  188  4  4  1  3  1  1  15  13 
E5  18  2  -  -  1  -  -  1  2 
E7  1  -  1  -  -  -  -  -  - 
E8  1  -  -  -  -  -  -  -  - 
E9  1  -  -  -  -  -  -  -  - 
E21  1  -  -  -  -  -  -  -  - 
E25  1  -  -  -  -  -  -  -  - 
E26  1  -  -  -  -  -  -  -  - 
E27  1  -  -  -  -  -  -  -  - 
E28  1  -  -  -  -  -  -  -  - 
E29  1  -  -  -  -  -  -  -  - 
F1  1  -  -  -  -  -  -  -  - 
F2  80  1  1  -  2  1  -  6  - 






Length of MFS1p insert (bp) 
 n.a. 
 150  267  308  338  369  377  519 
F3  11  -  -  -  -  -  -  -  - 
F4  13  -  -  -  -  -  -  -  - 
F5  4  -  -  -  -  -  -  -  - 
F6  7  1  -  -  -  1  -  -  - 
F7  3  -  -  -  1  -  -  -  1 
F8  28  1  -  -  2  3  -  2  2 
F9  1  -  -  -  -  -  -  -  - 
F10  3  1  -  -  -  -  -  -  1 
F19  1  -  -  -  -  -  -  -  - 
F20  1  -  -  -  -  -  -  -  - 
G1  94  2  -  -  1  -  -  3  1 
G2  1  -  -  -  -  -  -  -  1 
G6  -  1  -  -  -  -  -  1  - 
G7  2  1  -  -  -  -  -  -  - 
H3  1  1  -  -  -  -  -  -  - 
H4  14  4  -  -  -  -  -  1  3 
H5  1  -  -  -  1  -  -  1  - 
H6  17  -  1  -  1  -  -  3  5 
H9  1  -  -  -  -  -  -  -  - 
I1  4  -  -  -  -  -  -  1  - 
I2  1  -  -  -  -  -  -  -  1 
I4  5  -  -  -  -  -  -  -  - 
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Figure 47: Sensitivity of Z. tritici isolates with a deletion in MFS1p. EC50 values of the isolates 
with respectively a 148 or 165 bp deletion for tolnaftate are shown compared to the EC50 values of 
isolates with a WT MFS1p. The number of tested isolates (n) is given in the figure. Tolnaftate is used 
as an indicator for an increased efflux activity of Z. tritici isolates. EC50 values of the isolates with a 
deletion were located in the sensitivity range of the isolates with a WT MFS1p.  
 
Figure 48: Sensitivity of Z. tritici isolates with not characterised MFS1p to epoxiconazole. In 
2016 and 2017, Z. tritici isolates were observed that produced no amplicon during PCR that was 
used to identify MFS1p inserts. EC50 values of these isolates for epoxiconazole are shown and 
compared to EC50 of isolates carrying the same CYP51 haplotype and a WT MFS1p. Single EC50 
values are shown when only one isolate was detected and mean EC50 values and standard 
deviations were calculated when more than one isolate was identified. Mean EC50 and standard 
deviations were calculated over all isolates with the same CYP51 haplotype and a WT MFS1p or 
with a MFS1p that was not characterised, respectively. The number of tested isolates is given in the 
diagram. Only isolates without distinct CYP51 overexpression (121 bp insert in CYP51p) are shown. 
No clear trend in the differences between the EC50 or mean EC50 of isolates with a WT MFS1p and 
isolates for which MFS1p was not characterised were observed.  
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Table 27: EC50 values of different DMIs for Z. tritici isolates used in glasshouse studies. 
Epoxiconazole (ECA), mefentrifluconazole (MFA), and prothioconazole-desthio (PTH-D) were tested 
in microtiter tests by EpiLogic. EC50 values marked with an asterisk were generated in microtiter tests 
internally in BASF SE. CYP51 haplotype, absence or presence and respective size of CYP51p and 










EC50 (mg a.i. L-1) 
ECA MFA PTH-D 
3718 2004 E1 - - 0.047* 0.018* 0.005* 
7473 2017 E4 900 - 0,527 0,010 0,152 
7332 2017 E4 900 519 1,366 0,059 0,199 
7327 2017 F2 120 WT 0,540 0,153 0,085 
7438 2017 F2 120 519 1,035 0,782 0,151 
5302 2012 G2 900 - 1,128 0,735* 0,144* 
5950 2014 G2 300 369 1,732 2,99* 0,235* 
6072 2015 H6 900 519 2,517 0,431 0,181 
6090 2015 H6 900 519 3,002 0,197 0,215 
6101 2015 I2 900 - 1,33 0,188* 1,6672 






Der pilzliche Schaderreger Zymoseptoria tritici verursacht die Septoria-Blattdürre (STB) an 
Weizen, eine der wichtigsten Krankheiten hinsichtlich der Ertragsreduktion im 
Weizenanbau. Neben ackerbaulichen Maßnahmen und dem Anbau von Weizensorten mit 
geringerer Krankheitsanfälligkeit, beruht die Kontrolle dieses Pathogens überwiegend auf 
der Anwendung von blattaktiven Fungiziden mit unterschiedlichen Wirkmechanismen. In 
den letzten Jahrzenten stellten hierbei die Demethylierungsinhibitoren (DMIs) eine der 
meist genutzten Fungizidklassen dar. Bis heute kommt den DMIs noch immer eine große 
Bedeutung in der Bekämpfung von Z. tritici zu. DMIs inhibieren die Sterol 14α-Demethylase, 
ein wichtiges Enzym im Sterolbiosyntheseweg von Pilzen, welches durch das CYP51 Gen 
kodiert wird. Die langanhaltende und intensive Nutzung führte zu einer kontinuierlichen 
Sensitivitätsreduktion von STB gegenüber DMIs, die über einen langen Zeitraum genutzt 
wurden. Diese Sensitivitätsverschiebung beruht hauptsächlich auf der Akkumulation von 
Mutationen im CYP51 Gen. Hieraus wurden in der Vergangenheit zahlreiche CYP51 
Haplotypen selektiert. Zusätzlich wurde in den letzten Jahren berichtet, dass eine CYP51 
Überexpression und gesteigerte Effluxaktivität, die auf der Überexpression des MFS1 
Membrantransporters beruht, die DMI-Sensitivität von STB beeinflussen. Die 
Überexpression wird hierbei durch Insertionen in der Promotorregion des CYP51 (CYP51P) 
und MFS1 (MFS1P) Gens hervorgerufen. In der vorliegenden Arbeit wurde das Vorkommen 
unterschiedlicher DMI-Resistenzmechanismen in Z. tritici in den Jahren 2016 und 2017 
über Europa untersucht. Der Effekt unterschiedlicher Mechanismen auf die DMI Anpassung 
von STB wurde analysiert. Um die CYP51 Haplotypen zu bestimmen, wurde das CYP51 
Gen von allen Isolaten sequenziert. Zusätzlich wurde die CYP51P sowie MFS1P Region 
auf Insertionen untersucht, um eine CYP51 Überexpression sowie gesteigerte 
Effluxaktivität zu identifizieren.  
Im Zuge dieser Arbeit wurden neue CYP51 Mutationen in Z. tritici identifiziert. Obwohl diese 
wahrscheinlich nicht zu einer verringerten DMI Sensitivität führen, zeigt deren Entstehung, 
dass die Evolution des CYP51 Gens noch immer voranschreitet. Zusätzlich wurden neue 
CYP51 Haplotypen identifiziert, welche auf neuen Kombinationen von bereits existierenden 
CYP51 Alterationen beruhen. Aufgrund der Identifikation zahlreicher neuer CYP51 
Haplotypen wurde im Zuge dieser Arbeit eine neue Nomenklatur etabliert. Diese 
ermöglichte die Beschreibung der 57 CYP51 Haplotypen, die über alle Isolate von 2016 
und 2017 gefunden wurden. Des Weiteren ermöglicht diese Nomenklatur die zukünftige 
Beschreibung neu entstehender CYP51 Haplotypen. In dieser Arbeit wurde gezeigt, dass 
13 der 57 CYP51 Haplotypen ungefähr 89% aller untersuchten Isolate darstellen. Diese 
wurden als „häufig gefundene CYP51 Haplotypen“ bezeichnet. Innerhalb dieser CYP51 
Haplotypen zeigten Isolate mit den Haplotypen C8, G1 und F3 die höchste Sensitivität 
gegenüber Epoxiconazol, gefolgt von den Haplotypen E4 und F2, welche eine moderate 
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Anpassung zeigten. Isolate mit den Haplotypen F4, E3, D13, E5, F8, H4 und H6, welche 
die CYP51 Alteration S524T gemeinsam haben, zeigten die höchste Anpassung gegenüber 
Epoxiconazol. In vitro Sensitivitätsstudien mit diesen Haplotypen und verschiedenen DMIs 
deuten auf eine begrenzte Kreuzresistenz zwischen Epoxiconazol sowie Prothioconazol im 
Vergleich zu Mefentrifluconazol hin. Diese Ergebnisse konnten durch Selektionsstudien im 
Feld gestützt werden, die einen unterschiedlichen Trend in der Selektion von CYP51 
Haplotypen von Prothioconazol und Mefentrifluconazol zeigten.  
Über Europa wurde eine heterogene Verbreitung von den „häufig gefundenen CYP51 
Haplotypen“, mit einem Ost-West Gradient in der DMI Anpassung von Z. tritici, beobachtet. 
Die Mehrheit der Z. tritici Populationen in den West-Europäischen Ländern Irland, UK und 
den Niederlanden wies CYP51 Haplotypen mit moderater oder höchster Epoxiconazol-
Anpassung auf. In Zentral-Europa hingegen, z.B. in Deutschland und Polen wies der 
Großteil der Populationen CYP51 Haplotypen mit geringster oder moderater Anpassung 
innerhalb der „häufig gefundenen CYP51 Haplotypen“ auf. In Osteuropa wurde eine hohe 
Häufigkeit an Haplotypen mit höchster Sensitivität innerhalb der „häufig gefundenen CYP51 
Haplotypen“ gefunden. Im Vergleich zu früheren Studien wurde jedoch eine 
voranschreitende Sensitivitätsverschiebung in Richtung einer reduzierten DMI Sensitivität 
über Europa, insbesondere in Regionen mit intensivem Weizenanbau, beobachtet.  
Die Untersuchung des CYP51P führte zur Identifizierung eines 121, 863, 868 und 300 bp 
Inserts. Es wird angenommen, dass diese Inserts den bereits publizierten 120, 862, und 
866 bp Inserts entsprechen. Aus diesem Grund wurde das 121 bp Insert im Verlauf dieser 
Arbeit als 120 bp, das 863 bp als 862 bp und das 868 bp als 866 bp Insert bezeichnet. In 
vorherigen Studien wurde gezeigt, dass das 120 bp Insert im CYP51P mit einer 
gesteigerten CYP51 Expression einhergeht, wohingegen das 862 und 866 bp Insert 
wahrscheinlich keinen Einfluss auf die CYP51 Expression aufweisen. In dieser Arbeit 
korrelierte das 120 bp Insert mit einer im Durchschnitt 5- bis 8-fachen Sensitivitätsreduktion 
gegenüber Epoxiconazol. Im Gegensatz hierzu zeigten das 300, 862 und 866 bp Insert 
keine oder nur geringe Effekte. Im Jahr 2016 wurden Isolate mit einer CYP51 
Überexpression, basierend auf dem 120 bp CYP51P Insert, in einer geringen bis moderaten 
Häufigkeit in jedem untersuchten Land gefunden (mit Ausnahme von Dänemark). Im 
Vergleich hierzu wurde im Jahr 2017 ein Anstieg in der Häufigkeit dieser Isolate in einigen 
Ländern in Europa beobachtet. Das 120 bp Insert wurde fast ausschließlich in Kombination 
mit dem CYP51 Haplotypen F2 beobachtet. Zum ersten Mal wurde es im Zuge dieser Arbeit 
auch in Kombination mit anderen CYP51 Haplotypen gefunden. Diese Ergebnisse deuten 
darauf hin, dass die Evolution der CYP51 Überexpression und des CYP51P von Z. tritici 
weiter voranschreiten.  
Die Untersuchung des MFS1P führte zur Identifizierung von sieben verschiedenen Inserts 
mit einer Größe von 150, 267, 308, 338, 369, 377 bzw. 519 bp. Das 150, 338, 369 und 
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519 bp Insert wurde bereits in der Literatur beschrieben und es wurde gezeigt, dass diese 
Inserts zu einer gesteigerten MFS1 Expression führen. Hierbei wurde berichtet, dass das 
519 bp Insert im MFS1P den größten Effekt zeigt. In in vitro Sensitivitätsstudien dieser 
Arbeit korrelierte das 519 bp Insert mit einer bis zu 8-fachen Sensitivitätsreduktion 
gegenüber Epoxiconazol, wohingegen die kürzeren MFS1P Inserts zu geringeren Effekten 
führten. Im Jahr 2016 wurden Isolate mit einer gesteigerten Effluxaktivität, basierend auf 
dem 519 bp MFS1P Insert, nur in einer geringen Häufigkeit in Deutschland, Polen und in 
West-Europa gefunden. Das Vorkommen kleinerer MFS1P Inserts wurde hauptsächlich in 
UK und Irland beobachtet. Im Jahr 2017 wurde ein Anstieg in der Häufigkeit von kleineren 
MFS1P Inserts beobachtet, jedoch verblieb diese auf einem niedrigen Niveau mit 
Ausnahme von Irland und den Niederlanden. Die Häufigkeit des 519 bp Insert ist zwischen 
2016 und 2017 relativ stabil geblieben.  
Insgesamt konnte gezeigt werden, dass das Auftreten von verschiedenen CYP51 
Haplotypen noch immer den häufigsten und wichtigsten DMI-Resistenzmechanismus in 
Z. tritici in Europa darstellt. Im Vergleich zu früheren Studien wurde jedoch ein Anstieg in 
der Häufigkeit von Isolaten mit CYP51 Überexpression oder mit gesteigerter Effluxaktivität 
beobachtet. Sensitivitätsstudien im Gewächshaus zeigten, dass DMIs noch immer zu einer 
STB Kontrolle beitragen oder die Krankheit in manchen Fällen komplett kontrollieren 
können, auch wenn Isolate moderat oder stark angepasste CYP51 Haplotypen und/oder 
CYP51 Überexpression, sowie eine gesteigerte Effluxaktivität zeigten. Um eine weitere 
Verbreitung von immer stärker angepassten CYP51 Haplotypen und zusätzlichen DMI-
Resistenzmechanismen in Europa zu verhindern, sollten Antiresistenz-Strategien in der 
Anwendung von DMIs eine große Bedeutung zukommen. Vor allem sollten ebenfalls die 
Prinzipien des integrierten Pflanzenschutzes, wie z.B. eine geeignete Sortenwahl beachtet 
werden, um den STB-Krankheitsdruck und somit die Anzahl der Fungizidapplikationen zu 
verringern. Des Weiteren könnten Resistenzmanagement-Strategien auf der begrenzten 
Kreuzresistenz zwischen verschiedener DMIs beruhen, zum Beispiel durch die Anwendung 
von Mischungen oder der Alternierung verschiedener DMI Fungizide. Zudem sollten 
Fungizide mit anderen Wirkmechanismen in die Bekämpfungsstrategie einbezogen 
werden. Das Ziel all dieser Maßnahmen ist es die Selektion angepasster Z. tritici Isolate zu 
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